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ABSTRACT 
 
Langerhan’s cells (LCs) are the immune sentinels of the skin, sampling the cutaneous 
microenvironment and presenting captured antigen to T cells.  A sheet-like proliferation 
of LCs is termed Langerhan’s cell histiocytosis (LCH), an enigmatic and poorly 
understood disorder with a widely varied clinical spectrum and disease course.  In non-
pulmonary LCH all cases reported to date have been monoclonal. Clonality argues for 
LCH as a neoplastic rather than reactive disorder. 
After initial investigation of the limitations of formalin fixed paraffin embedded tissues 
for downstream analysis, lesions of LCH were collected from 4 sites across Scotland.  
To further define the spectrum of LCH, clonality was assessed using an X inactivation 
assay based on the polymorphous region of the Human Androgen Receptor.  To 
improve understanding of the assay, a study on post-mortem material was undertaken.  
This demonstrated a unique insight into patterns of X inactivation across different 
tissues of the same individual and highlighted potential pitfalls in interpretation.  
An important question was whether lesions of LCH associated with haematopoietic 
neoplasms were polyclonal or monoclonal proliferations?  For the first time, 
associations of LCH with B-cutaneous lymphoid hyperplasia (B-CLH), lymphomatoid 
papulosis (LyP) and mycosis fungoides (MF) are reported.  In two female cases, the LCs 
were polyclonal providing some reassurance that such lesions are reactive in nature and 
should not be regarded as potential second neoplasms.   
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In a more expanded study a wide variety of primary LCH lesions were assessed for 
clonality.  Significant limitations were posed by the quality of the material available; in 
2 cases the lesions were found to be polyclonal.  This is the first time such a result has 
been reported.  Monoclonality was identified in 2 other cases including one of 
pulmonary LCH.  The findings reported herein suggest that clonality and hence 
neoplasia cannot be assumed in all cases of primary non-pulmonary LCH. 
The possible functions of LCs in cutaneous lymphoma were explored.  In T-cell 
lymphoma 2 cases reported here suggest a role for LCs in disease progression.  In 
contrast, LCs play no significant part in the development or progression of cutaneous B-
cell proliferations although other types of dendritic cells probably have an important 
role. 
By studying proliferations of LCs in a variety of settings, this work has extended 
knowledge of the spectrum of LCH.   Displaying similar histopathological appearances, 
lesions of LCH may be best defined by clonality as well as cytokine expression and 
level of maturation.  In future, such markers may be employed as prognostic indicators 
allowing individualised and targeted management.  
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1.  THE LANGERHAN’S CELL AND LANGERHAN’S CELL HISTIOCYTOSIS 
 
1.1. INTRODUCTION 
 
1.1.1. The Langerhan’s cell 
 
In 1869 the German anatomist Paul Langerhan was responsible for the discovery of the 
dendritic cells (DCs) which came to bear his name.  Langerhan’s cells (LCs) exist 
predominantly within the skin, but have also been identified in a wide variety of tissues 
including the oesophagus (Yassin and Toner, 1976), anus (Sobhani et al., 2002), cervix 
(Hawthorn and MacLean, 1987), thymus (Rausch et al., 1977), lymph nodes 
(Silberberg-Sinakin et al., 1976) and in the lung, particularly in those with chronic 
airways disease (Van Pottelberge et al.).   In the skin LCs reside within the epidermis 
forming a network of extensive dendritic processes in the basal and supra-basal layers 
(Romani et al., 2003). In contrast to macrophages and monocytes, LCs and other types 
of DC are poor phagocytes but are highly efficient at antigen presentation (Streilein and 
Bergstresser, 1984). They sample the micro-environment and present antigen to cells of 
the adaptive immune system so playing a central role in the cutaneous immune response.  
 
LCs, in their role as professional antigen presenting cells (APCs), bear many surface 
proteins including HLA-DR antigen (Bjercke et al., 1985), surface receptors for the 
immunoglobulin Fc fragment (Schmitt et al., 1990) and the complement protein 
receptor C3b (CD35) (De Panfilis et al., 1990, Stingl et al., 1977).  Upon stimulation by 
antigen, LCs down-regulate E-cadherin thereby facilitating movement between 
keratinocytes. Secretion of matrix metalloprotienases allows passage through the 
basement membrane and the dermis where they extend cytoplasmic processes or 
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pseudopodia which cling to collagen fibrils.  Activated LCs down-regulate CCR6, the 
ligand for which is in the skin (MIP-3 alpha) and up-regulate CCR7.   The ligand for 
CCR7 is CCL21, also known as “secondary lymph node tissue chemokine”; this is 
present in lymph nodes and is chemo-attractant to DCs. CCR7 also plays a crucial role 
in the trafficking of B and T lymphocytes (Yoshida et al., 1997). Activated LCs move 
into afferent lymphatics by passing through intercellular gaps between neighbouring 
endothelial cells (Stoitzner et al., 2002). Migration is then to draining lymph nodes 
where processed antigen bound to a class II MHC molecule is presented to a naive T 
cell.  Co-stimulatory molecules are expressed on the LC which results in T cell 
activation (see Chapter 6). 
 
LCs, as well as other subtypes of DC, are derived from CD34+ progenitors in the bone 
marrow (Katz et al., 1979, Strunk et al., 1997). Although DC recruitment to the skin is 
poorly understood, CXCL14, a chemokine present in healthy skin, appears to mediate 
the recruitment of DC precursors to the epidermis.  Once in a supra-basal position the 
DCs differentiate into LC-like APCs (Schaerli et al., 2005). LCs also appear to have the 
ability to self-renew locally under steady state conditions though may be recruited in 
large numbers from the blood when required (Merad et al., 2002).  
 
1.1.2. Recognition of the Langerhan’s cell 
 
 
LCs have a relatively characteristic morphology with indistinct cytoplasmic borders, 
eosinophilic or pale cytoplasm and elongated convoluted nuclei which may appear 
deeply grooved and folded. The chromatin is fine and nucleoli are inconspicuous 
(Figure 1.1.).  Occasional multinucleate forms exist.  The LCs’ most characteristic and 
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unique ultrastructural feature is the rod shaped, membrane bound “tennis racket” shaped 
Birbeck granule (Mierau et al., 1982). Immunohistochemistry (IHC) may be invaluable 
in LC recognition.  LCs stain for S100 protein, CD1A, CD68 and CD31 (Dabbs, 2002, 
Rowden et al., 1983, Emile et al., 1995, Slone et al., 2003) although none of these 
markers is specific.  Langerin is a C-type lectin (see 6B.1.1) exclusively expressed by 
LCs.  Langerin is found on the surface of the LC as well as intra-cellularly.  It appears 
to play a role in Birbeck granule formation which plays an important role in subsequent 
antigen processing functions (Valladeau et al., 2000).  LCs are typically negative for B-
cell and T-cell lineage markers (except CD4) and are also negative for the follicular DC 
lineage marker CD21. 
 
 
Figure 1.1.  The Langerhan’s cell.  H & E x 40, a cluster of LCs displaying irregular 
nuclear contours, abundant cytoplasm and nuclear grooves. Inset – Electron microscopy 
image of a Birbeck granule. 
 
1.1.3. Langerhan’s Cell Histiocytosis 
 
 
The term Langerhan’s Cell Histiocytosis (LCH) encompasses a group of rare 
disorders characterized by an accumulation or proliferation of abnormal LCs. The 
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disease is more common in children but can occur in adults of all ages (Giona et al., 
1997). Its clinical spectrum is wide, ranging from an indolent isolated lesion to a rarer 
life-threatening multisystem disease commonly involving bone marrow, lymphatics, 
skin, liver, lung, and spleen (Bernstrand et al., 2003). LCH has a particular 
predilection for the bones of the skull in children and the rib, skull and pelvis in adults 
(Wester et al., 1982).  In its most common form the disease involves a single bone. The 
lesions are lytic in nature and typically involve the diaphysis.  Although single system 
disease may spontaneously regress (Smith et al., 1999), multisystem disease usually 
requires treatment with chemotherapy and steroids. Fatalities may still occur as a result 
of organ failure.  Diagnosis of LCH is based on recognition of LCs in biopsies of lesions 
that may also contain many eosinophils, histiocytes, neutrophils and small lymphocytes.  
However, the morphology and immunophenotype of LCs in LCH is essentially the same 
as for normal LCs, and there are no pathological features which reliably predict for 
disease extent or clinical course (Weiss LM, 2001).  There is little available data on the 
incidence of LCH in the UK and Republic of Ireland.  However, a recent study identified 
94 cases in children (0-16) in a 2 year period, giving an incidence of 4.1 per million per 
year.  The majority had single system disease (73%) and of the 27% with multisystem 
disease 7% had involvement of high risk organs including liver and bone marrow.  Three 
children subsequently died of LCH (Salotti et al., 2009). 
 
1.1.4. The clinical spectrum of Langerhan’s Cell Histiocytosis 
 
Neoplastic LCs consistently express CD1a and S-100 protein (Emile et al., 1995, 
Nakajima et al., 1982, Pileri et al., 2002). The Birbeck granule is not a constant feature 
however of neoplastic LCs and may be seen in 1-75% of these cells (Pileri et al., 2002). 
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In the same study the proliferation marker Ki67 stained between 2 and 25% of 
neoplastic LCs with a mean of approximately 10%. As scattered LCs are normally 
present in a number of organs the finding of a few cells in these sites is not necessarily 
indicative that the patient has LCH (Vernon et al., 1973). A sizeable number of cells is 
required before the diagnosis should be entertained. Unfortunately there is no 
recognised standard at any organ site for the number of cells required for the diagnosis.  
Clinical variants include Hand-Schuller Christian disease and Letterer-Siwe disease. 
Diagnostic difficulties are uncommonly posed by other cutaneous histiocytoses that 
affect children such as benign cephalic histiocytosis (Jih et al., 2002).   
 
1.1.4.1. Letterer-Siwe Disease  
 
The acute disseminated form of LCH that occurs predominantly in infants is rapidly 
progressive and affects primarily soft tissues with no or minimal bone involvement.  It 
is typically characterized by a purpuric rash, enlargement of lymph glands and spleen 
and invasion of the spleen, liver and bone marrow by LCs (Ferreira et al., 2009, 
Watanabe et al., 1983). 
 
1.1.4.2. Hand-Schuller-Christian disease 
 
There is involvement of several sites but in one organ system, most commonly bone.  
These patients, usually children, may present with multiple destructive bony lesions 
often with associated soft tissue masses (Jaffe et al., 2008). 
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1.1.4.3. Pulmonary LCH   
 
Pulmonary LCH or eosinophilic granuloma is a proliferation of LCs to a degree 
sufficient to cause microscopic nodules.   The disease occurs almost exclusively in 
cigarette smokers (Vassallo and Limper, 2002).  The patients may be asymptomatic or 
present with fever and weight loss.  The characteristic computerised tomography (CT) 
appearance is one of multiple nodular lesions of variable size.  Such nodules may be 
innumerable and typically less than 2 cm in size. In addition cavitated nodules and 
thick- and thin-walled cysts may also be present (Tazi, 2006). Diagnosis often requires 
open lung biopsy.  LCH in late phase typically displays a starfish configuration of 
scarring.  Isolated LCH of the lung usually undergoes spontaneous regression on 
cessation of smoking although a proportion of patients will progress to honeycomb 
fibrosis (Sundar et al., 2003). 
Stages of Pulmonary LCH  
 
• Early - Nodules of LCs in an inflammatory background comprising lymphocytes, 
plasma cells, eosinophils, neutrophils and macrophages. 
• Mid – Starfish shaped scars with pockets of LCs and a desquamative interstitial 
pneumonia – like reaction. 
• Late – Scars and cysts with scanty numbers of LCs, scattered lymphocytes and 
iron pigment.  
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1.1.4.4. Cutaneous LCH  
 
Cutaneous LCH is predominantly a disease of children.  It may be a disorder confined to 
the skin but concurrent disease in extra-cutaneous sites is common.  Cutaneous disease 
in adults limited to the skin is rare (Singh et al., 2003, Stefanato et al., 1998). 
 
1.1.5. Prediction of clinical outcome 
 
It is generally regarded that the degree of cytological atypia (unless extreme, suggesting 
a diagnosis of LC sarcoma), mitotic activity and presence or absence of necrosis are not 
useful determinants of clinical outcome (Risdall et al., 1983) The clinical course 
generally depends on the number of organs involved at presentation (Greenberger et al., 
1981) as outlined by the staging system proposed by the Histiocyte Society 
(www.histiocytesociety.org/document.doc?id=290, accessed April 2009). But 
exceptions occur; for example, the absence of bone lesions in the presence of multi-
organ involvement is a poor prognostic sign, while the presence of multiple bone lesions 
in the same circumstance is a marker of good prognosis.  There is progression of 
unifocal lesions into multisystem disease in about 10 % of patients, and spontaneous 
regression of multisystem disease may occur in rare instances.  The overall survival of 
patients with unifocal disease is higher than 95%; this figure, however, drops to 75% in 
subjects with two organs involved and continues to drop with an increasing number of 
affected sites.  Age seems to be a less important prognostic factor than the number of 
organs involved (www.histiocytesociety.org/document.doc?id=290, accessed April 
2009). Patients with disease localized to low risk organs such as skin, bone and lymph 
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nodes have the best prognosis and require minimal treatment. However, patients with 
lesions in high risk organs such as liver and bone marrow have a greater mortality and 
morbidity (Allen and McClain, 2007). Those with LCH in the orbit and skull are at 
increased risk of developing diabetes insipidus (Grois et al., 2006). Where only one 
bone is involved, the clinical course is generally benign.  The greatest challenge is 
treatment of LCH in patients with multisystem disease. Treatment modalities include: 
watchful waiting, surgery, steroid injection, chemotherapy, photodynamic therapy 
(PDT) and radiation therapy. Effects of treatment may include: slow growth and 
development; hearing loss; bone, tooth, liver and lung problems, as well as the risk of a 
second treatment related malignancy (Allen and McClain, 2007, Society). The 
Histiocyte Society classification guidelines/indications for systemic treatment are 
outlined in Appendix A. 
 
1.1.6. Aetiology of Langerhan’s cell histiocytosis 	  
 
LCH is an enigmatic disorder of unknown aetiology. A viral trigger has been postulated 
but evidence for this is limited and conflicting.  One study demonstrated the presence of 
human herpes virus 6 (HHV-6) in tissue samples of LCH by IHC and in situ 
hybridization (ISH).  The findings suggest a role for HHV-6 in the aetiology of this 
disease (Glotzbecker et al., 2004). Other studies however, employing ISH and 
polymerase chain reaction techniques (PCR) failed to find evidence of genomes for a 
wide range of viruses including HHV-6 (Glotzbecker et al., 2006, McClain et al., 1994), 
Epstein-Barr virus (McClain et al., 1994, Jeziorski et al., 2008), Herpes simplex virus 
and parvovirus (McClain et al., 1994).   
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The clonal nature of LCH was first established in 1994 by a group investigating a varied 
spectrum of the disease in 9 cases (3 disseminated, 3 intermediate and 3 unifocal forms) 
(Willman et al., 1994).  Their results revealed monoclonality in 9/9, establishing the 
dogma that LCH is a clonal proliferative disorder.  Monoclonality is a feature of all 
neoplasms but not all monoclonal populations are regarded as malignant.  These 
findings however do raise the possibility of, as yet unknown, underlying somatic 
mutations (see Discussion). 
 
1.1.7.  Langerhan’s cell proliferations in association with other neoplasms  
 
LCs may be seen in a wide range of neoplasms and non-neoplastic conditions. The cells 
may proliferate in the lung in several diffuse interstitial diseases and in reaction to 
neoplasms.  The proliferation may be of such degree in bronchiolitis obliterans as to 
make distinction of LCH from bronchiolitis a problem (Caminati and Harari, 2006).  
They may be found admixed with various neoplasms including primary pulmonary 
carcinomas, particularly non-mucinous bronchioloalveolar cell carcinoma.  It has been 
suggested that these tumours secrete a factor that is chemotactic for LCs (Colasante et 
al., 1995).  This association is discussed in more detail in Chapter 4. 
 
1.2. DISCUSSION 
 
As the aetiology and pathogenesis of LCH has not yet been established, these disorders 
remain the subject of much debate.  A major area of controversy centres on whether 
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LCH is a true neoplasm or a reactive disorder (Beverley et al., 2005).  The strongest 
evidence in support of the former comes from studies using the human androgen 
receptor (HUMAR) assay to assess clonality in a small number of cases of LCH.  As 
mentioned above, in the first study by Willman et al (1994) monoclonality was 
demonstrated in 9/9 females with a tenth female excluded due to extreme constitutional 
lyonisation.  This study utilised whole tissue samples and correlated their results with a 
count of CD1a + cells in the lesions.  Another study in the same year found 
monoclonality in 3/3 cases of multisystem disease (Yu et al., 1994). This study was 
more sophisticated in the sampling technique, using fluorescence activated cell sorting 
with a monoclonal antibody to CD1a.  Of note, to date, only 3 cases of unifocal disease 
(Willman et al., 1994) have been studied for clonality, these are the lesions which have 
the best prognosis, often do not require treatment and may spontaneously regress.  
Indeed the authors expressed some surprise at finding monoclonality in such lesions. 
 
Other differences identified between LCs in some cases of LCH and normal LCs have 
been used to argue in favour of a neoplastic process.  These include expression of co-
stimulatory molecules such as CD40, differences in expression of various cytokines, 
loss of heterozygosity at certain loci (e.g. 1p) (Murakami et al., 2002) and altered 
expression of cell cycle related proteins such as Bcl-2 (Savell et al., 1998).  In addition, 
a single case of LCH with a t(7;12)(q11.2;p13) has been reported, implicating genes at 
the breakpoint sites in the pathogenesis of LCH (Betts et al., 1998).   
 
Whilst there is persuasive evidence that some examples of LCH are true neoplasms, it is 
also possible that some of the differences listed above may reflect an altered state of 
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activation for the LC population, rather than a permanent disruption of growth control, 
particularly since the studies involved did not correlate their findings with clonality.  In 
contrast to non-pulmonary forms of LCH, in a study of pulmonary LCH, 13/13 cases 
were shown to be polyclonal using the HUMAR assay, supporting the contention that 
this form of the disease is a reactive condition probably related to cigarette smoking 
(Yousem et al., 2001). It therefore seems likely that LCH, as currently defined, 
represents a heterogeneous group of neoplastic and reactive disorders with shared 
pathological features.  This undoubtedly hinders progress in understanding the biology 
of LCH and designing effective treatments, since it is extremely difficult to draw 
meaningful conclusions from experimental results generated from a cohort of cases that 
may unwittingly contain more than one disease entity.  
 
In the literature proliferations of LCs found in association with other malignancies are 
typically termed LCH but seem likely to represent a reactive population recruited by a  
cytokine rich mileu.  The monoclonal or polyclonal nature of such proliferations has not 
been established but is clearly an important distinction to make in order to exclude the 
possibility of a potentially aggressive second neoplasm.   Some studies suggest that 
increased numbers of tumour infiltrating LCs are a good prognostic indicator (Tsujitani 
et al., 1987), probably due to effective tumour antigen presentation, while others suggest 
tumour infiltrating DCs may become effectively disabled (Gabrilovich et al., 1997) 
(detailed in Chapter 6).   Large LCH-like proliferations are most commonly found in 
association with haematological malignancies and as APCs of the skin it is possible that 
they may play a role in the suppression, development or maintenance of cutaneous 
lymphoid malignancies.  The role of LCs and other DC subsets in cutaneous lymphoma 
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and benign lymphoproliferations has not been well elucidated although improved 
markers are now available to aid in distinguishing DC subsets and to determine 
activation/maturation status. 
 
1.3. AIMS 
The objectives of this study are outlined below: 
1. Use a range of control tissues to assess the quality and quantity of both 
deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) from formalin fixed paraffin 
embedded (FFPE) tissue samples from whole sections and laser microdissected 
specimens.  This will establish the limitations of the LCH material available and 
determine the possibility of gene expression analysis and other downstream applications.  
2. Explore the X-inactivation assay which was first used to establish monoclonality in 
non-pulmonary LCH and polyclonality in pulmonary LCH.  To determine possible 
pitfalls of the assay, difficulties of interpretation and role of laser capture 
microdissection (LCM) in improving reliability.  
3. Explore the possibility that, at least in some cases, collections of LCs in association 
with other malignancies represent benign reactive proliferations,  not second neoplasms.   
4. Assess a large cohort of LCH cases, representing the full clinical spectrum of the 
disease, for clonality employing a combination of LCM and the HUMAR assay.  Only 
female patients will be studied as the assay depends on identification of patterns of X 
chromosome inactivation.    This work should identify cases for further studies aimed at 
identifying biological differences between benign /reactive LCs and neoplastic LCs. 
5. Determine the potential roles of LCs and other cutaneous DCs in driving cutaneous 
lymphoid malignancies. 
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2. NUCLEIC ACID EXTRACTION FROM FIXED AND FRESH TISSUES 
 
2.1. INTRODUCTION 
 
Histopathology stores contain vast amounts of FFPE tissues that are available for 
retrospective study.  In regions where there are local tissue banks and ethics procedures, 
anonymised tissue samples can be relatively easily acquired.  Both DNA and RNA may 
be extracted from whole tissue sections or stained slides. While DNA extraction and 
subsequent PCR has long been established, RNA extraction and gene expression 
profiling is an increasingly exciting and challenging area of research.  Nucleic acid 
degradation, particularly when dealing with “fragile” RNA, is the primary limitation to 
downstream applications.  Small biopsies or microdissected samples create further 
problems as DNA or RNA may require amplification prior to subsequent analysis such 
as comparative genomic hybridization or cDNA microarray profiling respectively.  
Unfortunately the vast majority of rare samples are FFPE which considerably hampers 
downstream analysis. With the creation of tissue banks and the co-operation of 
clinicians, pathologists and research nurses, fresh unfixed samples will become 
increasingly available for study.   
 
2.1.1. DNA from formalin fixed archival tissues 
 
Formalin fixation results in extensive protein-protein and protein-nucleic acid cross 
links with the formation of mono-methylol adducts with nucleotide rings (Feldman, 
1973).  Protease treatment breaks this web but some nucleic acid bases will still be 
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cross-linked to other bio-molecules. Extraction of DNA from FFPE tissue was first 
undertaken over 20 years ago based on proteinase K digestion (Goelz et al., 1985). The 
quality of nuclei acid extracted depends on the type and length of fixation; 
10% buffered neutral formalin and acetone are relatively good fixatives for subsequent 
DNA analysis while Carnoy’s, Zenker’s or Bouin’s are the least desirable fixatives.  
Longer periods of fixation (>1 week) and older tissue blocks (>5 years old) increase 
degradation reducing the fragment size available for PCR (Greer et al., 1991). However, 
FFPE tissues may yield DNA of sufficient quality for downstream analysis after >40 
years in storage (Shibata et al., 1988).  Investigators have found average fragment 
lengths from archived tissue of 300-400bp (Lehmann and Kreipe, 2001) although 
optimally processed samples may achieve fragment lengths of  >1000bp (Greer et al., 
1991).  
 
2.1.2. RNA from formalin fixed archival tissues and fresh tissue 
 
 
RNA isolated from FFPE tissues is typically of poor quality due to degradation that 
occurs prior to and during fixation.  Formalin also chemically modifies RNA by the 
addition of mono-methylol groups which hinder downstream analysis (Masuda et al., 
1999). Commercial kits are now available to extract RNA from FFPE tissues, although 
recovery is hampered if the tissue is fixed for greater than 24 hours in a fixative stronger 
than neutral buffered formalin or the tissue block is > 6 months old (www.Ambion.com, 
accessed September 2009).    The potential use of this vast archived resource has also 
prompted the development of microarray technology specifically designed to detect the 
shorter RNA fragments that are common in these types of samples 
www.bucher.ch/en/products/Arcturus/Paradise-RNA-Isolation-Amplification-Kits.html, 
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accessed July 2011). Gene expression profiling of nanogram (ng) quantities of RNA 
acquired from small biopsies, laser capture microdissection or flow sorting, requires 
prior linear mRNA amplification.  Extraction of good quality RNA from fresh tissues is 
also challenging, particularly if LCM is required to select specific cell populations as 
this requires cutting frozen sections, staining and dissection time, which may result in 
further RNA degradation.  
 
2.1.3. Laser capture microdissection 
 
LCM may be employed to isolate a specific cell population or structure of interest for 
further study (Figure 2.1.). The ability to isolate morphologically identifiable cell 
populations in tissue sections has greatly increased our understanding of many diseases.  
Important examples include lesions in which the tumour cell population is in the 
minority, in determining genetic mutations in in-situ malignancy and identification of 
loss of heterozygosity in “normal” tissue adjacent to tumours. Investigators using DNA 
extracted from LCM samples have shown that the malignant cells of Hodgkin’s disease 
are B-cell lineage (Kanzler et al., 1996), have described identical allelic losses in in-situ 
and invasive breast cancer (Zhuang et al., 1995) and found  loss of heterozygosity in 
normal tissue adjacent to breast carcinomas (Deng et al., 1996). Frozen sections are also 
amenable to LCM although limitations are posed by the small amounts of RNA 
involved.  Sectioning and staining may also cause RNA degradation and the investigator 
is further hampered by the poor morphology of frozen tissue compounded by the 
necessary absence of a cover-slip.  IHC may aid in recognition of specific populations 
and rapid protocols have been developed in order to limit nucleic acid degradation.  In 
2001, Specht et al. published the first application of combined quantitative TaqMan 
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reverse transcriptase PCR (QRT-PCR) and laser assisted microdissection for 
quantification of gene expression levels in archival FFPE tissue samples.  They 
demonstrated that mRNA levels in formalin-fixed samples routinely prepared from 
surgery can be reproducibly and precisely determined and that the values obtained are 
comparable to matched frozen specimens.  This work requires an extraction protocol 
that provides only minimally cross-linked RNA and small target sequences in a range of 
60 to 100 bp enabling the detection of fragmented and degraded RNA.  Results were 
obtained from as few as 50 cells (Specht et al., 2001). 
 
 
Figure 2.1.   Laser capture microdissection, before and after images (Arcturus Pixcell 
II, Life Technologies, Paisley, UK) A/D sections before LCM showing a renal blood 
vessel and glomerulus respectively. B/E sections after LCM showing area of tissue 
removed (star). C/F captured tissue removed by LCM. 
 
2.1.4. Aims 
 
I aim to explore the quantity and quality of DNA and RNA available from FFPE tissue 
in order to determine the best approach to investigating these rare tumour samples. 
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There are several anticipated challenges which include small biopsy size, dealing with 
bony tissues that have undergone decalcification, aging tissue blocks, impact of IHC on 
DNA quality and heterogeneous cell populations requiring LCM.  Where fresh tissue is 
available I aim to explore the application of gene expression studies to picogram (pg) 
quantities of RNA.  These aims are summarized below. 
 
• Most efficient buffer and methodology for DNA extraction from FFPE samples. 
• Typical DNA quality and quantity from FFPE samples including routinely 
processed surgical specimens, postmortem tissues and post-IHC samples. 
• Typical RNA quality and quantity from fresh and FFPE samples, including 
samples that have been microdissected. 
• Downstream analysis of LCM samples.  
 
2.2. METHODS 
 
A complete list of materials with source and catalogue number is given in Appendix A. 
 
Anonymised tissue consented for research was provided by the Tayside Tissue Bank. 
 
2.2.1. Optimal DNA buffer for extraction from FFPE samples 
 
 
FFPE renal cell carcinomas and matched normal renal tissue controls were sectioned at 
10 µm, de-paraffinised and stained with Haematoxylin and Eosin (H & E).  Each sample 
was microdissected to provide around 100 cells for PCR analysis.   Microdissection was 
performed using the Arcturus Pixcell II microscope (Life Technologies). Cells were 
isolated employing the laser by direct visualisation, these adhered to a microdissection 
cap. DNA was extracted according to the protocols below (2.2.1.2. - 2.2.1.4.).  
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 2.2.1.1.  Deparaffinisation and staining 
 
 
Sections on slides were sequentially put through the following immersions and 
washings: Xylene 5 min, xylene 5 min, 100% ethanol wash, 95% ethanol wash, 
70%  ethanol wash, purified water wash, Mayer’s Haematoxylin (freshly filtered) 1-2 
min, purified water wash, Scott’s Tap Water Solution (STWS) 30-60 s, 70% ethanol 
wash, 95% ethanol wash, Eosin (freshly filtered) 1-2 min, 95% ethanol wash, 
95%  ethanol wash, 100% ethanol wash, xylene 2-5 min.  Finally the slides were air 
dried for at least 5 min. 
  
2.2.1.2. DNA extraction method A 
 
Lysis buffer (Standard laboratory protocol) 
Lysis buffer was made up using the following reagents and pH balanced to 8.2: 1.211g 
10 mM Tris HCl, 3.727g  50 mM KCl, 0.508g  2.5 mM MgCl2, 450 µL 0.45% Tween. 
The working solution was 0.5 µL proteinase K added to 49.5 µL of lysis buffer, and 
kept on ice. The microdissection cap was inserted into a MicroAmp thin-walled reaction 
tube (Applied Biosystems) and inverted so that the buffer covered the surface of the cap.  
The inverted tube was placed in an incubator at 55°C for 2 hours. The samples were 
then centrifuged at 1,000 x g for 1 min (all centrifuge steps were carried out at room 
temperature using a tabletop microcentrifuge unless otherwise stated). Next the 
microdissection cap was removed.  The samples were then placed in a heat block at 
95°C for 15 min then allowed to cool to room temperature. 
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2.2.1.3. DNA extraction method B 
 
Standard buffer and adapted protocol supplied by the Department of Molecular 
Genetics (Ninewells Hospital and Medical School, Dundee). 
50 µL of 50 mM NaOH was added to each MicroAmp thin-walled reaction tube. The 
microdissection cap was inserted into the tube and inverted so that the buffer covered 
the surface of the cap.  The inverted samples were heated in a water bath at 95°C for 
10 min then neutralised with 5.0 µL of 1 M Tris at pH 7.6. The samples were 
centrifuged at 1000 x g for 1 min then cooled to room temperature. 
 
2.2.1.4. DNA extraction method C 
 
 PicoPure™ DNA Extraction kit (Arcturus) 
155 µL of Reconstitution Buffer was pipetted into one vial of Proteinase K (Qiagen).  
The tube was gently vortexed to mix the reagents and immediately placed on ice. 50 µL 
of Proteinase K extraction solution was pipetted into a 0.5 mL microcentrifuge tube. 
The cap with LCM captured cells was inserted into a MicroAmp thin-walled reaction 
tube. The microcentrifuge tube was inverted and shaken down so that the 50 µL volume 
of Proteinase K extraction solution completely covered the inside surface of the cap. 
The inverted tube was incubated at 65°C for > 16 hours. After incubation the samples 
were placed in a centrifuge for one minute at 1,000 x g and the microdissection cap 
removed. The microcentrifuge tube containing the extract was closed and placed in a 
heat block at 95°C for 10 min to inactivate the Proteinase K. The sample was then 
cooled to room temperature. 
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2.2.1.5. Polymerase chain reaction 
 
The following primer set was employed (MWG custom primers).  This set amplified 
intron 16 of the angiotensin converting enzyme gene (ACE) to produce a 287 bp product  
(Rigat et al., 1992). 
 
Sense 5’ – CTGGAGACCACTCCCATCCTTTCT- 3’ 
Antisense 5’ – GATGTGGCCATCACATTCGTCAGAT -3’ 
 
Mastermix 
 
The mastermix was made up as follows: Extracted DNA 10 µL,  dNTP mix (10 mM) 1 
µL, MgCl2  3 µL, 10 x buffer 5 µL, Forward primer (20 µg/ml) 2 µL, Reverse primer (20 
µg/ml) 2  µL, DMSO  2 µL, Nuclease free H2O  25 µL, Taq polymerase 0.25 µL.  
Cycling conditions: 1 cycle of 94°C for 1 min, 40 cycles of 58°C for 1 min, 72°C for 
2  min, 58°C for 2 min, 1 cycle of 72°C for 10 min, 15°C hold. 
 
The PCR products were run on a 1.5 % agarose gel employing a 100 bp ladder 
(hyperladder IV, Bioline). 
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Agarose gel electrophoresis 
 
A stock solution of 10 x TBE was made by adding together: 21.6 g TRIS, 11 g boric 
acid and 1.488 g EDTA in 150 mL of distilled water.  The solution was placed on a 
magnetic stirrer to dissolve.  The solution was then poured into a measuring cylinder 
and made up to 200 mL with distilled water.  A working solution of 0.5 x TBE was 
made by adding 50 mL of 10 x TBE to 950 mL of distilled water.   To make the gel, 
1.5 g of agarose was added to a conical flask containing 100 mL of 0.5 x TBE and 
heated in a microwave until the agarose dissolved.  5 µL of ethidium bromide was 
added to the solution in a fume hood. The molten gel was poured into the setting 
equipment and left to set for 30 min.  The gel electrophoresis running tank was filled 
with 0.5 x TBE. Once the gel had set it was placed in the tank with a covering layer of 
buffer.  The first lane was loaded with 5 µL of 100 bp ladder (hyperladder IV, Bioline).  
Into each consecutive well, 8 µL of PCR product mixed with 2 µL loading dye was 
added. The samples were run at 150 V for 1.5 hours and visualised under ultraviolet 
light. 
 
2.2.2. DNA quality assessment 
 
Anonymised tissue samples and a human blood DNA control sample were kindly 
supplied by the Tayside Tissue and Tumour Bank. 
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2.2.2.1. Surgical specimens 
 
FFPE blocks of follicular lymphoma, colorectal carcinoma and renal cell carcinoma 
were sectioned at 4 µm and stained with H & E.  The sections were visualized to ensure 
there was no significant tissue necrosis or autolysis.  Two whole tissue section curls 
from the paraffin block were then cut at 10 µm for DNA extraction (see method A 
below). 
 
2.2.2.2. Post-mortem tissues 
 
FFPE blocks of bone marrow (x 2), bone (x 3), liver (x 1) and lung (x 1) were retrieved 
from the pathology archives, sectioned at 4 µm and H & E slides prepared.  The sections 
were visualized to ensure there was no significant tissue necrosis or autolysis.  All 
blocks were > 5 years in age.  Whole tissue section curls from the paraffin block were 
then cut for DNA extraction (see method A below). 
 
2.2.2.3. Immunostained slides 
 
A case of LCH was sectioned and immunostained with CD1a, S100 and Langerin.  The 
CD1a and S100 sections were stained by the Department of Histopathology, Ninewells 
Hospital, Dundee, according to standard protocols.  Langerin staining was performed as 
per the methodology in Chapter 5. Scraped tissue from the slides was then added to the 
DNA extraction buffer (see method A below). 
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DNA extraction (method A). 
 
The microtome and forceps were cleaned thoroughly with absolute alcohol to prevent 
DNA contamination.  The microtome section thickness was set to 10 µm.  The first 
section was discarded as the surface of the block may be exposed to air and dust then 2 
x 10 µm sections were placed in a sterile eppendorf tube. 400 µL of buffer was added to 
each tube with 4 µL proteinase K (200 µg/mL). The samples were placed in an 
incubator at 55°C for 2 hours.  The samples were heated in a water bath at 95°C for 15 
min then allowed to cool to room temperature. 
 
PCR   
 
 
The specimen control size ladder master-mix (InVivoScribe Technologies - Specimen 
control size ladder – 6FAM) amplifies 5 undefined sets of products of different sizes 
(96 bp, 198 bp, 298 bp, 399 bp and 499 bp).  This was allowed to thaw and gently 
vortexed to mix. In a hood, 45 µL of the master-mix was added to each tube.  0.25 µL of 
HotStarTaq DNA Polymerase per reaction was added then gently vortexed.  Finally 5 
µL DNA was added and pipetted up and down to mix. 
 
Cycling conditions: 1 cycle of 95°C for 7 min, 35 cycles of 95°C for 45 s, 60°C for 45 s, 
72°C for 90 s, 1 cycle of 72°C for 10 min, 15°C hold. 
 
The PCR products were run on a 1.5 % agarose gel. 
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2.2.3. DNA quantification 
 
 
 2.2.3.1. DNA purification 
 
 
Qiaquick PCR Purification Kit (according to manufacturer’s standard protocol) 
 
Briefly, 5 volumes of Buffer PB was added to 1 volume of the DNA sample and mixed. 
A QIAquick spin column was placed in the provided 2 mL collection tube. The sample 
was applied to the column and centrifuged for 60 s, the flow-through was discarded and 
the column placed back into the same tube.  0.75 mL Buffer PE was added to the 
column and centrifuged for 60 s. The flow-through was discarded and the column 
placed back in the same tube.  The column was centrifuged for an additional 1 min at 
maximum speed then placed in a clean 1.5 mL microcentrifuge tube. To elute DNA, 
30 µL H2O was added to the centre of the QIAquick membrane, the column was left to 
stand for 1 min then centrifuged for 1 min. 
 
 2.2.3.2. Nanodrop estimation 
 
 
 
The NanoDrop 2000™ spectrophotometer was employed according to the 
manufacturer’s (Thermo Scientific) standard protocol.  For further details regarding 
DNA quantification please refer to 2.3.3. 
 
With the sampling arm open, 1 µL of the sample was pipetted onto the lower 
measurement pedestal. The sampling arm was closed and a spectral measurement 
initiated using the operating software on the PC. When the measurement was complete, 
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the sampling arm was opened and the sample wiped from both the upper and lower 
pedestals using a soft laboratory wipe.  
 
 2.2.3.3. Effects of histochemical stains on quantity estimation 
 
Increasing quantities of freshly filtered Eosin and the Arcturus Histogene stain were 
added to the Method A DNA extraction buffer without DNA.  Nanodrop measurements 
were taken (see Nanodrop estimation above) to determine the impact of histochemical 
stains on the spectral reading.   
 
2.2.4.  RNA from formalin fixed archival tissues and from fresh microdissected tissue. 
 
Ribonucleases (RNases) are stable enzymes, which even in tiny amounts will destroy 
RNA. Great care must be taken to ensure an RNA sample is not contaminated.  The 
commonest source of RNases is the hands and dust particles.  Latex gloves were worn 
and changed regularly, all surfaces and pipettes were wiped down with a solution of 
RNase away. A set of RNA only pipettes was used and the lids of tubes were kept 
closed between procedures.  Disposable sterile RNase free plasticware was used and 
glassware treated with a solution of 0.1% diethylpyrocarbonate (DEPC) at 37°C 
overnight.  The glassware was then autoclaved to eliminate any residual DEPC.  
Purified RNA was stored in water at –70°C.  
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2.2.4.1 . RNA extraction from FFPE tissue sections 
 
 
RecoverAll™ Total Nucleic Acid Isolation Kit (Ambion) according to the 
manufacturer’s standard protocol 
 
2.2.4.2. RNA extraction from microdissected fresh tissue 
 
 
Cryostat sectioning: The cryostat was pre-cooled.  The knife holder and anti-roll plate 
were cleaned with 100% ethanol.  A new disposable blade was inserted in the 
microtome and the microslide box placed nearby.  The cryomold containing the 
specimen was placed in the cryostat and left for 10 min to reach cutting temperature.  
8  µm sections were cut from each specimen.  A new disposable blade was used for each 
specimen.  The staining protocol below was employed immediately or slides stored at -
80°C. 
 
HistoGeneTM LCM Frozen Section Staining Kit (Arcturus): This procedure was 
undertaken in a hood with 4 slides prepared at a time.  Forceps were used to transfer 
slides from one plastic slide jar to the next.  Frozen sections were removed from the -
80°C freezer and allowed to thaw for no > 30 s.  The sections were dipped into slide jars 
as follows: 75%  ethanol for 30 s followed by distilled water for 30 s, slides were then 
placed on a staining rack,  100 µL Histogene staining solution was dropped onto the 
tissue and left for 20 s. The sections were dipped into slide jars as follows: distilled 
water for 30 s, 75% ethanol for 30 s, 95% ethanol for 30 s, 100% ethanol for 30 s, 
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xylene for 5 min. Slides were placed on a kimwipe to dry in the hood for 5 min.  One 
slide at a time was removed for LCM.  The remainder were stored in a dessicator. 
 
PicoPureTM RNA Isolation Kit (Arcturus): 50 µL extraction buffer was pipetted into a 
0.5 mL microcentrifuge tube.  A macro LCM cap was inserted onto the tube using the 
insertion tool.  The cap and tube assembly was inverted and the tube tapped to ensure all 
the extraction buffer covered the surface of the cap. The assembly was incubated for 
30  min at 42°C then centrifuged at 800 x g for 2 min to collect the cell extract into the 
tube. The cap was removed and discarded.  The RNA purification column was 
preconditioned by pipetting 250 µL conditioning buffer onto the purification column 
filter membrane and incubating for 5 min.  The column was centrifuged in the provided 
tube at 16,000 x g for 1 min.  50 µL 70% ethanol was pipetted into the cell extract and 
mixed well by pipetting.  The cell extract was transferred into the purification column 
and centrifuged for 2 min at 100 x g, followed by 16,000 x g for 30 s. 100 µL wash 
buffer 1 was pipetted into the column and centrifuged for 1 min at 8,000 x g. 100 µL 
wash buffer 2 was pipetted into the column and centrifuged at 8,000 x g for 1 min. 
Another 100 µL wash buffer 2 was pipetted into the column and centrifuged for 2 min at 
16,000 x g.  The column was transferred to a new 0.5 mL tube.  11 µL elution buffer 
was placed directly onto the membrane of the column and left to incubate for 1 min then 
centrifuged for 1 min at 1,000 x g, and for 1 min at 16,000 x g to elute the RNA.  The 
sample was stored at -80 °C. 
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2.2.4.3. RNA quantification and quality 
 
Briefly, 550 µL of gel matrix was pipetted into a spin filter and centrifuged at 1,500 x g 
for 10 min. 65 µL filtered gel was aliquoted into 0.5 mL microfuge tubes.   
Preparing Gel-Dye Mix. Pico dye concentrate was allowed to equilibrate to room 
temperature for 30 min. The dye concentrate was vortexed for 10 s, spun down and 1 µL 
of dye added to a 65 µL aliquot of filtered gel. The solution was vortexed. The tube was 
centrifuged at 13,000 x g for 10 min.  
 
Loading Gel-Dye Mix.  The RNA 6000 Pico chip (Agilent)  
was placed on the chip priming station. 9.0 µL of gel-dye mix was placed in the well 
marked G.  The plunger was positioned at 1 mL and the chip priming station closed. 
The plunger was depressed until it was held by the clip. After 30 s exactly the clip was 
released. After 5 s the plunger was pulled back to the 1 mL position. The chip priming 
station was opened and 9.0 µL of gel-dye mix pipetted into the wells marked G.  
 
Loading Conditioning Solution and Marker. 9.0 µL of the Conditioning Solution was 
pipetted into the well marked CS, then 5 µL of Pico marker was pipetted into all sample 
wells and the ladder well.  
 
Loading the Ladder and Samples. 1 µL of heat denatured and aliquoted ladder was 
pipetted into the well marked ladder, then 1 µL of sample pipetted into each of the 
sample wells. The chip was placed in the adapter of the IKA vortexer and vortexed for 
1 min at 2,400 x g. The chip was run in the Agilent 2100 bioanalyser. 
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2.2.4.4. Reverse transcription 
 
 
The DNase reaction was made up in a 10 µL final volume as follows: 5x 1st strand 
buffer 2 µL, RQ1 1 µL, RNA 7 µL (up to 750 ng).  The reaction was incubated at 37oC 
for 15 min then 1 µL of stop solution added followed by incubation at 65oC for 5 min. 
0.5 µL of random primer (diluted 3:10) was added followed by incubation at 70oC for 
10 min. The samples were chilled on ice and spun down.   8.5 µL premix was made up 
as follows: 5 x 1st strand buffer 2 µL, 0.7M DTT 1 µL, 10mM dNTPs 1 µL, H2O 4.5 µL. 
The premix was added to the DNase reaction to make a total volume of 20 µL then 
incubated at 25°C for 5 min.  Superscript was diluted 1:2 and 0.5 µL added to the 
reaction followed by incubation at 25°C for 10 min, 42°C for 50 min and 70°C for 10 
min.  cDNA was diluted 1:2 to give 40 µL.  
 
 
2.2.4.5. Real time PCR 
 
 
Primers employed: GAPDH, Actin, 18S (Applied Biosystems) 
 
 
The PCR reaction was made up as follows (total 12.5 µL): TaqM® 2X universal PCR 
mastermix 3.75 µL, forward primer (5uM) 0.5 µL, reverse primer (5uM) 0.5 µL, probe 
(5uM) 0.25 µL, H2O 5.0 µL, cDNA 2.5 µL. Each sample was run in triplicate and the 
reaction run on an Applied Biosystems Real-Time PCR system. 
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2.3. RESULTS 
 
2.3.1. Choice of DNA buffer 
 
DNA may be extracted from virtually all pathological specimens and in the setting of 
molecular diagnostics, is primarily used for PCR analysis.  Standard end-point PCR is 
essentially a qualitative assay but can be semi-quantitiative.  Three different DNA 
extraction buffers were used to determine which would provide the best quality DNA 
for PCR analysis.  Surprisingly, although nanodrop analysis of DNA quantity and 
quality showed no significant distinction between the different buffers, PCR assessment 
revealed DNA extraction method A provided the strongest results. Extraction method A 
consistently gave the strongest bands in the PCR reaction from these microdissected 
samples (see Fig 2.2.). 
 
 
 
 
Figure 2.2.  Choice of extraction buffer.  Extraction of DNA from approximately 100 
microdissected renal cell carcinoma cells (samples 1-3) and normal matched controls 
(samples 4-6) using 3 different extraction buffers and methods: A, B and C (2.2.1.2.-
2.2.1.4.).  In each of the 6 sets of samples the outstanding band is A. 
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2.3.2.  DNA quality formalin fixed paraffin embedded tissues 
 
The following figure represents an investigation into the quality of DNA 
available from FFPE routine surgical specimens. 
 
2.3.2.1. Surgical specimens  
 
 
 
 
Figure 2.3.  DNA quality assessment (1).  PCR amplification employing the 
specimen control size ladder master-mix (InVivoScribe Technologies).  This primer mix 
amplifies 5 undefined sets of products of different sizes (96 bp, 198 bp, 298 bp, 399 bp 
and 499 bp) allowing assessment of the fragment lengths present in a DNA sample.   
Sample 1 - follicular lymphoma, 2 - colorectal carcinoma and 3 - renal carcinoma show 
strong PCR products up to 198 bp in length.  Samples 2 and 3 have products 298 bp in 
length, a weak band at 298 bp was identified for sample 1 and although difficult to 
visualize here weak bands at 399 bp were present for samples 2 and 3. Sample 4 - 
human blood is used as a control, this DNA is extracted fresh and amplification of 
products >500 bp in length would be expected. Sample 5 is the negative control.  
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2.3.2.2. Postmortem tissues 
 
The following figure represents an investigation into the quality of DNA 
available from FFPE post-mortem tissues. 
 
 
 
 
Figure 2.4.  DNA quality assessment (2).  PCR amplification employing the 
specimen control size ladder master-mix (InVivoScribe Technologies).  This primer mix 
amplifies 5 undefined sets of products of different sizes (96 bp, 198 bp, 298 bp, 399 bp 
and 499 bp) allowing assessment of the fragment lengths present in a DNA sample.  
Samples 1-7 were extracted from FFPE post-mortem tissues.  Samples 1 and 2 - bone 
marrow, 3-5 - bone, 6 – liver and 7 - lung show weak PCR products 298 bp in length.  
Samples 8 and 9 were DNA extracted from sections that were immunostained with 
langerin. Sample 8 showed 1 band at 96 bp and sample 9 an additional band at 198 bp. 
Sample - 10 - human blood is used as a control, this DNA is extracted fresh and 
amplification of products >500 bp in length would be expected. Sample 11 is the 
negative control.  DNA extracted from FFPE post-mortem tissue, including bony 
samples, may yield PCR fragments up to 298 bp in length. 
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2.3.2.3. Immunostained slides 
 
 
The following figure represents an investigation into the quality of DNA 
available from immunostained FFPE samples. 
 
 
 
 
Figure 2.5.  DNA quality assessment (3). PCR amplification employing the specimen 
control size ladder master-mix (InVivoScribe Technologies).  This primer mix amplifies 
5 undefined sets of products of different sizes (96 bp, 198 bp, 298 bp, 399 bp and 499 
bp) allowing assessment of the fragment lengths present in a DNA sample. DNA 
extracted from slides of a case of LCH following immunostaining (1,2,3,5,6,8) and 
without staining (4,7).  Samples 1 and 5 CD1a, samples 2 and 6 S100, samples 3 and 8 
langerin, samples 4 and 7 unstained. Sample 9 negative control. Sample 10 -human 
blood is used as a control, this DNA is extracted fresh and amplification of products 
>500 bp in length would be expected.  The unstained slides (4 and 7) achieved PCR 
products of 298 bp in length.  Amplification of the other samples was poor with only 
sample 2 achieving a PCR product of 198 bp. DNA extracted from immunostained 
slides shows weak or absent PCR amplification for this primer set. 
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2.3.3. DNA quantification 
 
Spectrophotometry may be employed to quantitate the amount of DNA or RNA in a 
sample. The sample is exposed to ultraviolet light at wavelengths of 260 nm and 
280 nm.  A photodetector measures the light that passes through the sample.  The higher 
the content of nucleic acid in the sample the greater amount of light that is absorbed.  
The reading at 260 nm allows quantification of the amount of DNA in a sample.  The 
260/280 ratio estimates the purity of the nucleic acid; a value of 1.8 represents a pure 
DNA sample and 2.0 a pure RNA sample (Glasel, 1995). The NanoDrop 2000™  
allows for the analysis of 0.5 µl - 2.0 µl samples, without the need for cuvettes or 
capillaries and as such uses much less of a precious microdissected sample.  Samples of 
laser microdissected tissue extracted by method A were quantified before and after 
clean up with the Qiaquick PCR Purification kit (samples eluted in water) (Table 2.1).  
Histogene and Eosin were added to water to determine the possible impact of dyes on 
Nanodrop quantification (Table 2.2).  
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Sample Before clean up (ng/µl) After clean up (ng/µl) 260/280 
1 211 4 2.63 
2 262 6 1.81 
3 188 8 1.52 
4 399 15 1.49 
5 274 5 1.72 
6 174 14 1.55 
7 191 9 1.47 
 
 
Table 2.1. Effect of clean up upon DNA estimation.   The results show that PCR 
product clean up is required for accurate estimation of DNA in a sample.  No 
assumptions can be made about DNA quantity in pre-cleaned up samples, for example 
sample 1 might be expected to have a greater DNA content than sample 6.  The quantity 
of DNA in these microdissected samples is typically < 10 ng/µl.  
 
 
 
% Eosin Nanodrop (ng/µl) % Histogene Nanodrop (ng/µl) 
5 219 5 45 
2.5 76 2.5 13 
1.6 27 1.6 10 
 
 
 
Table 2.2. Effect of histochemical stains upon DNA estimation.  These results relate to 
the percentage of each dye in nucleic acid free water.  The presence of Eosin and to a 
lesser extent Histogene will result in an over-estimation of DNA quantification.   
 
2.3.4. RNA quantification and quality 
 
Briefly, in an RNase free environment (2.2.4.) fresh frozen tissue was sectioned in a 
cryostat, stained and dehydrated before microdissection.  The length of time taken for 
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microdissection varied considerably between different cells of interest and tissue types.  
A rapid technique allowed better RNA preservation. RNA was extracted according to a 
standard protocol and reverse transcribed (2.4.2.2.). 
 
The Agilent 2100 Bioanalyser is a microfluidics system (Agilent Technologies, USA) 
which may be used for sizing, quantification and quality control of total RNA and 
mRNA samples.  The RNA Pico chip contains an interconnected set of microchannels 
that is used for separation of nucleic acid fragments based on their size as they are 
driven through it electrophoretically. The RNA 6000 Pico kit allows determination of 
integrity of very low amounts of RNA as well as an estimation of the amount of the 
isolated RNA (Figure 2.6).  It is possible to analyse as little as 200 pg of total RNA or 
500 pg of mRNA (www.chem.agilent.com, accessed July 2010). Many microdissected 
samples however will be too dilute for analysis with the Pico chip. 
 
The following figure demonstrates an assessment of the quality of RNA available from 
microdissected tissue.  The tissue used to illustrate this is murine kidney. 
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Figure 2.6.   Agilent RNA quality.  RNA integrity is critical for the success of 
downstream applications.  Microfluidic capillary electrophoresis with the Agilent 2100 
bioanalyser (Agilent Technologies, USA) allows visualization of 28S and 18S 
ribosomal RNA bands (rRNA). A ratio of 2 is considered to represent “intact” RNA 
although this is difficult to achieve in clinical samples (Imbeaud et al., 2005).  An 
elevated threshold baseline and a decrease in the 28S:18S ratio indicates degradation.  
A) Good quality RNA from fresh tissue - scraped slide (rRNA ratio = 1.80).  B) poor 
quality RNA from laser microdissected fresh tissue showing extensive degradation 
(rRNA ratio = 0.38) . 
 
2.3.5. QRT-PCR using cDNA from FFPE tissue	  
 
QRT-PCR is used for accurate quantification of RNA/cDNA in a given sample.  A 
specialized thermal cycler collects light emissions from a fluorescence emitter during 
the exponential PCR phase.  An oligonucleotide probe is labelled with a fluorescent 
reporter dye (FAM) at the 5’ end and a quencher dye (TAMRA) at the 3’ end.  During 
the annealing phase the probe hybridizes to the amplicon.  FAM fluorescence is 
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suppressed by its proximity to TAMRA. During the extension step the Taq DNA 
polymerase cleaves FAM from the probe and the fluorophore emissions can be 
measured.  Increased emissions are recorded with each cycle. The data is displayed as a 
plot of fluorescence (x axis) versus number of cycles (y axis).  The cycle threshold (Ct) 
defines the number of cycles it takes before the amplicons are detectable above a 
threshold significantly above background fluorescence. A good internal control by 
definition has a constant expression level across the samples set being studied. 18S, 
GAPDH and actin are highly abundant and may be used as internal controls with little 
variance in expression across treatment conditions.  
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Figure 2.7.   QRT-PCR – FFPE human ovarian tissue.  RNA was extracted from 
ovarian carcinoma tissues (2.2.4.1.), reverse transcribed (2.2.4.4.) and QRT-PCR 
performed employing the housekeeping sequences actin and 18S (2.2.4.5.). Each sample 
was run in triplicate and the reaction run on an Applied Biosystems Real-Time PCR 
system.  Each coloured line on the graph represents a sample.  The Ct value is 
calculated at the point where amplicons are detected above background fluoresence. 
Amplification of actin shows the most abundant sample to have a Ct value of around 16 
(arrowed). Amplification of 18S shows the most abundant sample to have a Ct value of 
around 18 (arrowed). The “housekeeping” sequences 18S and actin amplified in all 
samples tested. Rare messages will be much more difficult or even impossible to detect. 
 
 
2.3.6. QRT-PCR from laser microdissected fresh tissue 
 
Laser microdissected cells may be used for QRT-PCR studies to determine over or 
under-expression of candidate genes when compared with a control population.    This 
experiment demonstrates the necessity of visualizing tissue to be used for molecular 
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analysis which, surprisingly, is often not done.  Where necessary, LCM may be 
employed to exclude necrotic debris and contaminating normal cells as shown in 
Figure 2.8.  RNA was extracted from a whole 8 µm frozen section of the renal 
carcinoma and a microdissected sample comprising a relatively pure population of 
tumour cells.  The QRT-PCR target chosen was p21 as it is known to be over-expressed 
in classical renal cell carcinoma (Haitel et al., 2001). 
 
 
 
 
 
 
 
Figure 2.8.  Tissue sampling for QRT-PCR.  A) Frozen section of renal cell 
carcinoma (H&E, magnification x 4); approximately 70% of this section consists of 
necrotic tissue; there is a scattered but viable tumour cell population. The entire tissue 
section was submitted for analysis. B) Viable cells in the same section (H&E, 
magnification x 20); the tumour cells surround densely hyalinised blood vessels. 
 
Note: The quality of image A is due to the poor morphology of the frozen section and 
extensive necrosis. 
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Figure 2.9.  QRT-PCR raw data. RNA was extracted from a renal cell carcinoma 
frozen section (2.2.4.2.), reverse transcribed (2.2.4.4.) and QRT-PCR performed 
employing the sequences actin and p21 (2.2.4.5.). The amplified samples were run on an 
Applied Biosystems Real-Time PCR system.  Each coloured line on the graph 
represents a sample.  Sample 1 – 50 microdissected cells, sample 2 – 250 
microdissected cells, sample 3 – single frozen section.  The Ct value is calculated at the 
point where amplicons are detected above background fluoresence. The sequences actin 
and p21 amplified in all 3 samples.  The fewer the cycles taken to reach the Ct the 
greater the number of copies in the original specimen.  Note in sample 3 there are more 
copies of actin and p21 (black arrows) than sample 1 (yellow arrows). 
 
As illustrated above, it might be expected that there were more copies of actin and p21 
in a sample extracted from a whole tissue section (sample 3) as opposed to a small 
microdissected population (samples 1 and 2).  The relative ratio of p21/actin in each 
sample was determined.  The ratio was significantly higher in the microdissected cells 
than the whole section (Fig 2.10).  This is not surprising given that the majority of cells 
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in sample 3 have undergone necrosis or are fibroblasts, endothelial cells or smooth 
muscle cells. 
 
 
 
Figure 2.10. The relative ratio of p21/actin in the microdissected vs whole section. 
Figure based on sample 2 (250 microdissected cells) and sample 3 (whole section). 
 
Importantly these results highlight the masking effect caused by contaminating cells 
(fibroblasts, endothelial cells, smooth muscle cells, etc) and necrotic tissue when 
performing such studies on whole tissue.  In this example p21 is almost 6 x more 
abundant in the targeted microdissected sample.  Although microdissecting small 
samples creates practical difficulties, cellular purity is essential to ensure valid results 
and quality must take precedence over quantity. 
 
2.3.7. RNA amplification of laser microdissected fresh tissue 
 
The typical yield of RNA from laser microdissected cells is not enough for cDNA 
microarray analysis and therefore pg and ng samples require prior mRNA amplification.  
This is expensive and time consuming taking several days to complete.  In my 
experience few microdissected samples are of sufficient RNA quality for amplification. 
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Figure 2.11. RNA amplification of laser microdissected tissue.  Agilent bioanalyser 
electropherogram of 2 rounds of amplified mRNA.  High quality mRNA has the shape 
of a broad peak, with the majority of transcripts in the size range of 1000–4000 bases 
(sizing data not illustrated here). It is common for high quality samples to contain low 
levels of rRNA contamination although in this case no rRNA was detected.  This 
sample was of sufficient quality for cDNA microarray analysis. This result is possible 
from pg quantities of laser microdissected total RNA. 
(www.chem.agilent.com/Library/usermanuals/Public/5185-5818_v4.0.pdf) 
 
2.4. DISCUSSION 
 
DNA extraction from formalin fixed samples is straightforward and can be performed in 
just over 2 hours.  Surgical specimens typically yield fragment lengths of 400 bp 
(Figure 2.3) in keeping with the results of other investigators (Lehmann and Kreipe, 
2001).  Older post-mortem tissues show greater DNA degradation typically yielding 
fragments of 300 bp (Figure 2.4). These results also show that decalcification of bone 
and bone marrow in EDTA (samples 1-5, Figure 2.4) does not preclude DNA analysis.  
Procedures associated with IHC significantly affect DNA quality although it may be 
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possible to optimise the staining protocols to limit damage.  RNA may be extracted 
from fresh frozen tissue and be of excellent quality; however the quality of RNA 
following LCM is relatively poor despite optimisation of staining procedures (Figure 
2.6).  The length of time required to microdissect is likely to be a factor.  LCM may be 
used for cell specific gene expression analysis and is a powerful tool in combination 
with QRT-PCR.  In tissues in which there is a heterogeneous cell population it is an 
essential procedure to prevent masking of results by “contaminating” cell populations 
(Figure 2.10).  RNA from paraffin sections may be extracted and used for QRT-PCR 
although the marked degradation associated with fixation will make detection of many 
transcripts difficult and subject to bias (Figure 2.7).   
 
While DNA work is straightforward, getting good quality RNA from microdissected 
cells is extremely difficult and time consuming.  One sample in 20 may be of good 
enough quality for downstream analysis and the pg quantities extracted may only be 
enough to perform 1 triplicate QRT-PCR experiment.  Amplification of RNA for 
hybridisation to a cDNA microarray is also very time consuming and expensive and 
difficult to ensure that the reaction is linear; crucial to acquiring useful data.   The 
findings in this chapter have prompted me to choose to work only with DNA from these 
tumour specimens unless fresh frozen tissue should become available.  
 
 
 
70 
2.5. CONCLUSIONS 
These preliminary investigations were vital to establish the limitations of the tissue 
available for study and the best use of precious tumour material.  The following was 
concluded: 
 
1. DNA extraction method A appears most efficient. 
2. DNA quality from FFPE sections typically yields 300-400 bp fragments. 
3. Post-mortem material, including bony samples, may be used for PCR studies. 
4. Immunostaining  procedure causes DNA fragmentation. 
5. Histochemical stains affect DNA quantification by nanodrop methodology. 
6. QRT-PCR is possible on sections of FFPE tissue for highly abundant house-
keeping genes such as actin and GAPDH but rare messages may be difficult to 
detect. 
7. Contaminating cells mask true gene expression analysis in QRT-PCR studies, 
this issue may be largely overcome by LCM. 
8. Although technically possible, amplification of pg quantities of RNA for 
downstream analysis is difficult, expensive and time consuming. 
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3. THE X INACTIVATION ASSAY 
 
3.1. INTRODUCTION 
	  
3.1.1. Why females are mosaics 
 
 
In each female somatic cell there are two X chromosomes, one paternally (Xp) and one 
maternally derived (Xm).  In order to reach an approximately equal dosage effect of 
genes from each X chromosome, one X is inactivated in an apparently random manner.  
Most of the genes on the selected X chromosome are transcriptionally silenced by a 
series of epigenetic events which include CpG island methylation and 
accumulation/hypomethylation of histones (Brinkman et al., 2006, Valley et al., 2006).  
Each chromosome is therefore represented at approximately 50%. This process of X-
inactivation is termed lyonisation (Lyon, 1961) and like the toss of a coin the female 
population shows a Gaussian distribution for this phenomenon with small numbers of 
individuals at either end of the spectrum showing predominant inactivation of either the 
Xm or Xp. The progeny of each stem cell faithfully reproduces the inherited pattern of 
lyonisation.  
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Figure 3.1.  Lyonisation. Random X inactivation occurs in the early embryo, the 
progeny of each cell reproduces the pattern of lyonisation.   
 
3.1.2.  X chromosome inactivation 
 
X inactivation is controlled by the X inactivation centre (Xic) which is located on the X 
chromosome.  The Xic ensures that all but one X chromosome in a cell is inactivated.  
Exclusive to placental mammals the Xic contains the Xist RNA gene (Hore et al., 2007).   
This gene localises to the X chromosome selected for inactivation and triggers gene 
repression.  X-inactivation occurs early in embryonic life. One of the earliest events is 
silencing of the Xp in extra-embryonic tissues (West et al., 1977, Takagi and Sasaki, 
1975).  
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In contrast to previously held belief, it is now clear that genes may still be expressed 
from the inactivated chromosome. Carrel et al (1996) have demonstrated that up to 15% 
of genes escape inactivation. This highlights the complexity of the phenomenon and 
may explain discordant results between disease phenotype and skewed lyonisation in 
certain X-linked diseases (see below) (Edwards et al., 2007, Hore et al., 2007, Carrel et 
al., 1996). 
 
3.1.3. Skewed X chromosome inactivation 
 
Marked preference for one X chromosome is termed skewing and while there are no 
precise cut-off points for this definition a ratio of >70% expression of one allele has 
been proposed, extreme skewing may be determined at a ratio of > 80%, 90% or 95% 
(Amos-Landgraf et al., 2006, Busque et al., 2009).  Extreme skewing may happen by 
chance (Gaussian distribution), the possibility being naturally increased if the wave of 
lyonisation occurs when the stem cell population is small.  For example skewing (> 
75%) will occur 37% of the time if the number of cells present at the time of X 
inactivation is 4.  
 
Most studies examining this phenomenon have investigated peripheral blood as this is 
minimally invasive and access to other tissues is limited.  Busque et al  have shown that 
the phenomenon of skewing in the peripheral blood has a relatively low incidence in the 
neonate of 8.6% while this increases to 37.9% in women >60 years of age (Busque et al., 
1996).  Significant age related skewing in peripheral blood has been confirmed in 
numerous studies (Fey et al., 1994, Gale et al., 1997, Hatakeyama et al., 2004, 
Christensen et al., 2000, Busque et al., 2009) although reported levels of skewing vary 
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predominantly due to inconsistencies in the definition of skewing and technical 
variations. Sandovici et al investigated the peripheral blood of 178 women over 2 
decades and found no significant changes over time in X inactivation ratios.  However, 
in those women who were first sampled over the age of 60 they did find several 
individuals who acquired significant changes in X-inactivation ratios.  They concluded 
that such changes were not the result of a slow process of stem cell selection over time 
but the outcome of a sudden or catastrophic event (Sandovici et al., 2004). 
 
Numerous theories have been proposed to attempt to explain acquired skewing and it is 
likely that several or all of them have a role to play.  Skewing may occur as a secondary 
post-inactivation phenomenon, for example when a specific mutation confers a survival 
advantage to a stem cell or its progeny, or when an X chromosome carrying a particular 
gene is selected.  The theory of a genetic selection factor for skewing is supported by 
the finding that elderly monozygotic twins tend to favour the same active X 
chromosome (Christensen et al., 2000). Age related skewing may also be in part due to 
depletion of the stem cell population as suggested by several investigators (Abkowitz et 
al., 1988, Gale et al., 1997, Champion et al., 1997). The concept of a slow genetically 
based selection process, however, is at odds with the findings of Sandovici et al 
(Sandovici et al., 2004) and recipients of bone marrow transplants, who accordingly 
have a small number of the donors stem cells, usually show balanced X chromosome 
inactivation (Tonon et al., 1998).  
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 3.1.3.1. Possible mechanisms of skewing 
 
The following mechanisms have been proposed to explain the phenomenon of 
constitutional (i) and acquired skewing (ii-iv). 
 
i) Genetic predisposition (Naumova et al., 1998, Kristiansen et al., 2005, 
Plenge et al., 1997). 
ii) Stem cell loss (Abkowitz et al., 1988, Champion et al., 1997, Gale et al., 
1997). 
iii) Mutation or a gene conferring a survival advantage or disadvantage 
(Sandovici et al., 2004, Knudsen et al., 2007). 
iv) Loss of methylation giving impression of skewing (Hatakeyama et al., 2004, 
Lopatina et al., 2002). 
 
Extreme skewing can be protective in regard to certain X-linked disorders.  For example, 
in Wiskott-Aldrich syndrome  extreme skewing may be seen in favour of the normal 
allele;  in cell lineages affected by the disorder the active X is the one that carries the 
normal allele (Fearon et al., 1988). Unbalanced X inactivation may have negative 
consequences in female carriers of conditions such as Duchenne muscular dystrophy. 
These unfortunate patients manifest variable phenotypes including progressive 
myopathy (Yoshioka et al., 1998).  Skewed X-inactivation may have more general and 
wide reaching implications and has been found at a greater incidence in young women 
with breast cancer.  The role of acquired or chance skewing as a risk factor for 
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malignancy in apparently normal females is currently under investigation (Medema and 
Burgering, 2007).   
 
3.1.4. Timing of X inactivation 
 
Tan et al (Tan et al., 1993) investigated different tissues of the post-implantation mouse 
embryo which carried an X-linked lacZ transgene.  Inactivation of this transgene led to 
loss of β-galactosidase activity allowing identification of X inactivation.  The brain and 
somite completed X inactivation by 8.5 days post-coitum (dpc) but the notochord, heart, 
gut and cranial mesenchyme completed later on 11.5dpc.  This data suggests that 
different tissues of the embryo may have lineage-specific timing for the initiation of the 
inactivation process. Alternatively in those tissues that completed activation later this 
may be explained by slower progression of methylation.  Indeed methylation appears to 
occur in a wave with studies showing that genes closer to X chromosome controlling 
element (Xce) are methylated ahead of those further away (Figure 3.2). 
 
 
 
Figure 3.2.  Progression of methylation. The phosphoglycerate kinase (PGK) gene, 
closest to Xce, is methylated before the glucose-6-phosphate dehydrogenase (G6PDH) 
gene (Grant et al., 1992) which is methylated before the hypoxanthine-guanine 
phosphoribosyltransferase (HPRT) gene (Lock et al., 1987). 
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A subsequent and conflicting study investigating female mouse embryos bearing the 
T(X;16)16H translocation and heterozygous for HPRT and PGK-1 showed that X 
inactivation was complete for these genes on 9.5 dpc as no transcripts were found from 
the normal X chromosome (Lebon et al., 1995). 
 
If X inactivation occurred before cells committed to specific lineages then all tissues 
would have a similar X inactivation ratios. The data in this area is limited by the 
difficulty in obtaining multiple tissues from the same individual for study.  Busque et al 
(1996) found that on reanalysing previous studies (Fialkow, 1973)  similar skewing 
ratios were found for blood and skin suggesting that they arise from a  comparable 
number of stem cells and that lyonisation occurs before stem cells commit to tissue 
lineages. Some studies however have shown varying patterns of inactivation in different 
tissues of the same individual (Knudsen et al., 2007, Gale et al., 1994, Sharp et al., 
2000).   A study of patterns of lyonisation in a range of tissues in the neonate would 
provide useful data as it eliminates the complication of age related skewing. 
 
3.1.5. Clonality analysis  
 
A clone is a population of cells derived from a single somatic cell progenitor.  A tumour 
is similarly a clonal cell population but derived from a progenitor which has undergone 
a mutation or series of mutational events (Wainscoat and Fey, 1990).  Tumours are 
represented by a dynamic and evolving population from which new subclones may 
emerge from daughter cells which have gained a proliferative advantage.  Histological 
examination of tumours illustrates this heterogeneity with different regions of the same 
tumour displaying a variety of features.  These may include variation in architecture 
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such as an admixture of solid and glandular patterns, mild to severe cytological atypical 
and variation in expression of immunomarkers.  Similarly clones within a tumour will 
have different proliferative and metastatic capabilities with a dominant subclone often 
taking precedence (Fidler and Kripke, 1977).   
 
Different methodologies may be applied to assess the relationship between multifocal 
tumours.  For example multiple tumour nodules within the liver associated with clonal 
p53 mutations are likely to indicate a common origin with subsequent spread rather than 
multiple independent tumours (Oda et al., 1992).  Similarly identical T-cell receptor or 
IgH gene rearrangements imply a common origin for a lymphoid neoplasm which has 
progressed and may appear histologically very different from the original presenting 
tumour.  Where specific mutations which act as genetic markers are unknown, clonal 
analysis must depend on phenotypic assays where genes are not mutated but 
differentially expressed.  This includes studies such as X chromosome inactivation 
patterns and flow cytometry to detect abnormally expressed genes (Chen and Prchal, 
2007). 
 
Clonal X inactivation analysis has been described as an early and stable marker of 
clonality independent of later genetic events (Fey et al., 1992, Jones, 1996).  For 
example variations in loss of heterozygosity may occur in a tumour or tumours which 
are still clonally related but the pattern of X inactivation will remain constant.  In one 
study, geographically distinct gastric tumours were examined for X inactivation patterns 
and LOH.  These showed uniformity in inactivation patterns but marked variability in 
LOH in a given tumour (Nagel et al., 1995). 
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There are various assays based on polymorphisms at different loci on the X 
chromosome.  Gene expression (Prchal and Guan, 1993) or protein analysis (Linder and 
Gartler, 1965) may be employed as only the active X chromosome (Xa) will be 
translated/transcribed.  Alternatively clonal analysis may be based on changes in 
methylation patterns (Vogelstein et al., 1985) that occur when the X chromosome is 
inactivated.  There are several highly polymorphic loci at which this may be achieved, 
including PGK, (Shan et al., 1997, Gong et al., 2007) HPRT (Park and Chapman, 1994) 
and the HUMAR (Gong et al., 2007, Allen et al., 1992) (see Figure 3.2).   
 
Errors in interpreting X-chromosome inactivation patterns may arise from inherent 
skewing in the cell population of interest (mechanisms outlined in 3.1.3.), this is 
particularly important in the haematopoietic system where age related skewing is well 
documented and clonality may be used to define the pathology.  Other potential pitfalls 
in interpretation include incomplete digestion by methylation sensitive enzymes, or at 
the PCR stage, where allelic fragments of different sizes will amplify with different 
efficiencies (see 3.1.5.2.).   
 
In solid organs the progeny of a single stem cell will lie in a group or “patch”.   A larger 
patch will result if adjacent stem cells have the same inactivation pattern (Tsai et al., 
1996, Chaturvedi et al., 2002).  Clearly, if only the cells within a patch are submitted for 
X chromosome inactivation studies, a normal population will yield a monoclonal result.  
Studies employing G6PD staining patterns under direct visualisation have been 
employed to investigate patch size in a variety of human tissues including breast, 
 
 
80 
thyroid and colon (Novelli et al., 2003).  One study has shown the patch size of the 
normal human thyroid gland to be very large, however the authors point out that the 
gland is a small organ arising from a tiny submandibular analge (therefore likely to have 
few contributing stem cells).  Similarly the same may be true of other small endocrine 
organs such as the pituitary (Jovanovic et al., 2003).  The liver by contrast is the largest 
organ in the body and one study employing the HUMAR assay has estimated the patch 
size to be in the region of 1.10 mm2 (Toshiya, 1999).  Information of patch size in other 
solid organs is extremely limited. 
 
3.1.5.1 Methylation based assays of X inactivation 
 
Using assays which rely on the methylation of a gene is an indirect methodology to 
determine X inactivation patterns.  Of note, methylation has been shown to be lost in 
mice (Singhal et al., 1987) and immortalised fibroblasts (Lopatina et al., 2002) with 
aging.  As highlighted by Hatakeyama et al, in an individual who has the Xm and Xp 
represented equally at 50%, loss of methylation or reactivation of only one X 
chromosome could lead to the appearance of extreme skewing (Hatakeyama et al., 
2004) (Figure 3.3). 
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Figure 3.3.  Possible impact of aging on methylation based assays. A) A balanced 
pattern of X inactivation with each AR represented at 50%.  In the HUMAR assay only 
the methylated (undigested) gene will be amplified (red).  B) If aging is associated with 
loss of methylation of only one of the X chromosomes (in this case Xp) then the  
HUMAR assay will show 100% skewing as only AR Xm will amplify (red).  
 
Swierczek et al (2008) investigated this possibility of epigenetic dysregulation as an 
explanation for the skewing seen in the blood of aging females.  A quantitative 
transcriptionally based PCR clonality assay found no evidence of skewing in 40 normal 
elderly females.  The HUMAR assay showed 30% skewing in the same cohort.  They 
therefore concluded that the HUMAR assay was unsuitable for evaluating clonal 
haematopoiesis in elderly females.  In response, Busque et al (2009) undertook a larger 
study employing the HUMAR assay, a TaqMan single nucleotide polymorphism assay 
and a quantitative transcriptionally based PCR assay. The assays showed similar 
skewing ratios (42%, 38% and 40% respectively) and highly concordant X inactivation 
ratios.  Their findings suggest that the HUMAR assay is as robust a technique as the 
quantitative transcriptional assay and that potential loss of methylation with aging may 
 
 
82 
not be a significant contributing factor to the skewing results seen in the literature 
(Busque, Paquette et al. 2009). 
 
 3.1.5.2. The human androgen receptor assay 
 
This PCR assay identifies differential methylation of a CpG site which lies close to a 
highly polymorphic CAG repeat region within the first exon of the HUMAR gene (Allen 
et al., 1992). In informative females the CAG repeat sequences may vary by 1 (3bp) – 
>20 (60bp) repeats. The methylation sensitive enzyme HpaII digests the unmethylated 
active X so that following the digestion step only the AR on the inactive X is available 
for amplification.  One large study (n>1000) has demonstrated 92% of females are 
informative (Amos-Landgraf et al., 2006). 
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Figure 3.4.  Diagramatic representation of the rationale of the HUMAR assay.  In 
cases where females are informative (heterozygous for CAG repeat sequences in the 
first exon for the HUMAR gene), amplification of pre-digested DNA results in 2 peaks 
(one representing the maternal HUMAR and the other the paternal HUMAR).  Post-
digestion with HpaII only the methylated allele is available for amplification. In a 
polyclonal population of cells (A) 2 peaks will still be seen but in a monocloncal 
population of cells (B) only 1 peak will be identified following amplification of digested 
DNA.  
 
Sharp (unpublished data, personal communication) used plasmids of differing HUMAR 
clone length to investigate the impact of different lengths of the CAG repeat sequence 
on the rate of formation of products in the PCR reaction. As expected, as the length of 
the CAG repeat sequence increased, the peak area of the fluorescently labelled product 
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fell.  The decrease in peak area was proportional to the increase in the length of the 
CAG repeat.  Any bias in allele amplification may be corrected for using relative 
amplification measured from the undigested sample (Hatakeyama et al., 2004).   
 
Ratio = (D1/U1) / (D1/U1 + D2/U2) 
 
D1 and D2 represent the two peak areas from the digested sample where D1 is the 
shorter allele and D2 the longer allele, U1 and U2 are the corresponding bands in the 
undigested sample.   
 
3.1.6. Aims 
 
To explore the X inactivation assay using multiple tissues from the same individual.  
This will allow a unique insight into variations in inactivation ratios across normal 
tissues and will thereby be informative when performing the assay to establish clonality 
in putative lesions of LCH and LC proliferations.  As these studies will include a range 
of tissues as yet untested in the literature they may also provide some evidence to 
indicate the timing of X inactivation in the embryo. 
 
3.2. METHODS 
 
A complete list of materials with source and catalogue number is given in Appendix A. 
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3.2.1. Ethical approval 
 
Permission to do undertake the study was granted by the committee of the Tayside 
Tissue and Tumour Bank, Ninewells Hospital. 
 
3.2.2. Case selection 
 
 
Samples were selected from post-mortems completed in the last 5 years.  The standard 
post-mortem consent includes permission for the tissue blocks to be used for research 
purposes.  In total 30 cases were collected.  Tissues studied were standard blocks of 
heart, lung, liver, spleen and kidney.  The control case was a female carrier of X-linked 
retinitis pigmentosa; a clinical case referred to the department of Human Genetics, 
Ninewells Hospital and Medical School, Dundee. 
 
3.2.3. DNA extraction and clean up 
 
 
The lysis buffer from method A was employed (2.2.1.2.) and samples cleaned up 
according to the manufacturer’s standard protocol (2.2.3.1.).    
 
3.2.4. Restriction enzyme digestion 
 
 
A 10 µL digest reaction was set up as follows: 8 µL DNA (up to 800 ng), 1 µL buffer I, 
1µL Hpa II enzyme. The mix was incubated at 37°C for 16 hours.  Next the enzyme was 
inactivated by incubating the samples at 95°C for 10 min.  The digest reactions were 
then cleaned up (2.2.3.1). 
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3.2.5. HUMAR assay/PCR 
 
 
HUMAR- F (forward primer)  5’ - gct gtg aag gtt gct gtt cct cat – 3’ 
HUMAR- R-FAM (reverse primer) 5’ - tcc aga atc tgt tcc aga gcg tgc – 3’ 
Primers were diluted to a working stock of 5 µM in molecular biology grade water. 
 
The following mastermix was made up: 2 µL forward primer, 2 µL reverse primer, 2 µL 
10 x buffer, 2 µL dntps, 9.9 µL H2O, 0.1 µL HotStarTaq, 2 µL DNA.  
 
Cycling conditions:  1 cycle of 95°C for 15 min, 40 cycles of 94°C for 45 s, 55°C for 30 
s, 72°C for 30 s. 
 
The products were run on the ABI 3130XL bioanalyser (Applied Biosystems) against 
the GS500 ROX size standard (Applied biosystems).  ROX is designed for sizing DNA 
fragments in the 35-500 bp range, and includes 16 single-stranded fragments of 35, 50, 
75, 100, 139, 150, 160, 200, 250, 300, 340, 350, 400, 450, 490, and 500 bps. It allows 
very precise sizing of DNA fragments by electrophoresis.  
 
The following mix was made up: 1 µL PCR product with 0.5 µL GS500 ROX size 
standard and 8.5 µL deionised formamide.  The samples were denatured in a heat block 
at 95°C for 2  min and chilled on ice before loading. 
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3.3. RESULTS 
3.3.1. Sensitivity of PCR reaction 
 
 
Increasing amounts of DNA were used in the assay. The results show that 10 ng of good 
quality input DNA is sufficient to view a band on agarose gel electrophoresis and the 
reaction works across a wide Mg2+ concentration range (25-43.75 µM) (Figure 3.5). 
 
 
 
 
	  
Figure 3.5.  Sensitivity of PCR reaction. A) 10ng of input DNA is sufficient for the 
HUMAR assay, B) The assay works over a wide range of Mg2+ concentration (25 µM). 
 
3.3.2. Enzyme digestion control 
	  
A suitable control is required to ensure adequate enzyme digestion.  The control in this 
study is a heterozygous carrier for X-linked retinitis pigmentosa.  The patient presented 
with progressive visual impairment.   
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Figure 3.6.  HUMAR assay images, ABI 3100 Genetic Analyzer - control case. This 
female is informative (heterozygous for CAG repeat sequences in the first exon for the 
HUMAR gene), amplification of pre-digested DNA (A) results in 2 peaks (one 
representing the maternal HUMAR and the other the paternal HUMAR).  Post-digestion 
(B) there is only a very small peak for the first allele.  This female shows extreme 
skewing towards 1 X chromosome.  The degree of skewing is calculated below. 
 
Skewing ratio  (see 3.1.5.2)   = (D1/U1) / (D1/U1 + D2/U2)   
                          = (2924/56838) / (2924/56838 + 57129/26840) 
                          = 0.023 
Expressed as a percentage           2% 
 
 
The results of the HUMAR assay (peripheral blood) demonstrate that expression of the 
disease phenotype is due to extreme skewing, with the X chromosome bearing the 
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mutated gene active in most cells (98%).  This finding is in keeping with a study which 
has shown extreme skewing in blind female carriers (Friedrich et al., 1993). 
 
3.3.3. Assay results 
 
 
All 30 sets of tissues were reviewed histologically to confirm the absence of significant 
pathology and determine sample purity. The heart samples from all individuals in the 
study were submitted for initial analysis to determine which individuals were 
informative for the assay.  13/30 individuals were heterozygous for the HUMAR 
(informative) (Figure 3.7.), 3/30 were homozygous (not informative) and 14/30 had un-
interpretable results or failed due to poor DNA quality.  
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The following figure illustrates the results of the HUMAR assay on the hearts of four 
females.  The results show that each female (A-D) is informative for the assay.  
 
 
 
Figure 3.7.  HUMAR assay images, ABI 3100 Genetic Analyzer - post-mortem hearts. 
Samples A-D each represent amplified DNA from post-mortem hearts. All females are 
informative (heterozygous for CAG repeat sequences in the first exon for the HUMAR 
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gene).  Amplification of pre-digested DNA (A-D) results in 2 peaks (one representing 
the maternal HUMAR and the other the paternal HUMAR).  
The following table gives the HUMAR assay data for the post-mortem study.  It includes 
the allele sizes for the maternal and paternal products, the peak areas for undigested (U1 
and U2) and digested (D1 and D2) samples and the ratio of each X chromosome in a 
given  tissue (PR). 
 Code Organ Allele sizes U1 U2 
 
D1 
 
D2 PR 
Heart 267/275 30514 24501 16254 12258 52/48 
Lung 267/275 50570 37465 9477 9517 42/58 
Liver 267/275 12951 11129 30309 29096 47/53 
Kidney 267/275 37220 25665 33111 33823 40/60 
 
19 
 
Spleen 267/275 45546 33913 50907 42873 47/53 
Heart 267/283 10863 5320 67662 33717 50/50 
Lung 267/283 37242 25942 39330 22264 55/45 
Liver 267/283 14223 8145 67682 39317 50/50 
Kidney 267/283 34455 23031 2805 1884 50/50 
 
20 
 
Spleen 267/283 20674 13411 50262 43580 43/57 
Heart 267/275 31296 20076 11579 4243 64/36 
Lung 267/275 18914 12397 11142 13118 36/64 
Liver 267/275 56875 50158 32360 17360 62/38 
Kidney 267/275 23015 20447 41003 17177 68/22 
 
6 
 
Spleen 267/275 33722 22768 30684 34958 37/63 
Heart 272/278 34041 34567 30569 29287 52/48 
Lung 272/278 36536 32097 41744 33447 52/48 
Liver 272/278 14273 10725 29817 23634 49/51 
Kidney 272/278 9777 8042 42893 33547 51/49 
 
21 
 
Spleen 272/278 7382 6269 37076 31711 50/50 
Heart 278/286 23136 16134 30094 21698 49/51 
Lung 278/286 26845 19298 37605 16199 63/37 
Liver 278/286 19715 8114 48941 13698 59/41 
Kidney 278/286 32822 23889 5250 3723 51/49 
 
14 
 
Spleen 278/286 38690 22726 41723 14628 63/37 
Heart 275/311 61790 17730 51170 16636 47/53 
Lung 275/311 98715 45250 29336 9511 59/61 
Liver 275/311 42369 8091 12484 2401 50/50 
Kidney 275/311 36584 3589 12047 1751 60/40 
 
11 
 
Spleen 275/311 18775 3509 10973 3103 40/60 
Heart 275/283 5534 3978 62303 21890 67/33 
Lung 275/283 31070 23522 15860 15961 43/57 
Liver 275/283 79295 13981 13572 18466 11/89 
Kidney 275/283 12231 6598 54999 54452 35/65 
 
12 
 
Spleen 275/283 16710 6524 14271 24626 18/82 
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 Code Organ Allele sizes U1 U2 
 
D1 
 
D2 PR 
Heart 237/281 9299 2938 18712 17114 26/74 
Lung 237/281 23734 8485 47464 11324 60/40 
Kidney 237/281 19931 6358 21119 3012 69/31 
 
16 
 
Spleen 237/281 44803 13021 9149 1700 61/39 
Heart 275/286 9850 6743 FAIL   
Lung 275/286 15421 11671 6987 1840 74/26 
Liver 275/286 53088 28329 11973 2734 70/30 
 
15 
 Kidney 275/286 7663 5564 29886 8708 71/29 
1 Spleen 273/281 11310 9204 7388 1062 85/15 
Heart 262/272 34059 16572 12234 10571 36/64 
Lung 262/272 49970 27378 21007 7529 60/40 
Liver 262/272 14997 12145 6662 2202 71/29 
 
8 
 
Kidney 262/272 14965 8434 17729 15029 40/60 
Heart 275/283 19679 11587 8068 3418 58/42 
Lung 275/283 32762 22131 5467 4973 43/57 
Liver 275/283 19507 12468 4688 17297 15/85 
Kidney 275/283 14504 8633 3191 2442 44/56 
 
10 
 
Spleen 275/283 24895 20880 1230 2804 27/73 
Heart 277/288 29774 13595 3829 662 72/28 
Lung 277/288 12433 7488 4775 2218 56/44 
Liver 277/288 5554 2760 7043 617 85/15 
Kidney 277/288 18090 11133 2751 2701 39/61 
 
29 
 
Spleen 277/288 13433 8223 FAIL   
 
 
 
Table 3.1. Raw data HUMAR assay post-mortem tissuses.  Peak areas pre-digestion 
(U1, U2) and post-digestion (D1, D2) as specified by ABI 3100 Genetic Analyzer 
software for each organ and percentage ratios (PR). Skewed results (>80% dominance 
of one allele) in bold.  Number of individuals: 13;  number of organs tested: 56;  
number of skewed results: 5 in 4 individuals;  skewing identified in: liver x 3 (n=11), 
spleen x 2 (n=10).  No skewing identified in: heart (n=10), lung (n=12) or kidney 
(n=12). 
 
 
 
93 
The following table defines the range of X inactivation ratios for the females with 
results for 4 or more organs. 
Case Age Mean StDev  1 StDev 
19 82 45.6 4.7 
 
40.9-50.3 
20 68 49.6 4.3 
 
45.3-53.9 
6 64 53.4 15.6 
 
37.8-69.0 
21 82 50.8 1.3 
 
49.5-52.1 
14 60 57.0 6.6 
 
50.4-63.6 
11 62 51.2 8.4 
 
42.8-59.6 
12 87 34.8 22.1 
 
12.7-56.9 
16 66 54.0 19.1 
 
34.9-73.1 
8 69 51.7 16.6 
 
35.1-68.3 
10 76 37.4 16.6 
 
20.8-54 
29 74 63.0 19.9 
 
43.1-82.9 
 
Table 3.2. Descriptive statistics X inactivation study of post-mortem tissues.  Mean 
value of the first X chromosome in individuals with 4 or more organs examined range: 
34.8-63.0.  SD in individuals with 4 or more organs examined - range: 1.3-22.1.  
Number of females with no results >1StDev from the mean: 1 (case 21).  Number of 
females with 1 result >1 StDev from the mean: 3. Number of females with 2 results >1 
StDev from the mean: 7 
 
3.4. DISCUSSION 
 
 
A significant number of cases (46%) failed due to poor DNA quality that yielded either 
no/un-interpretable results.  The initial sample population included female foetuses 
(n=7) and women over the age of 60 years (age range 60-87, n=23).  No foetal tissue is 
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included in these results due to poor DNA quality and in 2 cases results yielded 3 allelic 
peaks.  The reason for poor foetal material is likely due to a history of intra-uterine 
death associated with a delay in post-mortem and subsequent DNA degradation.  In the 
cases with 3 allelic peaks the possibility of a chromosomal disorder should be 
considered.  Similarly many of the adult tissues failed to amplify.   A possible reason is 
prolonged tissue fixation; the length of formalin steeping can be extremely variable in 
post-mortem cases and is generally significantly longer than for surgical specimens.  
Some post-mortems are delayed several days for a variety of reasons and degradation 
may occur more rapidly in some tissues than others. When amplification was successful 
in one tissue, most of the other tissues from that individual yielded results.   
 
Of the 13 females with results, 4 had 1 or more tissues which showed marked skewing 
(>80%).  Skewing was identified in the spleen in 2/10 (20%) females.  This result is to 
be expected as the spleen may be regarded as broadly comparable to the peripheral 
blood which has been variably reported to show skewing in 20-42 % of females (Fey et 
al., 1994, Hatakeyama et al., 2004, Busque et al., 2009). 
  
This study reveals the first cases of skewing identified in the liver of elderly females 
with 3/11 (27%) displaying this phenomenon.  Again this result is not entirely 
unexpected as the liver comprises a stable cell population with remarkable regenerative 
capability in response to injury. One female in this study showed skewing in both the 
liver and spleen, the skewing was in the same direction (favouring the same parental X).  
This correlates with monozygotic twin studies in which with advanced age there was a 
strong tendency for the same cell line to predominate in each pair (Christensen et al., 
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2000).  Other studies have investigated X inactivation patterns in different (accessible) 
tissues of the same individual. Sharp et al looked at blood, buccal and urinary epithelia 
in 2 groups of females (aged ≤ 25yrs and ≥ 60 yrs) and found that there was a 
significant association between the inactivation ratios of the tissues in the young and 
elderly but that this diminished with age.  In addition, particularly in the older 
population, extreme skewing in one, two or all three tissues was an occasional event. No 
individuals showed extreme skewing in opposite directions (Sharp et al., 2000). Another 
group investigated patterns in blood, skin, muscle and colon with similar results. In 6 of 
11 patients (55%) with a skewed pattern in the blood, there was no skewing in the skin 
(Gale et al., 1994).  An investigation of inactivation ratios in blood, buccal cells and 
duodenal biopsies in 80 females (19-90 yrs) showed good correlation of X inactivation 
in all tissues, this correlation increasing with age for blood but also buccal cells. No 
duodenal biopsies showed skewing.  Again there was a tendency for the same X 
chromosome to be the preferentially active X in both blood and buccal cells (Knudsen et 
al., 2007). Of further note in Case 10 there was skewing of 85% in the liver and a shift 
towards skewing favouring the same parental X in the spleen (75%).  A larger study to 
look for a positive correlation between spleen and liver may be of value. 
 
Although the aetiology of non-random X inactivation is not yet understood the findings 
of this study and those outlined above would support the theories of either stem cell 
senescence or a growth advantage conferred by a parental specific X chromosome.  
Further support to this is given by the absence of skewing in the lung, kidney and heart, 
organs which show little or no regeneration. In this study 3/11 females had 1 result >1 
standard deviation from the mean and 7/11 had 2 results >1 standard deviation from the 
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mean.  This is further evidence that inactivation ratios within different tissues of an 
individual can be markedly variable and therefore data regarding the inactivation status 
of one tissue cannot be used to make assumptions about another tissue in the same 
individual.  A more comprehensive study is required to look at permanent, stable and 
labile tissues in both foetuses and elderly women in order to gain an insight into the 
possible mechanisms of age-related skewing. 
 
In this study sections were examined histologically to exclude significant pathologies 
such as scarring or a lymphoid infiltrate.  Each block was selected to provide as pure a 
sample as possible.  When investigating X inactivation ratios in normal tissues a 
significant background population of cells from a different lineage may render the 
results meaningless. Studies of duodenum (Knudsen et al., 2007) and colon (Gale et al., 
1994) would include both lymphoid and epithelial populations and as such would be un-
interpretable.  Similarly problematic is the assessment of tumours for monoclonality.  
For example, if an individual who is constitutionally skewed in favour of an active Xp 
develops a tumour in which Xm is active, and there is less than 90% tumour purity 
within the tissue sample analysed, then results of the HUMAR assay could show 
inactivation ratios well below 10 making interpretation extremely difficult.    To solve 
these issues, pure populations of tumour or benign cells of interest may be isolated by 
LCM. A homologous or embryologically related normal tissue control to identify age 
related or constitutional skewing would allow the most informed assay interpretation 
although unfortunately such material is rarely available.  
 
 
3.5. CONCLUSIONS  
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These preliminary investigations were vital to establish the limitations of the tissue 
available for study. This study has provided useful insights into the HUMAR assay and 
the variations in the balance of X inactivation ratios between individuals.  It also 
highlights the often poor DNA quality of FFPE samples.  The principal conclusions are 
defined as: 
 
 
1. In a significant number of cases post-mortem material was not of suitable 
quality for HUMAR analysis. 
2. Skewing was identified in the spleen and liver only. 
3. Assays for clonality (particularly in the elderly) in the peripheral blood, liver 
and spleen must take into account the possibility of age related skewing. 
4. A wide range of X inactivation ratios were identified in multiple tissues of 
some females though not in others. Such variability would be more in keeping 
with X inactivation occurring following the establishment of organ specific 
stem cells. 
5. It is clear that in studies to identify monoclonality, if control tissue of the same 
lineage is not available, the importance of sample purity cannot be 
overemphasized.   
 
3.6. FUTURE WORK 
 
There is very little in the literature looking at X inactivation in solid organs. This study 
should therefore be expanded to include a greater number of individuals and tissues.  
Ideally this would include a large foetal/neonatal population.  Such a study would 
provide an important insight into the timing of X inactivation as well as the 
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phenomenon of age related skewing.  This is a fascinating area of research with many 
unanswered questions.  The female is undoubtedly at an advantage as a mosaic but 
unbalanced X inactivation may be protective or detrimental and the implications of age-
related skewing are as yet unknown. 
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4. LANGERHANS CELL HISTIOCYTOSIS IN ASSOCIATION WITH OTHER 
LYMPHOPROLIFERATIVE DISORDERS 
 
4.1. INTRODUCTION  
 
 
4.1.1. LCH in association with other lymphoproliferative disorders 
 
As well as the characteristic clinical presentations described in chapter 1 (1.1.4), LCH 
has been described in association with a variety of other tumour types, preceding, after, 
or synchronous with the other tumour. The most common associations are with 
lymphoma and leukaemia (Neumann and Frizzera, 1986, Egeler et al., 1993, Egeler et al., 
1998). The treatment of LCH, which includes chemotherapy and radiotherapy, may play a 
role in eliciting a secondary neoplasm and, in particular, may promote the later 
development of acute non-lymphoblastic leukaemia (Egeler et al., 1998). However, in 
other instances, abnormal proliferations of LCs histologically indistinguishable from 
true LCH may be seen concurrently with a malignancy. These lesions often present 
as single small foci within or lying adjacent to the neoplasm and have been described in 
association with a number of solid tumours including thyroid carcinoma (Macak and 
Michal, 1993) and basal cell carcinoma (Izikson et al., 2004).  Cases of LCH in lymph 
nodes draining a malignant neoplasm have also been reported (Richmond et al., 1995, 
Schofield et al., 1992). The most common synchronous association, however, appears to 
be with malignant lymphoma in which the LC infiltrate may be present in more than 
1  lymph node (Quintanilla-Martinez et al., 1992). Sequential lymphomas with a 
nodular LC infiltrate have also been reported (Adu-Poku et al., 2005). It is possible that, in 
some instances, the presence of dual pathology is coincidental and both are true 
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neoplasms; however, the lack of evidence for LCH elsewhere or indeed progression is most 
supportive of an exaggerated reactive phenomenon.  
 
Type of neoplasm After Concurrent Precedeing 
Malignant lymphoma (n=39) 11 (28%) 24 (61%) 4 (10%) 
Leukaemia (n=22) 2 (9%) 6 (27%) 14 (64%) 
Lung carcinoma (n=12) 1 (8%) 9 (75%) 2 (17%) 
Solid tumour (n=18) 2 (11%) 2 (11%) 14 (78%) 
 
Table 4.1. Temporal relationship between LCH and other neoplasms (Egeler et al., 
1993).  
 
4.1.2. Possible pathogenetic mechanisms at work   
 
 
In some cases where a second malignancy develops after LCH this may be a therapy 
related process, particularly with examples of leukaemia following LCH.  Alternatively 
a common progenitor may explain a second malignancy; for example the same 
immunoglobulin heavy chain (IgH) rearrangement has been identified in concurrent 
LCH and follicular lymphoma (Magni et al., 2002). In two separate examples of LCH 
following T-ALL the  same T-cell receptor (TCR) rearrangement in both the T-ALL & 
LCH was identified in each case (Feldman et al., 2005).  This raises the possibility that 
both lesions arose from a common stem cell or that there was lineage switching in a 
single neoplasm.  In some examples, however, we see both lesions present in the same 
tissue at the same time and it may be possible that LCs are part of a host response to the 
other neoplasm rather than a second malignancy. 
 
 
101 
 
4.1.3. Aim 
 
To use the HUMAR assay to determine whether LCH-like lesions seen in association 
with other lymphoproliferations are true neoplasms exhibiting monoclonality or a 
polyclonal reactive phenomenon.  As this distinction could have therapeutic implications 
it is important to establish the biological nature of these lesions.  Specifically, if the LCH 
(like) lesion is a potentially aggressive 2nd neoplasm it may require chemotherapy 
whereas if it were a benign reactive process, treatment would only be necessary for the 
associated lesion.  
 
 4.1.3.1. Test cases and control tissues 
 
Five cases of LCH-like proliferations occurring in the context of other 
lymphoproliferative disorders, of which 4 were neoplasms and 1 was a reactive condition.    
Two of the cases were female and the HUMAR assay could be employed to determine 
whether the infiltrate of LCs was clonally restricted. A case of isolated nodal LCH 
provided suitable control material. Two of these cases (5 and 6) are discussed in more 
detail in Chapter 6. 
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4.1.4. Case presentations 
 
 
 4.1.4.1. Case 1 
 
 
A 58-year-old man was admitted for investigation of progressive weight loss, poor 
appetite and lethargy. A diagnosis of idiopathic aplastic anaemia was made. He re-
presented 5 months later with an enlarged right-sided cervical lymph node. Biopsy 
showed a T-cell lymphoblastic lymphoma (T-LL) associated with small foci of LCH. 
He was treated with CHOP (cyclophosphamide, hydroxydaunorubicin, oncovin, 
prednisolone) and 3-monthly pulses of vincristine and prednisolone together with oral 
methotrexate and mercaptopurine. One year later he developed very rapid progression 
of his lymphadenopathy with nodes in the groin, axilla, and submandibular region. He 
underwent a further course of chemotherapy but died 5 months later. 
 
 4.1.4.2. Case 2 
 
This case of nodal Hodgkin’s lymphoma associated with LCH in a 52-year-old woman 
has been already been published (Adu-Poku et al., 2005). She developed a classical 
Hodgkin lymphoma affecting the right groin and four years later a high grade follicular 
lymphoma of the nasopharynx and breast.  Both neoplasms included small foci 
described as LCH.  
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 4.1.4.3. Case 3 
 
 
A 52-year-old woman presented with a 5-month history of a nodule on her forehead. 
This was excised and diagnosed as a cutaneous B-cell pseudolymphoma which included 
a prominent infiltrate of LCs. No further treatment was given.  A red nodule was also 
noted on her left cheek, and this was said to have been present for approximately 
20 years. The lesion on the cheek persisted without change and the wound on the 
forehead healed completely without signs of a recurrent lesion. The patient has reported 
no further skin lesions and was alive and well when last seen 18 months after 
presentation. 
 
 4.1.4.4. Case 4 
 
 
The following case of nodal LCH was used as a control.  A 60-year-old woman with a 
medical history of duodenal ulceration and peripheral vascular disease presented with 
an enlarged right-sided jugulo-digastric lymph node. This was excised and a diagnosis 
of LCH made but no further treatment was given. The patient subsequently developed 
papillary transitional cell carcinoma of the bladder and adenocarcinoma of the cervix 
but was free of LCH with no history of relapse 54 months after diagnosis. 
 
 4.1.4.5. Case 5 
 
 
This case is described in more detail in Chapter 6.  This man presented at age 57 with 
ulcerating lesions on the face and left thigh.  The clinical features and histological 
findings were in keeping with lymphomatoid papulosis (Lyp).  Over the following 
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12 years he had multiple recurrences each resolving spontaneously.  A subsequent 
biopsy revealed tumour stage mycosis fungoides (MF). Sheets of LCs were present 
closely associated with the neoplastic cell population. Review of previous biopsies 
revealed a similarly dense LC population.  He developed shortness of breath and lung 
nodules.  Subsequent biopsies showed features in keeping with transformed MF.  The 
patient was managed palliatively.  
 
 4.1.4.6. Case 6 
 
 
This case is described in more detail in Chapter 6.  This man presented at age 38 with an 
18 month history of an extensive rash. Multiple biopsies showed atypical lymphocytes 
infiltrating the epidermis in keeping with MF.  The dermal component included large 
aggregating nodules of LCs. He was managed with oral chlorambucil, allopurinol and 
psolaren/UVA (PUVA) therapy on a regular basis to good effect.  He later presented 
with weight loss, breathlessness and persistent diarrhoea.  Cavitating lung lesions were 
identified on chest x-ray and a barium follow through was suspicious of small bowel 
lymphoma.  Stomach and duodenal biopsies revealed a high grade T-cell lymphoma 
with no LC component.  The patient was managed palliatively.   
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4.2. METHODS 
 
A complete list of materials with source and catalogue number is given in Appendix A. 
 
 
4.2.1. Ethical approval 
 
 
Permission to do the study was granted by the Committee of the Tayside Tissue 
Bank, Ninewells Hospital. 
 
4.2.2. Case selection 
 
The tissues were obtained from the pathology archives of Raigmore Hospital, 
Inverness and Ninewells Hospital, Dundee, Scotland, UK. 
 
4.2.3. Immunohistochemistry 
 
The following is an outline of the immunohistochemical protocol employed in the 
relevant cases by the Department of Histopathology, Raigmore, Inverness.  Similar 
methodologies were employed by the Department of Histopathology, Ninewells 
Hospital and Medical School, Dundee. All biopsies were processed routinely and 
embedded in paraffin wax from which 5 µm sections were cut and stained with H & E. 
IHC was carried out on 4 µm sections on the Dakocytomation TechMate 500 
Plus (Dakocytomation, Ely, UK) with the Dakocytomation ChemMate System and 
antibodies to the following antigens: CD1a (diluted 1:10), CD2 (diluted 1:150), CD3 
(diluted 1:100), CD4 (diluted 1:75), CD5 (diluted 1:200), CD7 (diluted 1:150), CD8 
(diluted 1:20), CD10 (diluted 1:20), CD20 (diluted 1:700), CD21 (diluted 1:30), CD23 
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(diluted 1:50), CD30 (diluted 1:80), CD34 (diluted 1:300), CD43 (diluted 1:300), CD56 
(diluted 1:50), CD68 (diluted 1:2000), S-100 (diluted 1:3000), b-cl2 (diluted 1:300), and 
terminal deoxynucleotidyl transferase (TdT) (diluted 1:50). Sections were predigested 
for 10 min at room temperature with pronase before incubation with antibodies to 
CD21 and S-100. Antigen retrieval was performed for detection of CD1a, CD7, CD8, 
TdT, CD20, CD23, CD34, CD43, and CD68 by pressure-cooking sections in citric 
buffer, pH 6, for 1.5 min at full pressure, and for CD2, CD3, CD4, CD5, CD10, CD30, 
CD56, and bcl-2, by pressure cooking in EDTA buffer, pH 8, for 1.5 min at full 
pressure. 
 
4.2.4. Microdissection  
 
 
Sections of FFPE tissue were cut at 8 µm and stained with H & E. The sections were 
dried overnight in a fume hood, baked in an oven at 42°C for 4 hours, and stored in a 
desiccator to ensure thorough drying. LCs were microdissected and imaged using a 
laser dissecting microscope.   A serial section immunostained with CD1a was used to 
confirm the cell type.  
 
4.2.5. DNA extraction 
 
 
The DNA was then extracted from the microdissected sample in 50 µL DNA lysis 
buffer containing 10 mmol/L Tris-HCl, 50 mmol/L KCl, 2.5 mmol/L MgCl2, and 
0.45% Tween. The pH of the buffer was adjusted to 8.2.  Proteinase  K (0.5 µl) 
was added  
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to  the buffer immediately before extraction. The samples were incubated at 55°C for 
2 hours, spun down, and heated at 100°C for 15 min to denature the proteinase K. 
 
4.2.6. HUMAR assay  
 
 
In this study, clonality at the HUMAR gene locus was assessed using primer sequences 
and cycling conditions previously described (3.2.5). The HUMAR assay in this study 
was undertaken by Dr Susan Bray of the Tayside Tissue and Tumour Bank.  The 
reaction comprised 20 µL of DNA, 3 µL of water, 25 µL of Hot-StartTaq PCR Master 
Mix (Qiagen), and 1  µL of each primer (20 pmol/µL), androgen receptor primer A 
labelled with 6-carboxyfluorescein at the 5’ end (5’-CCGAGGAGCTTTCCAGAATC-
3’) and androgen receptor primer B (5’-TACGATGGGCTTGGGGAGAA-3’). PCR 
samples were incubated at 95°C for 15 min, followed by 50 cycles of 94°C for 30 s, 
59°C for 40 s, and 72°C for 30 s. This was followed by a final incubation step of 72°C 
for 30 min.  Identical primers and reaction conditions were used for the digested DNA.  
 
4.2.7. DNA digestion and purification 
 
 
DNA digestion was performed using the restriction endonuclease HpaII. DNA (26 µL) 
was digested with 1 µL of HpaII in 3 µL of 10 x SuRE/Cut buffer at 37°C overnight. 
The digestions were purified using the Qiaquick PCR Purification Kit according to the 
manufacturer’s standard protocol (2.2.3.1.). 
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4.2.8. DNA analysis 
 
The samples were diluted 15 x with water and 1 µL loaded onto the ABI 3100 Genetic 
Analyzer (Applied Biosystems). 
 
4.3. RESULTS 
 
4.3.1. Pathological findings 
 
 4.3.1.1. Case 1 
 
The lymph node architecture was almost completely effaced by sheets of large 
lymphoid cells with scanty cytoplasm, vesicular nuclei with irregular contours, and 
prominent nucleoli. Frequent mitotic figures and apoptotic bodies were present in these 
areas and the lymphoid cells displayed a CD3, CD5, CD7, CD34, CD43, TdT and Bcl–2 
positive phenotype. There was weak positivity with antibodies to CD79 but no 
expression of CD1a, CD2, CD4, CD8, CD20, CD68 or Mac387. A diagnosis of T-LL 
was made. Also present within the lymph node were relatively discrete nodules of CD1a 
and S-100 positive LCs. 
 
 4.3.1.2. Case 2 
 
The histological features in the excised lymph node were those of classic Hodgkin’s 
disease, mixed cellularity subtype. A well-defined nodule of LCs measuring 4 mm 
across and showing central necrosis was also identified within the involved lymph node.  
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Figure 4.1.  Micrographs of cases employed in the study.  (A) Case 2. Low power 
view of Hodgkin’s lymphoma, cluster of LCs stained brown with CD1a (starred). (B) 
Case 3.  Low power view of the cutaneous B-cell pseudolymphoma, stained with H & 
E. The pale area (arrowed) represents a cluster of LCs surrounded by small 
lymphocytes. (C) Case 3. High power view of a cluster of LCs stained with H & E 
(arrowed) and (D) stained brown with CD1a (starred). (E) Case 4. Nodal LCH: high-
power view stained with H & E, reactive germinal centres (black stars) and sheets of 
LCs (red stars) and (F) Case 4. Low power view of LCs stained brown with S-100 
(starred)  
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4.3.1.3  Case 3 
 
The skin sections showed features of B-cell cutaneous lymphoid hyperplasia (B-CLH) 
(so-called cutaneous B-cell pseudolymphoma). There was a dense nodular and diffuse 
lymphocytic infiltrate filling most of the mid and upper dermis and extending to the 
superficial subcutis.  Discrete B-cell follicles were noted, some showing reactive 
germinal centres (CD10+, Bcl-2-).  Between the follicles there was a mixed population 
of small and large lymphocytes, most being of T lineage. Occasional eosinophils and 
histiocytes were also seen. The consensus diagnosis was B-CLH.  In addition, within 
the interfollicular areas, there were several medium- to large-sized sheets of CD1a and 
S-100 positive LCs as well as numerous LCs scattered throughout the dermal infiltrate 
and within the epidermis. 
 
4.3.1.4. Case 4 
 
Much of the lymph node architecture was preserved but there was a partial effacement 
of paracortical areas by large nodules and sheets of CD1a and S-100–positive LCs. 
These were admixed with relatively few small lymphocytes and eosinophils. The 
appearances were typical of LCH. 
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4.3.1.5. Case 5 
 
A biopsy of the ulcerated facial nodule showed features in keeping with the clinical 
impression of LyP with a small number of scattered large atypical lymphocytes with 
irregular vesicular nuclei and prominent nucleoli. Biopsies from the skin of the right 
shoulder showed sheets of large lymphoid cells with irregular vesicular nuclei extending 
into the deep dermis. The large atypical lymphocytes were of T-cell lineage expressing 
CD4, CD43 and CD30. There was loss of expression of pan–T-cell antigens (CD2, 
CD3, CD5, and CD7).  These changes were interpreted as representing tumour stage 
disease. Both biopsies included an admixture of small lymphocytes, eosinophils, and 
plasma cells as well as large nodular aggregates of LCs.  Subsequent lymph node biopsy 
revealed sheets of large atypical T cells admixed with eosinophils but only scanty 
scattered LCs. 
 
4.3.1.6. Case 6 
 
Features of MF were present in repeated skin biopsies throughout the course of the 
disease. In some of these, a disproportionate degree of epidermotropism was noted with 
atypical lymphocytes lining up alongside basal keratinocytes over several contiguous 
rete ridges. Most of the biopsies included nodules of LCs. Subsequent biopsies of the 
stomach and duodenum revealed disseminated disease with large atypical T cells widely 
infiltrating the lamina propria.  The features were in keeping with a high grade T-cell 
lymphoma.  LCs were not represented. 
 
 
 
112 
4.3.1.7.  Points to note from clinicopathological descriptions 
 
• Due to the formation of well defined sheets or clusters of LCs it should be 
possible to assess clonality in the female patients using the HUMAR assay. 
• Intimate association of LCH nodules and other pathology means LCM is 
necessary to isolate the LCs for clonality studies.  Previous work in Chapter 2 
highlights the need to sample a pure population of cells, particularly when normal 
tissue of the same lineage is absent. 
 
 
 
Figure 4.2.  Images taken before and after specific cell capture. The “gaps” in the 
“aftershot” figures represent the cells examined and the remaining cells are those that 
are excluded from the examination.   A nodule of LCs in the pseudolymphoma “before 
shot” (A) and (B) “after shot”.  (C) Sheets of cells in true nodal LCH “before shot” and 
(D) “after shot”.   No significant background cellular population was sampled.	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4.3.2. Clonality analysis 
 
 
Figure 4.3.  HUMAR assay images, ABI 3100 Genetic Analyzer.  LCs in nodal LCH 
pre-digestion (A) and post-digestion (B); the loss of one peak indicates monoclonality.  
LCs in cutaneous pseudolymphoma pre-digestion (C) and post-digestion (D) and in 
Hodgkin’s lymphoma pre-digestion (E) and post-digestion (F).  The persistence of 
2  peaks indicates polyclonality. 
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LCs Allele sizes U1 U2 
 
D1 
 
D2 PR (%) 
Nodal LCH 237/246 8740 10701 0 38324 0/100 
Pseudolymphoma 227/251 13762 7191 39894 20913 50/50 
Hodgkin’s lymphoma 231/240 74053 66127 114391 92413 52/48 
 
Table  4.2. Raw data HUMAR assay LC in association with lymphoproliferations.  Peak 
areas pre-digestion (U1, U2) and post-digestion (D1, D2) as specified by ABI 3100 
Genetic Analyzer software. Percentage ratios (PR) reveal monoclonality in the nodal 
LCH only. 
 
4.3.3.  Summary of the pathological findings 
 
 
In all the cases described, prominent nodules of LCs were present admixed with the 
primary pathology. The LCs displayed typical features characterized by abundant pale 
staining cytoplasm, vesicular nuclei with markedly irregular nuclear contours, small 
nucleoli, and a CD1a and S-100-positive immuno-phenotype. The coexisting pathology 
included 2 cases of MF, one associated with preceding LyP. In each case, multiple 
skin biopsies showed evidence of a significant LC population in the skin but 
absence of these cells on dissemination of the lymphoma (axillary lymph node, 
duodenum, and stomach). In the other 3 cases, the concurrent lymphoproliferations 
comprised a T-LL, Hodgkin’s lymphoma, and a cutaneous B-cell pseudolymphoma 
(Table 4.3). A case of nodal LCH was included as a control sample (Case 4). 
 
• All cases showed intimate relationship between the primary lymphoproliferation 
and “LCH” 
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• Disseminated lesions of LCH not found in any case; LCH nodules only seen in 
association with lymphoproliferative lesions 
• In Case 5 (LyP) and Case 6 (MF) LCH nodules are only seen in association with 
‘low-grade’ form of lymphoma; no LC nodules were present following lymphoma 
transformation to higher grade disease and dissemination 
• LC nodules in the case of nodal LCH are indistinguishable from those in other 
cases 
 
4.3.4.  HUMAR assay results 
 
 
Three of the cases were female and, therefore, potentially informative; one was the case of 
true nodal LCH (case 4) and the others were the Hodgkin’s lymphoma (Case 2) and the 
cutaneous B-cell pseudolymphoma (Case 3). PCR analysis of DNA extracts from the 
microdissected LCs (Figure 4.3.) produced 2 discrete peaks after initial amplification of 
the HUMAR gene. Repeat PCR after digestion with HpaII produced only a single peak 
when DNA from the case of nodal LCH was amplified but 2 peaks remained in the 
microdissected LCs sampled from the cases of Hodgkin’s lymphoma and cutaneous 
pseudolymphoma. These results indicate a clonal restriction of the LC population in the 
case of nodal LCH, whereas the LC infiltrate seen in association with the cutaneous 
pseudolymphoma and the Hodgkin’s lymphoma is polyclonal. 
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Lymphoproliferative disorders associated with LCH 
Mycosis fungoides* 
Lymphomatoid papulosis* 
T-cell lymphoblastic lymphoma 
B-cutaneous lymphoid hyperplasia* 
Classic Hodgkin’s lymphoma / follicular lymphoma 
 
Table 4.3. Lymphoproliferative disorders described in association with LCH. 
 * association not previously described 
 
4.4. DISCUSSION 
These cases contribute to the small but growing body of literature that describes LCH-
like lesions associated with other tumors. LCH associated with nodal T-LL has been 
previously described in 3 cases, including one in which the tumour cells were 
positive for CD79a (Quintanilla-Martinez et al., 1992, Li and Borowitz, 2001). An 
association with MF, LyP, or cutaneous pseudolymphoma has not been described 
before. In cases of LCH associated with malignant lymphoma, the 2 lesions are most 
frequently concurrent and usually present at the same anatomical site, as occurred in all the 
cases noted above. Thus, although the nodules and sheets of LCs appear consistent with 
a diagnosis of LCH, they are unusual in that they have a close relationship with the 
concurrent lymphoproliferation, often intermingled with the lesional lymphoid cells. 
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Furthermore, proliferations of LCs in this context often lack the background cellular 
population typical of classic LCH. Moreover, none of these cases, or similar cases 
reported in the literature (Egeler et al., 1998) developed systemic spread of LCH.  In 2 of 
our cases (5 and 6), there was no evidence of an accompanying LC infiltrate after 
dissemination of cutaneous lymphoma to lymph nodes or gastrointestinal tract. In 
Case 6, when the MF was treated with PUVA, the nodules of LCs disappeared, 
suggesting that the 2 lesions were mutually dependent. These findings all support the 
contention that when concurrent, the LCH-like proliferation represents a reaction to 
the adjacent lymphoproliferation. This interpretation is further supported by the results of 
the HUMAR assay. Several studies have established the clonal nature of true LCH based on 
a non-random pattern of X-chromosome inactivation (Yu et al., 1994, Willman et al., 1994, 
Willman, 1994).  One group (Wu et al., 1999) has used the combination of LCM and the 
HUMAR assay to show clonality in DC tumours after 2 cases of low-grade B-cell 
NHL.  This study has demonstrated clonality in a case of nodal LCH.  However, in 
pulmonary LCH, almost always associated with cigarette smokers, the LC 
population is frequently polyclonal (Yousem et al., 2001) and this finding may be 
used to argue that pulmonary LCH represents a distinct disease entity that is reactive 
rather than neoplastic in nature. Indeed, most adults with isolated LCH of the lung will 
undergo spontaneous regression of the disease upon cessation of smoking (Sundar et al., 
2003). Using similar methodology, these results have shown for the first time, in 2 cases, 
that LCH-like lesions arising in the context of other lymphoproliferative disorders are 
also polyclonal and most likely reactive in nature.  
In summary, this work reports the rare occurrence of an LCH-like lesion occurring 
concurrently in a lymph node also harboring T-LL and for the first time similar lesions in 
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skin affected by MF, LyP and cutaneous B-cell pseudolymphoma. This study also includes a 
case of one of the most common associations, that of Hodgkin’s lymphoma. Within 
the literature such lesions are often labelled as LCH.  This term is misleading given the 
lack of clinical evidence that these lesions follow an aggressive course and in light of the 
molecular genetic studies that have demonstrated the polyclonal nature of the LC 
population in the above 2 cases. It seems likely that, in a significant proportion of cases, 
these lesions are reactive cytokine-mediated proliferations as suggested by Egeler et 
al (Egeler et al., 1998). Therefore, in the interim, without knowledge of clonal status, 
it may be appropriate to adopt the somewhat looser but perhaps more accurate 
terminology, LCH-like lesion. 
This work has demonstrated for the first time that lesions typically described as LCH are 
not always true monoclonal neoplasms and in some cases represent reactive proliferations.  
Further studies to define the clonal nature of lesions which are not associated with 
lymphoproliferations would go some way to understanding this enigmatic disease.  
Establishing the clonal nature of a lesion would be likely to yield prognostic information 
and guide treatment.  
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4.5. CONCLUSIONS  
 
 
The HUMAR assay may be employed to determine whether LCH-like lesions seen in 
association with other lymphoproliferations are true neoplasms exhibiting monoclonality 
or a polyclonal reactive phenomenon. As this distinction could have therapeutic 
implications it is important to establish the biological nature of these lesions.  Specifically, 
if the LCH (like) lesion is a potentially aggressive 2nd neoplasm it may require 
chemotherapy whereas if it were a benign reactive process, treatment would only be 
necessary for the associated lesion.   The following could be concluded. 
 
1. Nodules of LCs resembling LCH may be found in association with a variety of 
 lymphoproliferative disorders.  An association with MF, LyP and B-CLH has not 
been previously described. 
2.  In the two female cases studied the lesional LCs resembled LCH but were 
identified as polyclonal populations in keeping with a reactive infiltrate. 
3. The presence of nodules or sheets of LCs associated with lymphoproliferative 
 disorders does not justify a diagnosis of LCH.  These findings may have important 
clinical implications. 
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5. CLONALITY IN LANGERHANS CELL HISTIOCYTOSIS 
 
5.1. INTRODUCTION  
 
As outlined in Chapter 1, this rare group of disorders is characterised by an 
accumulation or proliferation of LCs in one or more organs.  LCH displays a varied 
clinical course with many lesions resolving spontaneously while others will progress to 
multisystem and lethal disease.  LCH can therefore be viewed as a group that from 
various clinic-pathological perspectives are best considered a spectrum of disorders 
rather than distinct individual entities. 
 
 Adult                    Children 
 Solitary                   Multiple 
 Spontaneous resolution              Clinically aggressive 
 Reactive?                  Neoplastic? 
 
5.1.1. Comparison of cells of LCH and normal LCs 
 
From earlier studies it is clear that a number of differences exist between the LCs of 
LCH and their normal counterparts.  These include expression of cytoplasmic and cell 
surface antigens, altered cytokine production and impaired antigen presenting 
capabilities.  Both normal and lesional cells of LCH may be specifically identified by 
langerin/CD207 which is responsible for formation of the Birbeck granule, a unique 
cytoplasmic structure (Valladeau et al., 2001). 
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One study found strong expression of the co-stimulatory molecule CD40 in 15/15 cases 
of paediatric LCH with the lesional T cells expressing CD40 ligand (Egeler et al., 
2000).   In another study, which similarly found expression of CD40 in LCs of LCH, in 
bone and chronic lesions, MHC class II antigens remained intra-cytoplasmic and there 
was failure to express the maturation markers CD83 and DC-LAMP.  In disease that 
spontaneously regressed, a more mature phenotype (DC-LAMP+ve) was noted 
(Geissmann et al., 2001).  Lesional LCs (13/13 cases) have been found to express CCR6 
a marker of immature DCs and also over-express the ligand for CCR6 (CCL20).  The 
same study found expression of a number of pro-inflammatory cytokines including 
CCL5 and CXCL11 (Annels et al., 2003).  Similarly, De Graaf et al (1996) found a rich 
cytokine milieu in LCH lesions, LCs staining positively for TNF-alpha, IL-4, TGF-
alpha and TGF-beta.  The background populations of lymphocytes, macrophages and 
eosinophils were also a source of cytokines. Both pro-inflammatory and anti-
inflammatory cytokines are typically present.  IL-10 is anti-inflammatory and often 
found in lesions of LCH (Egeler et al., 1999), maturation may be inhibited by down-
regulation of co-stimulatory molecules and MHC class II molecules (Steinbrink et al., 
1997).  Of note in one small study IL-10 was found to be absent in lesions of pulmonary 
LCH (in contrast to the studies above investigating non-pulmonary LCH) correlating 
with a more mature phenotype with expression of co-stimulatory molecules including 
B7 and CD40.  It is proposed that ongoing cytokine production without down-regulation 
plays a role in the pathogenesis and persistence of LCH (de Graaf et al., 1996) and LCs 
of LCH control the recruitment and retention of lesional cells enabling disease 
progression (Annels et al., 2003).   
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Cells of LCH express a number of cell adhesion molecules not found in resting 
epidermal LCs, these include Fascin (Pinkus et al., 2002), CD54 (intercellular adhesion 
molecule-1) and CD58 (leukocyte function antigen-3) (de Graaf et al., 1994).  Such 
expression may facilitate migration of LCH to distant sites.   Normal LCs express E-
cadherin which mediates adhesion to keratinocytes, E-cadherin is down-regulated on 
maturation and migration (Tang et al., 1993).  The LCs of disseminated rather than 
isolated cutaneous LCH are more likely to show negative or low expression of E-
cadherin (Geissmann et al., 1997). 
 
The findings discussed above suggest in cases of non-pulmonary LCH there is a 
maturational arrest/block at an early stage of activation possibly due to immune 
dysregulation (Steinbrink et al., 1997).  The cytokine “storm” appears to drive 
recruitment and retention of lesional cells as well as facilitating disease progression 
through autocrine/paracrine mechanisms and altered expression of cell-adhesion 
molecules (Egeler et al., 1999, Geissmann et al., 2001, Geissmann et al., 1997).  In 
contrast, pulmonary LCH and disease which regresses spontaneously or existed as 
isolated cutaneous disease is more likely to be associated with a more mature phenotype 
and absence of IL-10 (Tazi et al., 1999, Geissmann et al., 2001).   
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Expression Role Reference 
CD40 over-expressed Co-stimulatory molecule 
(Geissmann et al., 2001, Egeler et 
al., 2000) 
MHC class II remains intracytoplasmic Antigen presentation (Geissmann et al., 2001) 
Failure to express CD83, DC-LAMP Maturation markers (Geissmann et al., 2001) 
CCR6 over-expressed Marker of immature DCs (Annels et al., 2003) 
CCL5, CXCL11 overexpressed Proinflammatory cytokines (Annels et al., 2003) 
Fascin expressed Cell adhesion molecules (Pinkus et al., 2002) 
TNF-α, IL-4, TGF-α and TGF-β Cytokines (de Graaf et al., 1996) 
CD54, CD58 expressed Cell adhesion molecules (de Graaf et al., 1994) 
E-cadherin expression reduced Cell adhesion molecule (Tang et al., 1993) 
 
 
Table  5.1. Summary of altered expression patterns in lesional cells of LCH. 
 
5.1.2. Clonality in LCH 
 
Although two studies included relatively small numbers of cases, lesions of LCH 
occurring as multisystem disease, isolated disease and those that followed a benign 
course have been found to be clonal; see Chapter 1 (1.2.) (Willman et al., 1994, Yu et 
al., 1994).  A subsequent study found lesions of pulmonary LCH to be polyclonal 
although some nodules associated with a polyclonal LCH background demonstrated 
clonality, these were considered to represent clonal evolution from LC hyperplasia.  In 
these cases, extra-pulmonary manifestations of LCH are rare and the typical disease 
course is resolution following smoking cessation (Yousem et al., 2001).  Thus LCH 
shares features of both a reactive and neoplastic process.  Some of the arguments for 
and against neoplasia are highlighted below. 
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5.1.2.1.  Evidence for a neoplastic process 
 
• Clinically aggressive behaviour 
• No identifiable growth stimulus (autonomous growth) 
• Clonal proliferation (Yu et al., 1994), (Willman et al., 1994) 
• Genetic abnormalities (Murakami et al., 2002) 
• Predominantly applies to disseminated (+ restricted) LCH 
 
5.1.2.2.  Evidence for a reactive process 
 
• Spontaneous regression  
• Growth stimulus identified 
   cigarette smoking (pulmonary LCH) 
   relapses following infection 
• Polyclonal proliferation (Yousem et al., 2001) 
• Predominantly applies to pulmonary LCH  
 
5.1.2.3. Shared pathological features  
 
• Discrete lesions 
• CD1a, S-100 positive LCs 
• Often cytologically bland, i.e. resemble normal LCs 
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5.1.3. Aim 
 
Assess a large cohort of LCH cases, representing the full clinical spectrum of the 
disease, for clonality employing a combination of LCM and the HUMAR assay.  Only 
female patients will be studied as the assay depends on identification of patterns of X 
chromosome inactivation.  This work should identify cases for further studies aimed at 
identifying biological differences between benign and/or reactive LCs and neoplastic 
LCs. 
 
5.2. METHODS 
 
 
5.2.1. Optimisation of Langerin antibody 
 
 
Samples of breast skin held by the Tayside Tissue Bank for research purposes were used 
for antibody optimisation. This work was undertaken with the assistance of Kate 
Mclean of the Tayside Tissue and Tumour Bank. 
 
4µm sections were cut onto immunoslides and baked in the oven at 60°C for 1 hour then 
dipped into the following series of solutions: Histoclear 5 min, Histoclear 5 min, 
absolute alcohol 5 min, absolute alcohol 5 min, methylated spirit 5 min.  The slides 
were then rinsed in cold running water and placed in hot water to warm before 
employing the pressure cooker.  For antigen retrieval under pressure, the slow cooker 
was set to brown for 13 min, ensuring the slides were covered by citric acid buffer 
(10mM, pH 6.0).  Next the slides were placed into hot water and cooled by running in 
cold water (to boil without pressure the cooker was set to 10 min and the lid left off). 
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Dilution (DakoREAL 
diluent) Antigen retrieval method Staining system 
1/100 Boiling and Pressure Envision 
1/100 Boiling only Envision 
1/100 Boiling and Pressure Chem-mate 
1/100 Boiling only Chem-mate 
1/200 Boiling and Pressure Envision 
1/200 Boiling only Envision 
1/200 Boiling and Pressure Chem-mate 
1/200 Boiling only Chem-mate 
 
 
Table 5.2. Immunohistochemical optimisation of Langerin antibody 
 
Slides were reviewed and scored for optimal staining quality of the epidermal LCs.  
 
 
5.2.2.  Ethical approval 
 
 
Consent and ethical approval for work on FFPE LCH material was given by LREC.  
This consent allowed collection of samples from multiple sites including Tayside, 
Lothian and Strathclyde. 
 
22 female cases of LCH from 3 sites were included in this study.  Age range from 1 to 
65 years.  The breakdown of cases was as follows: 
 
Nodal  = 1, Skull  = 3, Bony (excluding skull) = 9, Skin  = 1, Pulmonary  = 8 
 
5.2.3.  Microdissection 
 
For microdissection and DNA extraction protocols please refer to 4.2.4 and 2.2.1.2 
respectively.
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5.2.4. HUMAR assay 
 
The protocols outlined in Chapter 3 were followed.  Please refer to: 
 
 3.2.3.  DNA extraction and clean up 
 3.2.4.  Restriction enzyme digestion 
 3.2.5.   HUMAR assay/PCR 
 
5.3. RESULTS 
5.3.1. Langerin immunohistochemistry 
 
 
 
 
 
 
 
Figure 5.1.  Epidermal LCs highlighted by Langerin antibody (red arrows).  Dendritic 
processes extending through keratinocytes can also be visualized (yellow arrows). 
Optimal results were obtained with the Envision system at an antibody dilution of 1/100 
with boiling and pressure.  
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5.3.2. HUMAR assay results 
 
 
 
 
 
 
Figure 5.2.  Micrograph LCH lymph node of 2 year old. H & E (A) x 20, (B) x 40 
(A) The image shows a reactive germinal centre (outlined by yellow arrows) separated 
from a nodule of LCs (outlined by blue arrows) by a cuff of lymphocytes (yellow star). 
(B) The image shows sheets of LCs together with relatively scanty numbers of 
background lymphocytes (examples indicated by black arrows). The region illustrated 
in B was microdissected and submitted for clonality analysis (assay images Figure 5.3.).   
 
Note:  This is the typical image quality of LCM slides which must remain 
uncoverslipped. 
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Figure 5.3.  HUMAR assay images, ABI 3100 Genetic Analyzer; LCH axillary node 
of 2 year old.  Two independent extractions and bioanalyser runs. The red arrow marks 
a stutter peak (see below for explanation), the vertical blue arrow is the first allelic peak 
and the vertical yellow arrow the second allelic peak.  The horizontal arrows highlight 
the bioanalyser sizing of each peak with the first figure indicating the number of base 
pairs and the second the area under the peak.  Run 1 (A) pre-digestion, (B) post-
digestion.  Run 2 (C) pre-digestion, (B) post- digestion.  The persistence of 2 peaks 
indicates polyclonality. 
 
Note: the first peak in Figure 5.3. is a stutter peak.  Stutter is a naturally occurring by-
product of the amplification process which may be regarded as a DNA polymerase 
extension artefact.  A minor peak occurs immediately before the first allelic peak, 
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typically one repeat smaller than the main allele generated. Stutter may be identified by 
its size and position and occurs in a reproducible and predictable fashion although the 
mechanism is poorly understood (Leclair et al., 2004). 
 
 
 
 
Figure 5.4.  Micrograph LCH skull of 1 year old.   H & E x 40.  Each image shows 
sheets of LCs together with relatively scanty numbers of background eosinophil 
leucocytes (examples indicated by black arrows) and lymphocytes (examples indicated 
by yellow arrows).  Small capillaries are noted in the background containing red blood 
cells (yellow star). Each of these regions (present within separate biopsy fragments) 
were microdissected and submitted for clonality analysis (assay images Figure 5.5.).   
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Figure 5.5.  HUMAR assay images, ABI 3100 Genetic Analyzer; LCH skull of 1 year 
old.  Three extractions from different regions of the lesion. The red arrow marks a 
stutter peak, the vertical blue arrow is the first allelic peak and the vertical yellow arrow 
the second allelic peak.  The horizontal arrows highlight the bioanalyser  sizing of each 
peak with the first figure indicating the number of base pairs and the second the area 
under the peak.  Region 1 (A) pre-digestion, (B) post-digestion.  Region 2 (C) pre-
digestion, (D) post- digestion.  Region 3 (E) pre-digestion, (F) post-digestion.  The 
persistence of 2 peaks in each of the 3 regions indicates polyclonality. A previous run 
(not illustrated) showed similar evidence of polyclonality. 
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Figure 5.6.  HUMAR assay images, ABI 3100 Genetic Analyzer; LCH skull of 
33 year old.  The red arrows mark stutter peaks, the vertical blue arrow is the first allelic 
peak and the vertical yellow arrow the second allelic peak.  The horizontal arrows 
highlight the bioanalyser sizing of each peak with the first figure indicating the number 
of base pairs and the second the area under the peak (A) pre-digestion, (B) post-
digestion. The loss of one peak indicates monoclonality.  
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Figure 5.7.  Low power view of slide microdissected from LCH lung of 55 year old. 
Yellow arrows outline the nodule of LCH with the red arrow highlighting the 
surrounding lunch parenchyma.  “Punched out” clear areas surround the yellow star.  
These are the regions that have been microdissected and submitted for clonality analysis 
(assay images Figure 5.8.). 
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Figure 5.8.  HUMAR assay images, ABI 3100 Genetic Analyzer. LCH lung of a 
55 year old.  The red arrows mark stutter peaks, the vertical blue arrow is the first allelic 
peak and the vertical yellow arrow the second allelic peak.  The horizontal arrows 
highlight the bioanalyser sizing of each peak with the first figure indicating the number 
of base pairs and the second the area under the peak (A) pre-digestion, (B) post-
digestion. A weak result but the loss of one peak suggests monoclonality.  
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Figure 5.9.  HUMAR assay images, ABI 3100 Genetic Analyzer; digest control. 
Control DNA from an individual who showed extreme constitutional skewing was 
employed as an enzyme digest control.  Vertical blue arrow is the first allelic peak and 
vertical yellow arrow the second allelic peak.  Horizontal arrows highlight bioanalyser 
sizing of each peak, the first figure indicating the number of base pairs and the second 
the area under the peak. Left, pre-digestion, Right, post-digestion (see 3.3.2). 
 
5.3.3.  Summary of all clonality results 
 
1. LCH associated with other lymphoproliferations –? polyclonal 
• LCs associated with pseudolymphoma – polyclonal (Chapter 4) 
• LCs associated with Hodgkins lymphoma – polyclonal (Chapter 4) 
2. Non- Pulmonary LCH – current dogma -  clonal proliferative disorder 
• Skull of a 1 year old – polyclonal 
• Axillary node of a 2 year old – polyclonal 
• Skull LCH – clonal 
• Nodal LCH  – clonal (Chapter 4) 
3. Pulmonary LCH – current dogma - polyclonal reactive disorder 
• Lung 55 year old - monoclonal 
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5.4. DISCUSSION 
 
Of the 22 cases included in this study, 6 were insufficient for further analysis due to 
extremely limited numbers of LCs in the samples or LCs which could not be easily 
separated from the background population even by LCM. These included cases in which 
a background of inflammatory cells predominated.   In particular most of the lung 
specimens revealed few LCs and instead were dominated by regions of scarring and 
scattered langerin or CD1a positive cells. Most of the tissues selected for further study 
included examples of LCH within the bone.  These samples would probably have been 
immersed in formic acid or EDTA for some time prior to paraffin embedding and 
although previous work (Chapter 2) demonstrated this did not preclude DNA extraction 
and PCR analysis, this is a possible factor in such a high proportion failing to amplify.  
In addition to poor DNA quality further limitations are posed by a relatively low 
number of cells included in each sample.  Nanodrop estimation of DNA quantity and 
quality did not prove helpful in determining which samples were most likely to amplify.  
The results are disappointing but highlight the difficulties of working with suboptimal 
specimens. Of note, in Chapter 4, the assay was straight forward, however this is likely 
to be related to the more optimal fixation conditions in nodal and cutaneous specimens.  
Both types of specimen are typically formalin fixed for short periods.   
 
From a total of 16 female specimens of LCH only 4 cases demonstrated results for both 
undigested and digested samples.  These included cases of LCH in an axillary node of a 
2 year old (Figure 5.3.), in the skull of a 1 year old (Figure 5.5.), the skull of a 33 year 
old (Figure 5.6.) and the lung of a 55 year old (Figure 5.8.).   
 
 
137 
 
In 2 cases (nodal and skull LCH) the results were consistently polyclonal over multiple 
assays.  Significantly, previous studies of clonality have included only small numbers of 
cases (Yu et al n=3 and Willman et al n=10).  The results herein suggest that, in conflict 
with the limited literature available, not all cases of non-pulmonary LCH are 
monoclonal.  Monoclonal results in LCH have been demonstrated in 3 cases, the skull 
of a 33 year old, lung of a 55 year old and nodal LCH (Figure 4.3.).   
 
There is good evidence that many examples of LCH are true neoplasms (see 5.1.2.1.),  
but in other cases (2/5 in this study), although superficially identical, the features simply 
reflect an altered state of LC activation.  This work supports the concept that LCH 
represents a heterogeneous group of neoplastic and reactive disorders with shared 
pathological features.  It seems likely that some of the larger studies (includes all studies 
in Table 5.1) will have unwittingly included cases of LCH which have greatly differing 
biological properties and aggressive propensities depending on their clonal status.   It is 
inappropriate to group reactive entities with their potentially more aggressive neoplastic 
counterparts.  In the case of the rather enigmatic LCH an important first step, at least in 
females, is to no longer assume monoclonality based on a small number of studies.  
Future research should aim to stratify the disease based on clonality and in this way we 
may be able to unravel important differences between these two groups.  It seems likely 
for example that monoclonal and polyclonal LCH may differ significantly in expression 
of many of the markers outlined above including cell adhesion molecules, maturation 
markers and co-stimulatory molecules (Table 5.1).   
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There is an increasing awareness that managing a patients malignancy will be most 
effective by closely defining the biological characteristics of the neoplasm and tailoring 
therapy to the individual.  This may be accomplished by a variety of methods, for 
example mutational analysis or protein expression.  In the case of LCH the relative 
rarity of the disease, limited material for research and particularly the paucity of fresh 
frozen samples, has hampered study in this area.  Clearly the best way to approach any 
future work would be to set up a multicentre study combining collection of fresh 
material with expert pathological, surgical and clinical input.  Clonal assessment should 
be at the core of any LCH stratification and close correlation with the clinical outcome 
is essential. 
 
5.5. CONCLUSIONS  
 
 
Although the cohort available for study was small and the DNA was of generally poor 
quality the following could be concluded.   
 
1.  In 2 cases (nodal LCH and skull LCH) the results were consistently polyclonal.  
 This work reveals that, in conflict with current literature, not all cases of nodal or 
 bony LCH are clonal.  These results disrupt the current concept that LCH is a 
monoclonal disorder and highlight the need for clonality assessment in disease 
 stratification. 
2.  Monoclonal results were found in 3 cases, pulmonary LCH, skull LCH and nodal 
LCH.  
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5.6. FUTURE WORK 
 
Several cases of LCH in males were identified.  Following LCM and DNA extraction 
samples were pooled to provide a number of cases (n=13) with a DNA content 
sufficient for analysis by array comparative genomic hybridization (array CGH).  Using 
a vast set of labelled probes printed on a glass slide array CGH determines copy number 
changes which result in gains or losses in DNA content for a particular location in the 
genome.  This whole genome approach may be used to identify genes of interest for 
further study.  The use of LCM, effectively excluding any background normal cell 
population, should greatly increase the ability to detect copy number changes.  The 
array CGH work is currently being undertaken by the Microarray Facility at the 
Regional Cytogenetics Laboratory, Western General Hospital, Edinburgh. 
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6.  INVESTIGATING THE POSSIBLE ROLE OF LANGERHAN’S CELLS IN 
CUTANEOUS B AND T CELL LYMPHOMA 
 
The work in Chapter 4 has demonstrated that proliferations of LCs found in association 
with other lymphoproliferative disorders may represent a reactive rather than neoplastic 
cell population.  What role might benign proliferations of LCs be playing in these 
malignancies?  Some studies suggest that increased numbers of tumour infiltrating LCs 
are a good prognostic indicator (Tsujitani et al., 1987), probably due to effective tumour 
antigen presentation, while others have found that tumour infiltrating DCs may become 
effectively disabled (Gabrilovich et al., 1997).   We predominantly see large LCH-like 
proliferations in association with haematological malignancies and as APCs of the skin 
it seems likely that they will play a role in the suppression, development or maintenance 
of cutaneous lymphoid malignancies.  There is relatively little known about the part that 
LCs and other cutaneous DC subsets play in lymphomagenesis or disease progression 
but increasing knowledge of the varied and perhaps counterintuitive functions of these 
cells certainly suggests a central function.  The role of LCs and other DC subsets in 
cutaneous lymphoma and benign lymphoproliferations has not been well elucidated 
although improved markers are now available to aid in distinguishing DC subsets and to 
determine activation/maturation status.   
 
The following chapter is split into 2 parts (6A and 6B).  The first looks at two unusual 
cases of the cutaneous T cell lymphoma - MF.  Both cases had unusually large 
infiltrates of LCs and both followed an atypical and extremely aggressive clinical course.  
No similar cases have been described in the literature.  These reports are followed by a 
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discussion of recent research, which sheds some light on the possible role of LCs in the 
progression of T cell lymphomas.  The second part focuses on cutaneous B cell 
lymphoproliferations and unravelling the possible role played by LCs and other 
cutaneous DC populations intimately associated with these entities.  This is followed by 
a discussion of the possible role of the different DC subtypes in disease emergence and 
progression. 
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6A.  LANGERHAN’S CELL RICH MYCOSIS FUNGOIDES 
 
6A.1. INTRODUCTION 
 
Discussed here are two fatal cases of MF, each associated with a massive infiltrate of 
dermal LCs.   The unusual histological findings are presented as well as a description of 
the progression to extra-cutaneous disease.  The role of dermal LCs is discussed in brief 
as well as the possible mechanisms by which tumours disrupt normal functioning and 
maturation of LCs and other DCs to evade cytotoxic attack.   
 
6A.1.1. Mycosis fungoides 
 
 
MF is the commonest primary T-cell lymphoma of the skin (Willemze et al., 1997) 
accounting for 0.5% of all NHL (Kim and Hoppe, 1999).  The disease can occur in 
childhood and has a wide age range, but is most common in men over the age of 50.  
Most patients present with disease confined to the skin as patches or plaques which in 
the early stages may mimic a benign dermatosis such as eczema or psoriasis.  Early skin 
biopsies may be non-diagnostic containing very sparse atypical lymphocytes and it may 
take several years before a firm diagnosis is reached.  Differentiation between other 
types of cutaneous T-cell lymphoma (CTCL) is important as these will typically require 
much more aggressive management. Several variants of MF have been identified 
including small cell type, CD8+ (Dummer et al., 2002), interstitial (Su et al., 2002) and 
granulomatous forms (Ackerman and Flaxman, 1970). Scarabello et al (2002) found a 
prominent granulomatous reaction in 1.8% of cutaneous lymphomas (primary and 
secondary) which in several cases led to the incorrect diagnosis of a granulomatous 
dermatitis.   
 
 
143 
 
6A.1.2. Disease progression and prognostic factors 
 
 
Patients with MF have varying risks for disease progression and death.  The most 
important predictive factors are patient age (improved survival in patients presenting at 
>57 years), T classification (T1-limited patch/plaque, T2- generalised patch/plaque, T3- 
tumour, T4- erythroderma) and the presence of extra-cutaneous disease (Kim et al., 
1999).  MF is typically indolent and has a long natural history but in most patients 
lesions will become more generalised with progression to erythroderma and tumour 
formation. In patients presenting with T1 disease their relative risk for death is similar 
to that of a matched control population (Kim et al., 1999).  In some cases, 
transformation to a large cell T-cell lymphoma occurs, the risk being greater in stage 
IIB-IV than for stage I-IIA. In a series of 115 cases one group identified 26  cases of 
transformation.  Only 14% of cases presenting as stage I-IIA eventually transformed 
(Diamandidou et al., 1998).  Another study (Vergier et al., 2000) found the median time 
from diagnosis of MF to transformation was 6.5 years with a mean survival from 
transformation to death of 22 months.  Multivariate analysis showed that age >60 years 
and extra-cutaneous spread were associated with the poorest prognosis.   To fit the 
criterion the large cells must represent >25% of the neoplastic infiltrate or form 
microscopic nodules (Salhany et al., 1988).  A common clonal origin for the 
transformed MF and original neoplasm has been established (Wood et al., 1993, Wolfe 
et al., 1995). When immune-positive for CD30, the histopathological features may 
overlap with those of other cutaneous lymphoproliferative disorders such as LyP and 
anaplastic large cell lymphoma. 
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6A.2. CASE REPORTS 
 
6A.2.1. Case 1 
 
 
This man presented in 1988 aged 57 with two ulcerating lesions, one on the right side of 
the face in the pre-auricular region and the other on the left thigh.  The clinical features 
and histological findings were in keeping with MF.  There was no evidence of extra-
cutaneous disease.  Over the following 12 years he had multiple recurrences involving 
the trunk, limbs and left ear, each resolving spontaneously.  In 2002, he presented with a 
right ear lesion, two shoulder lesions and extensive chronic superficial dermatitis. The 
clinical features were in keeping with tumour stage MF.  He had a good general 
response to PUVA and the tumours partially responded to PDT although the right 
shoulder lesion persisted. There was no evidence of lymphadenopathy or pulmonary 
disease on CT; blood film and count were normal.  A biopsy from the right shoulder in 
2003, revealed small numbers of atypical lymphoid cells infiltrating the epidermis and 
forming a band-like infiltrate within the mid to deep dermis. Sheets of LCs 
accompanied by prominent eosinophil leukocytes were present closely associated with 
the neoplastic cell population.  The possibility of concurrent LCH was raised but this 
infiltrate was considered to be more likely to represent a reactive phenomenon. Review 
of previous biopsies in 2002 and early 2003 revealed a similarly dense LC population.  
In September 2003 he had an episode of acute breathlessness.  Chest x-ray showed 
lesions in both lungs suggestive of metastasis and CT showed multiple pulmonary 
nodules throughout both lung fields.  Clinical examination revealed shotty nodes within 
the right axilla. Nodal biopsy demonstrated cores of tissue in which no residual lymph 
node architecture was identified.   The cores exhibited extensive necrosis and were 
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widely infiltrated by plump atypical looking lymphoid cells.  These cells stained 
positively for CD45 and CD4 and were negative for CD3, CD5 and CD7.  A sparse 
number of CD8 positive cells were present.  A section stained for MIB-1 showed a high 
proportion of proliferating cells.  Molecular genetic studies identified evidence of clonal 
rearrangement of the TCR gamma gene.  The high labelling index of the viable cells, 
together with the morphological features, were suggestive of high grade disease and in 
keeping with transformed MF.  There was no evidence of lymphocytosis or circulating 
Sezary cells.  The patient was managed palliatively and died in December 2003.  
 
6A.2.2. Case 2 
 
 
This man presented in 1993 aged 38 with an 18 month history of an asymptomatic 
psoriatic type rash which involved all four limbs, thorax, abdomen and scalp.  The rash 
consisted of spongy and oedematous lesions and was purplish in colour.  There was no 
evidence of lymphadenopathy.  Multiple biopsies were taken over a 7 year period. The 
majority of samples showed atypical lymphocytes infiltrating the epidermis in keeping 
with MF.  The dermal component however comprised scanty neoplastic lymphocytes 
associated with large aggregating nodules of LCs.  These appearances were initially 
believed to represent the granulomatous variant of MF.  However, later review and 
immunohistochemical analysis with CD1a and S100 revealed these to be LCs.  The 
possibility of LCH was considered but on balance this was felt likely to represent a 
reactive infiltrate.  There was no evidence of extra-cutaneous disease. He was managed 
with oral chlorambucil and allopurinol to good effect.  He was commenced on alpha 
interferon in 1996 and received PUVA therapy on a regular basis.  In 1997 he developed 
further nodules on his forearms and legs and topical nitrogen mustard was added in.  In 
January 2000 he presented with weight loss, breathlessness and persistent diarrhoea.  
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Cavitating lung lesions were identified on chest x-ray and a barium follow through was 
suspicious of small bowel lymphoma.  Bronchial biopsy was non-diagnostic but raised 
the possibility of an infective aetiology.  Stomach and duodenal biopsies revealed a high 
grade T-cell lymphoma with no LC component.  The patient was not fit for 
chemotherapy and was managed palliatively.  He died 2 months later. 
 
 
 
Figure 6A.1. Images of cutaneous lesions.  Case 1 A) ulcerating erythematosus 
shoulder lesions and plaque (anterior) B) deeply ulcerating ear lesion. Case 2 C) and D) 
arm lesions, extensive, erythematous tumour stage MF.  
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6A.3. RESULTS 
6A.3.1. Pathological findings 
 
 
 6A.3.1.1. Case 1 
 
 
A biopsy of the ulcerated facial nodule at presentation showed features in keeping with 
the clinical impression of LyP. The dermis deep to and surrounding the ulcer contained 
an infiltrate of small lymphocytes, plasma cells, and polymorphs. In addition, there was 
a small number of scattered large atypical lymphocytes with irregular vesicular nuclei 
and prominent nucleoli.  Unfortunately there were no biopsies of the eczematous rash or 
plaque which were clinically thought to represent development of MF.  Biopsies of the 
nodule on the right shoulder showed sheets of large lymphoid cells with irregular 
vesicular nuclei and prominent nucleoli underlying the ulcerated area and extending into 
the deeper dermis where they assumed a perivascular distribution.  An admixture of 
small lymphocytes, eosinophils, and plasma cells was present. The large atypical 
lymphocytes were of T-cell lineage, expressing CD4 and CD43 as well as CD30. 
However, there was loss of expression of other pan–T-cell antigens (CD2, CD3, CD5, 
and CD7). Staining for CD8 and CD56 was negative. Given the clinical impression of 
background MF and the persistence of the lesions, these changes were interpreted as 
representing tumour stage disease.   
 
6A.3.1.2. Case 2 
 
 
Features of MF were present in repeated skin biopsies throughout the course of the 
disease. In some of these, a disproportionate degree of epidermotropism was noted with 
the presence of linear epidermotropism manifest by atypical lymphocytes lining up 
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alongside basal keratinocytes over several contiguous rete ridges.  Most of the biopsies 
showing features of MF also contained nodules of CD1a and S-100–positive LCs. 
Interestingly, although the last skin biopsy showed features of MF, no nodules of LCs 
were seen. Biopsies of the stomach and duodenum showed similar features with large 
atypical T cells widely infiltrating the lamina propria; LCs were not represented. 
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Figure 6A.2.   LC rich MF. Case 1, (A) H & E x 4.  The infiltrate appears as multiple 
coalescing nodules within the dermis (black arrows).  The epidermis is highlighted by a 
blue arrow.  B)  Abundant LCs are demonstrated by immuno-positivity for CD1a (deep 
brown staining). C)  Transformed MF, CD30 highlights the neoplastic cell population, 
two large neoplastic cells with prominent nucleoli are arrowed. Case 2, D) H & E x 20, 
neoplastic, cerebriform T cells infiltrate the epidermis (blue arrow) to form pautrier 
micro-abscesses (outlined by black arrows).  E) Abundant LCs within the dermis 
demonstrated by CD1a staining (outlined by black arrows), epidermis is highlighted by 
a blue arrow. 
 
 
150 
6A.3.1.3. Disease specific survival and the development of extracutaneous 
disease 
 
 
Case 1 presented in 1988 with T1, stage IA disease (limited patch/plaque, <10% body 
surface area).  In 2002 the disease had progressed to T3 disease with tumour stage MF.  
The patient then went onto develop nodal involvement with transformed MF (stage 
IVA) and possibly pulmonary involvement (stage IVB).  He died in 2003, 15 years after 
presentation.  In patients presenting with T1 disease the overall survival rates at 5, 10 
and 20 years were 97%, 88% and 64% respectively (Kim et al., 1996).  The disease 
specific survival (DSS) (a survival calculation in which death events must be 
specifically related to MF such as progressive disease, fatal infections, MF related 
complications) at 5 and 15 years was 100% and 98% respectively in patients with stage 
1A disease. In a study of 525 patients only 77 presented with or developed extra-
cutaneous disease (nodal or visceral). The most common visceral sites of involvement 
were the lungs, oral cavity, pharynx or CNS.   Of those presenting with T1 disease the 
risk for development of extra-cutaneous disease at 5, 10 and 20 years was 1%, 2% and 
2% respectively (Kim et al., 2003). 
 
Case 2 presented in 1993 with T2, stage 1B disease. In 1997, 5 years after diagnosis, the 
disease progressed to tumour stage MF.  In 2002 he developed extra-cutaneous disease 
involving the stomach and duodenum as transformed MF (stage IVB). He died 9 years 
after presentation.  In patients presenting with T2 disease the overall survival rates at 5, 
10 and 20 years were 72%, 55% and 28% respectively.  However, in patients with stage 
IB disease, the DSS at 5 and 15 years was 95% and 85% respectively. Of those 
 
 
151 
presenting with T2 disease the risk for development of extra-cutaneous disease at 5, 10 
and 20 years was 8%, 9% and 9% respectively (Kim et al., 2003). 
 
6A.4. DISCUSSION 
 
DCs play a crucial role in the anti-tumour immune response presenting tumour antigens 
to resting naive T cells in the draining nodes (Nefedova et al., 2005). One study found 
increased numbers of LCs in several types of neoplastic skin lesion including actinic 
keratosis, Bowen’s disease and squamous cell carcinoma (McArdle et al., 1986).   Other 
investigators however have found a reduction in LC number adjacent to basal cell 
carcinomas (Bergfelt et al., 1994) and melanoma (Toriyama et al., 1993). Discussed in 
more detail in Chapter 4, large numbers of LCs histologically similar to LCH have been 
found in association with a variety of haematological and solid malignancies including 
thyroid and lung cancer.  Some evidence within the literature suggests increased 
numbers of LCs within a tumour may confer a better prognosis. One group found an 
improved prognosis in HPV infected squamous cell carcinoma and adenocarcinoma of 
the lung (Miyagi et al., 2001) while another group found that the number of LCs within 
Stage III gastric carcinomas correlated with a better prognosis (Tsujitani et al., 1987).  
In particular, increased numbers of LCs in the epidermis of patients with MF have been 
associated with an improved outcome; death resulting from mycosis fungoides and 
Sézary syndrome was significantly (P = 0.003) less frequent in patients with LC 
densities > 90 cells/mm2 as compared with patients with lower numbers (Meissner et al., 
1993). In the same study ultra-structural investigations showed apposition between LCs 
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and atypical lymphoid cells.  This was a constant finding and less frequently observed 
in stage III than stage II lesions (Meissner et al., 1993). 
  
Increased numbers of LCs within the skin may arise due to increased retention/failure to 
migrate to draining nodes, influx of precursors from the blood or in-situ division.  In a 
quiescent state most cutaneous LCs are immature, being capable of capturing and 
processing antigen and producing large numbers of MHC II complexes, but are unable 
to activate T cells.  Antigen uptake results in LC maturation (Cumberbatch et al., 1991) 
and the switching on of co-stimulatory molecules required to stimulate T cells.  There is 
simultaneous down-regulation of antigen presenting abilities with a significant 
reduction in phagocytic capacity (Reis e Sousa et al., 1993, Romani et al., 1989).   
 
Several authors have now reported defective DC function in human and animal tumours. 
One group demonstrated that DCs isolated from breast cancer patients had a marked 
reduction in ability to uptake antigen, migrate, and stimulate T cells (Gabrilovich et al., 
1997).  Another study showed that despite large numbers of DCs within rat colon 
carcinoma, the vast majority failed to express B7 an essential co-stimulatory molecule 
for T cell activation (Chaux et al., 1997). The same group found that inhibition of 
tumour derived VEGF significantly improved the function of LCs.  Several factors, 
which may be tumour derived, are known to affect the maturation (and therefore 
function) of LCs such as IL-10 (Beissert et al., 1995, Macatonia et al., 1993).  One 
group has demonstrated that supernatant from cultured T7 tumour cells applied topically 
increases the number of LCs within the epidermis but inhibits migration from the 
epidermis to local lymph nodes.  Two progressor tumours (evade immune destruction) 
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but not two regressor tumours (immunologically destroyed) displayed these findings 
(Lucas and Halliday, 1999).    In addition, studies in mice have shown that CD4 T cells 
need peripheral MHC class II expressing DCs (includes LCs) for their survival (Nasreen 
et al., 2003, Brocker, 1997). Of particular interest, in a study culturing CTCL cells with 
DCs, DC immaturity was central to prolonged growth of the malignant cells.  The DCs 
retained their ability to phagocytose apoptotic tumour cells. They may have stimulated 
tumour growth by presenting CTCL antigen back to the neoplasm or through release of 
growth factors.  There is further discussion of this topic in Chapter 6B (6B1.2, 6B1.3). 
 
6A.4.1. Possible interactions between neoplastic cells of cutaneous CTCL and LCs 
 
• Cytokines released by tumour may increase recruitment of LCs to the dermis.   
• LC maturation may be inhibited by tumour derived factors such as IL-10 and 
VEGF.   
• Failure of maturation could result in maintenance of phagocytosis and antigen 
presenting capabilities with failure of expression of co-stimulatory molecules 
and inhibition of migration to draining nodes. 
• LCs may phagocytose apoptotic tumour cells and present tumour antigen via 
MHC class II molecules. Presentation of antigen to CD4+ T cells is known to 
enhance survival. 
• CD40 on dendritic cells is ligated by T cells.  This may enhance LC survival. 
• LCs may produce growth factors which stimulate the CTCL. 
 
The role of intra-tumoural LCs is currently the subject of much debate particularly in 
the developing era of immunotherapy.  The ability of LCs and other types of DC to 
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stimulate or inhibit immune responses appears central to the phenomenon of tumour 
tolerance or an anti-tumour response.  LCs and T lymphocytes have a unique co-
dependent relationship which may modify the role of LCs in cutaneous T-cell 
lymphomas.  
 
6A.5. CONCLUSIONS 
 
Investigation of the histological, immunophenotypic and clinical features in these cases 
has resulted in the following conclusions. 
 
1 Both patients followed an extremely aggressive and highly unusual clinical course 
in respect of DSS and the development of extra-cutaneous disease. 
2 The striking feature of these biopsies is the presence of abundant dermal LCs.  
3 It is possible that in the cases described herein LCs have played a role in the 
disease progression and clinically aggressive outcome. 
4 It would be worthwhile investigating unusually aggressive cases of MF for dermal 
LC content. 
 
 
 
 
 
 
 
 
 
 
155 
6B. DENDRITIC CELLS IN CUTANEOUS B-CELL 
LYMPHOPROLIFERATIVE DISORDERS 
 
6B.1. INTRODUCTION 
 
 
Dendritic cells are key initiators and regulators of immune responses.  They are potent 
APCs that are present in almost all peripheral tissues, including the skin.  They 
constitute a heterogeneous, dynamic and plastic population of cells that orchestrate 
cutaneous immunity and are critical to adaptive and anti-tumour immune responses 
(Banchereau and Steinman, 1998, Hart, 1997). In addition to LCs, members of this 
group found in the skin include dermal or interstitial DCs (DDCs) and plasmacytoid 
DCs (PDCs). Like LCs, DDCs are derived from CD34+ bone marrow haematopoietic 
progenitors (Strunk et al., 1997, Caux et al., 1996) and migrate to the skin and other 
non-lymphoid organs where they exist in a steady state but with the ability to divide in-
situ to maintain population levels (Bogunovic et al., 2006). In order to rapidly expand 
the dermal population, DDCs and macrophage precursors may be recruited in large 
numbers from circulating blood monocytes under the influence of inflammatory 
cytokines.  In contrast PDCs lack myeloid markers (such as CD11c).  The expression of 
several features, including the pre-TCR α-chain, suggest a lymphoid precursor (Strobl et 
al., 1998, Rissoan et al., 1999). They bear a morphological resemblance to plasma cells 
and develop into DCs in response to IL-3 (Grouard et al., 1997). PDCs have been 
described in normal skin at low levels (Ebner et al., 2004) and are similarly recruited to 
sites of inflammation/allergic responses and cutaneous malignancy (Blomberg et al., 
2003, Vermi et al., 2003,  Jahnsen et al., 2000, Cella et al., 1999).  
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6B.1.1. Dendritic cell maturation 
 
While immature DCs are extremely efficient at antigen capture and processing, they are 
poor stimulators of T cells.   Following antigen uptake, DCs undergo a series of 
activation or maturational events, both phenotypic and functional, which result in 
migration to local lymph nodes and a greatly enhanced ability to stimulate naive CD4+ 
and CD8+ T lymphocytes (Cella et al., 1997, Steinman, 1991). Maturation and 
migration have been shown to occur within a day (De Smedt et al., 1996).  Both innate 
and acquired immunity are enhanced by the synthesis of high levels of IL-12 and the 
expression of co-stimulatory molecules such as CD40 (Cella et al., 1996). Other 
maturational changes include up-regulation of CD83 together with the co-stimulatory 
molecules CD80 and CD86 required for T cell activation (Schwartz, 1992).   Their 
striking efficiency means that even a small number of mature DCs are able to induce a 
strong T cell response (Bhardwaj et al., 1993).  Depending on the nature of the 
activating stimulus, immature DCs may give rise to different types of effector cells that 
are able to prime distinct T-cell subsets, thereby differentially inducing TH1, TH2 and 
cytotoxic immune responses.  In addition, activated DCs may be involved in the 
generation of tolerance and may modulate established immune responses via stimulation 
of T-regulatory cells (Steinman et al., 2003). 
 
DCs also express a variety of cell surface molecules that belong to a group known as C-
type lectins.  Examples of these include DEC205/CD205, Langerin/CD207, DC-
SIGN/CD209 and BDCA-2/CD303.  C-type lectins recognise and bind carbohydrate 
structures that are normally part of microbial pathogens as well as certain tumour-
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associated glycoproteins, thereby facilitating antigen uptake and the generation of a 
specific immune response.  Thus, DCs may initiate and regulate immune responses 
directed against neoplasms as well as infectious agents (Aarnoudse et al., 2006, Ebner et 
al., 2004).  Aditionally, certain C-type lectins are selectively expressed on different DC 
subsets and can be detected immunohistochemically.  Expression patterns are discussed 
below.  
 
6B.1.2. T-regulatory cells, alternatively activated DCs and tolerogenic DCs 
 
It is widely appreciated that immature DCs can have tolerogenic properties.  One study 
demonstrated that co-culture of T cells and immature DCs resulted in induction of non-
proliferating CD4+ T cells that did not respond to repeated antigenic stimulation 
(Jonuleit et al., 2000).  Other studies show that DCs exposed to antigen but not to pro-
inflammatory cytokines or other maturational stimuli down-regulate immunity and may 
result in induction of regulatory T cells (Legge et al., 2002, Dhodapkar et al., 2001). 
Antigen specific CD25+CD4+ T regulatory or suppressor cells can inhibit inflammatory 
responses as well as tumour-specific immune responses.  This probably occurs through 
direct contact with DCs with a subsequent reduction in CD4+ and CD8+ T cell activation.  
Moreover, maturing PDCs produce abundant CCL4 (ligand for CCR5) (Penna et al., 
2002) which as proposed by one group  may play a role in CD25+CD4+ T regulatory cell 
attraction and subsequent immune suppression (Adorini et al., 2004).  DCs treated with 
immunosuppressive molecules such as IL-10 fail to express co-stimulatory molecules 
with subsequent impairment of T cell activation (Wakkach et al., 2003).  Riboldi et al 
demonstrated that human DCs matured in the presence of anti-inflammatory molecules 
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such as IL-10 (alternatively activated DCs) secreted pro-angiogenic isoforms of 
vascular endothelial growth factor (VEGF) while immature or classically activated DCs 
did not.  The data showed that VEGF production was not identified in PDCs (Riboldi et 
al., 2005).  Resolution of inflammation is associated with increased levels of IL-10 as 
well as other anti-inflammatory signals including release of VEGF. In addition it is 
postulated that certain persistent micro-organisms may be taken up by DCs which 
subsequently fail to mature, so resulting in tolerance through the generation of anergic T 
cells, production of regulatory T cells (with suppressive activity) or deletion of reactive 
T cells (Steinman et al., 2003, Steinman and Nussenzweig, 2002).  
 
A distinct subset of DCs may also play a role in suppressing local and systemic 
inflammation.  A study in mice has revealed a naturally occurring tolerogenic or 
regulatory DC which upon stimulation produced low levels of pro-inflammatory 
cytokines and preferential production of IL-10.  These DCs suppressed the 
lipopolysaccharide induced inflammatory response, probably through several different 
mechanisms including inhibition of macrophage activation and suppressive effects on 
T  cell function (Fujita et al., 2006).  
 
6B.1.3. Role of DCs in antigen-specific tumour immunity and mechanisms of tumour 
evasion 
 
In addition to presenting exogenous antigen, DCs that are present in tissues throughout 
the body are able to present self antigens from apoptotic cells (Albert et al., 1998).  This 
function appears to play an important role in the induction of peripheral tolerance.   
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DCs may also take up tumour antigens with subsequent maturation and induction of 
specific anti-tumour immunity – the basis of cancer immunotherapy (Steinman and 
Dhodapkar, 2001). In several tumour types, including diffuse large B-cell lymphoma 
(Chang et al., 2007), increased numbers of DCs have shown to correlate with a more 
favourable prognosis. DCs harvested from patients with low-grade Non-Hodgkin’s 
lymphoma  cultured in tumour-derived protein and re-infused at three monthly intervals 
showed a strong cellular response to the protein as well as a clinical response (Hsu et al., 
1996).  Vaccination with tumour antigen laden DCs however is problematic as several 
studies have now demonstrated that DCs within tumours may display defective antigen 
presentation with inhibition of maturation/activation (Gabrilovich et al., 1996).  In 
particular secretion of IL-10 by tumour cells suppresses maturational events in DCs 
(Koch et al., 1996, Brown et al., 2001) and has been shown to induce tolerance through 
induction of T-cell anergy (Steinbrink et al., 1997).  Moreover, a tumour that does not 
send out “alarm or danger” signals may not elicit sufficient DC activation, resulting in a 
failure to express T cell co-stimulatory molecules (Smyth et al., 2001). Inhibition of DC 
maturation may also result in stimulation and differentiation of immunosuppressive IL-
10 producing T-regulatory cells and induction of tolerance towards the tumour (Levings 
et al., 2005).  
 
6B.1.4. Immunohistochemical determination of DC subtypes 
 
CD83 has proved a useful marker appearing to be selectively expressed in DCs (LCs, 
DDCs, PDCs) (Zhou and Tedder, 1995).  Using immunohistochemical markers, a 
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spectrum exists between DDCs expressing BDCA1 and DC-SIGN at one end and at the 
other macrophages expressing CD163. The expression of other markers such as HLA-
DR and FXIIIA are determined by microenvironment, activation and maturational status 
(Zaba et al., 2007, Nestle et al., 1993).  Studies to determine stages of DC development 
in paraffin sections must take into account the lack of specific markers and overlapping 
expression patterns between DC subtypes. 
 
6B.1.4.1. Epidermal Langerhan’s cells 
 
LCs express CD45, CD4 and the myeloid markers CD33 and CD13.  They exhibit 
strong positivity for CD1a and can be identified unequivocally by the C-type lectin 
langerin/CD207 which is responsible for formation of the cytoplasmic structure unique 
to the LC – the Birbeck granule (Valladeau et al., 2001).  Langerin is an endocytic 
receptor which is partially down-regulated upon maturation (Valladeau et al., 2000). 
CD83 and DC-LAMP are expressed on full maturation (Lechmann et al., 2001).  LCs 
do not express Factor XIIIa or DC-SIGN/CD209 (Caux et al., 1996, Valladeau and 
Saeland, 2005). 
 
6B.1.4.2. Dermal dendritic cells 
 
DDCs express the coagulation factor XIIIa (Caux et al., 1996) and the C-type lectin DC-
SIGN/CD209 (Soilleux et al., 2002a) both of which have also been observed on 
macrophages.  DC-SIGN is known to bind a large number of both viral and bacterial 
micro-organisms (van Kooyk and Geijtenbeek, 2003). Soilleux et al (Soilleux et al., 
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2002a) found that, in adult and fetal tissues, DC-SIGN was observed primarily on 
immature (CD83-negative) DCs. However, within lymphoid organs DC-SIGN may be 
positive on both immature and mature DDCs (Engering et al., 2004).  Immature DDCs 
strongly express CD1a (Dzionek et al., 2000, Sugita et al., 1999) which in tissue culture 
experiments is down-regulated upon maturation (Cao et al., 2002). Two subsets of 
DDCs have been characterised, one which is CD1ahigh/DC-SIGN- and the other 
CD1alow/DC-SIGN+ (Turville et al., 2002, Nestle et al., 1993) . DC-LAMP (de Saint-Vis 
et al., 1998) and CD83 (Zhou and Tedder, 1995) are expressed upon full maturation. 
 
6B.1.4.3. Plasmacytoid dendritic cells 
 
BDCA-2 expression is strictly confined to PDCs (Dzionek et al., 2001). These cells 
express CD123 (not found on DDCs or LCs) and produce high levels of IFN-α in 
response to viral stimulation (Colonna et al., 2004, Cella et al., 1999). DC-SIGN 
expression on PDCs is controversial.   Soilleux et al (Soilleux et al., 2002a) found DC-
SIGN expression on a small subset of BDCA-2+ PDC precursors in peripheral blood 
and also in association with CD123+/BDCA2+ DCs in nasal polyps.    Other studies 
however report absent or undetectable DC-SIGN on PDCs (Patterson et al., 2001, 
Soilleux et al., 2002b). In human blood BDCA-2 and BDCA-4 are restricted to PDCs 
and in-vitro maturation results in complete down-regulation of BDCA-2 (Dzionek et al., 
2000). CD83 is expressed on full maturation.  PDCs do not express DC-LAMP. 
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 LC DDC PDC 
CD1A + + §¥≠ - 
Langerin + ≠ - - 
DC-LAMP + ‡ + ‡ - 
CD83 +‡ + ‡ + ‡ 
DC-SIGN - + § ¥ -  * 
Factor XIIIa - + - 
CD123 - - + 
BDCA-2 - - + ≠ 
 
 
Table 6B.1. Immunohistochemical determination of DC subtypes. 
§ Defines 2 subsets.  DDCs may be CD1ahigh/DC-SIGN- or CD1alow/DC-SIGN+ (Nestle et al., 
1993, Turville et al., 2002) 
 ¥ found primarily on immature (CD83-) DCs (Soilleux et al., 2002a, Dzionek et al., 2000) 
‡ expressed only after full maturation (Lechmann et al., 2001) * although controversial most 
PDCs probably do not express DC-SIGN (Soilleux et al., 2002b, Patterson et al., 2001)  
≠ expression appears to be down-regulated upon maturation (Valladeau et al., 2000, Cao et al., 
2002).   
 
6B.1.5. Cutaneous B-cell lymphoproliferations 
 
Emerging evidence suggests that cutaneous B-cell lymphoproliferations (CBCLPs) 
represent a spectrum of disease, with B-CLH at one end, and overt cutaneous mucosa  
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associated lymphoid tissue lymphoma (cutaneous MALT lymphoma) at the other.  The 
proposal of a disease spectrum is supported by good evidence, employing 
immunoglobulin gene rearrangement studies, showing progression of a small number of 
cases of B-CLH to cutaneous MALT lymphoma (Nihal et al., 2003, Sangueza et al., 
1992, Wood et al., 1989). In most instances the aetiology is unknown.  However both 
entities may occur following a period of chronic antigenic stimulation arising, for 
example, in a background of vaccination (May et al., 2005), insect bites (Barr-Nea et al., 
1976), tattooing (Sangueza et al., 1992), drugs (Brady et al., 1999) and infection 
including herpes zoster and Borrelia burgdorferi (Goodlad et al., 2000, Garbe et al., 
1991).  It has been proposed that persistent antigenic stimulation may result in the 
evolution of a neoplastic clone facilitating progression of B-CLH to cutaneous MALT 
lymphoma (May et al., 2005, Sangueza et al., 1992, Garbe et al., 1991). This may be 
viewed as analogous to the association of chronic Helicobacter Pylori infection of the 
stomach and early marginal zone lymphoma in which bacterial eradication results in 
disease regression.   
  
B-CLH may pose a diagnostic challenge simulating lymphoma both histologically and 
clinically (Arai et al., 2005, Baldassano et al., 1999). The lesions of B-CLH are most 
commonly found on the head, neck and extremities and tend to be less extensive than 
cutaneous MALT lymphoma, typically comprising a heterogeneous population of B and 
T lymphocytes, plasma cells, macrophages and DCs (Medeiros et al., 1989, Nihal et al., 
2003, Wood et al., 1989). The architecture is variable and the infiltrate may be top or 
bottom heavy, nodular or diffuse. Lesions of B-CLH lack significant atypia.  In 
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cutaneous MALT lymphoma the finding of B-cell atypia, groups of plasma cells at the 
periphery of the lymphocytic infiltrate, light chain restriction or IgH gene rearrangement, 
proved useful diagnostic adjuncts (Arai et al., 2005, Gallardo et al., 2002, Baldassano et 
al., 1999). However, clonal IgH gene rearrangements are well recognised in bone fide 
cases of lymphoid hyperplasia (Flaig et al., 2000, Bouloc et al., 1999). One study 
identified dominant clonality in 27 of 44 cases of B-CLH using a PCR based assay 
(Nihal et al., 2003).  While the clinical implications of such a finding remain unclear, a 
potential increased risk of progression to cutaneous lymphoma may prompt closer 
clinical follow up. 
 
 
 
Figure 6B.1.   Cutaneous MALT lymphoma.  A) H & E x 2, lymphoid follicles were 
present in 15/18 cases, the arrows highlight a dense nodular infiltrate within the dermis.  
The epidermis is highlighted by a blue arrow.  B) H & E x 10, the group of cells 
highlighted by arrows displays plasmacytic differentiation, a common feature of this 
lesion. 
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6B.1.6. Aims 
 
  
Given the critical role that DCs play in adaptive and anti-tumoural immune responses, 
they are almost certain to be directly involved in the genesis of B-CLH, and may also 
influence the evolution and growth of cutaneous MALT lymphoma.  Previous studies 
have hinted at such a function, but these have been few in number, of relatively limited 
scope, and have produced conflicting results (Carbonnelle et al., 2007, Pigozzi et al., 
2006, Schmuth et al., 2001). One recent study has demonstrated a significant PDC 
component in lesions of cutaneous MALT lymphoma and to a lesser extent in B-CLH 
(Kutzner et al., 2009). This study aims to explore the hypothesis that DCs play a central 
role in the generation and regulation of CBCLPs by comparing the number, subtype and 
maturational status of DCs in biopsy specimens showing features of B-CLH (n=14) and 
cutaneous MALT lymphoma (n=18). 
 
6B.2. METHODS 
 
A complete list of materials with source and catalogue number is given in Appendix A.  
 
 
6B.2.1. Ethical approval and case selection 
 
Multicentre ethics approval granted cases to be retrieved from the surgical pathology 
files of Raigmore Hospital, Inverness, Ninewells Hospital, Dundee and the Department 
of Pathology, NHS Lothian-University Hospitals Division.  All cases were reviewed 
and the diagnoses confirmed according to morphology, immuno-phenotyping and 
genotyping criteria.  The criteria used to differentiate B-CLH from cutaneous MALT 
lymphoma was based largely on those described by Baldassano et al (Baldassano et al., 
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1999) and the WHO-EORTC classification (Burg et al., 2005).  Fourteen biopsies from 
11 patients showing features of B-CLH and 18 biopsies from 14 patients with cutaneous 
MALT lymphoma were identified and included in this study.  In cases designated 
cutaneous MALT lymphoma, an estimate was also made of the proportion of the dermal 
infiltrate composed of neoplastic cells as compared to reactive elements (<50% or 
>50%).  
 
6B.2.2. Dendritic cell immunohistochemistry 
 
IHC was performed in the histopathology laboratory at Raigmore Hospital in Inverness 
by Carol McKenzie. 
 
IHC was performed on serial sections (3 µm) of FFPE tissue.  After overnight drying in 
a 60°C oven, sections were dewaxed, rehydrated and washed.  Heat induced antigen 
retrieval was performed by pressure cooking in either 0.01M Citric buffer pH 6 
(Langerin, Factor XIIIa, CD1a and CD83) or 0.01M EDTA buffer pH 8 (DC-SIGN, 
BDCA-2, DC-LAMP) at full pressure (15 lbs) for 1.5 min. To ensure reproducibility, 
reliability, quality and standardization of the staining technique, the DAKO 
TechMate™500 Plus (DAKO, Ely, UK) staining machine was used with DAKO 
ChemMate™Capillary Gap Microscope slides, DAKO REAL Buffer Kit, DAKO 
REAL peroxidase-blocking solution, DAKO Real Detection system and DAKO 
Haematoxylin.  Antibodies were diluted using DAKO antibody diluents.  All antibodies 
were commercially available for paraffin section protocols.  Appropriate positive and 
negative controls were used.  For negative controls, the primary antibody was replaced 
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with antibody diluent.  Primary antibodies: Langerin (Novocastra, diluted 1:100), DC-
SIGN (Dendritics, diluted 1:500), BDCA-2 (Dendritics, diluted 1:30) DC-LAMP 
(Dendritics, diluted 1:100), CD1a (Novocastra, diluted 1:10) CD83 (Novocastra, diluted 
1:50) and Factor XIIIA (Novocastra, diluted 1:100).  Staining for CD1a, Langerin, 
CD83, DC-LAMP, FXIIIA and BDCA-2 was performed on all 32 biopsies.  Ten cases 
of B-CLH and 10 of cutaneous MALT lymphoma were stained with antibodies to 
CD123, and staining for DC-SIGN was undertaken on 12 cases of B-CLH and 
10 cutaneous MALT lymphoma.    
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Figure 6B.2. Immunohistochemical staining of case of B-CLH.  Some of the positive 
cells are highlighted by black arrows.  A) CD1a x 40, B) DC-LAMP x 40, C) BDCA-2 
x 40, D) DC-SIGN x 40, E) CD83 x 40, F) Langerin x 40, G) FXIIIA x 40 
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6B.2.3. Cell counting  
 
 
The number of positive cells/mm2 was calculated.  Counting was undertaken using the 
Nikon NIS-Elements D 2.30 software.  Cells were counted in boxes measuring 0.1 mm2.  
In each case the entire area of the lymphoid infiltrate was examined or in very extensive 
infiltrates up to 4 mm2 (400 boxes). Slides were scored without knowledge of the 
diagnosis.   
 
6B.2.4. Statistics  
 
Dr Lee Baker of the Centre for Oncology and Molecular Medicine, University of 
Dundee, assisted with statistical advice. 
 
Comparison was made between the median number of cells/mm2 staining with each 
antibody in B-CLH versus cutaneous MALT lymphoma.  The two-sample t-test was 
applied to those results which were normally distributed and the Mann-Whitney test to 
those results that were not. The Mann-Whitney test determines the chance of obtaining 
greater observations in one sample versus another.  The null hypothesis states that the 
samples are drawn from a single population and the probability of a result is equal in 
each. 
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6B.3. RESULTS 
6B.3.1. Pathological features 
 
All 14 biopsies of B-CLH were characterized by the presence of lymphoid follicles and 
in 12/14 of these, variable numbers of follicles possessed reactive germinal centres.  
The interfollicular areas of the infiltrate contained a polymorphic infiltrate consisting 
predominantly of small T-cells, with only scattered B-lymphocytes, including 
occasional B-blasts.  There were also variable numbers of histiocytes, plasma cells and, 
in some cases, eosinophils.  In all 14 cases, the plasma cells showed a mixed pattern of 
staining with antibodies to kappa and lambda.  Light chain IHC was generally non-
contributory with respect to the B-lymphocytes present in the interfollicular areas 
(absent staining), apart from 3 biopsies in which a polyclonal pattern of staining was 
seen. The cases of cutaneous MALT lymphoma showed a spectrum of changes.  A 
neoplastic population of cells was demonstrable in all biopsies, but with varying 
proportions of residual reactive lymphoid tissue.  Lymphoid follicles were present in 
15/18 cases (Figure 6B.1.A), and in most (13/15), a proportion of these contained 
reactive germinal centres.  In these lesions the neoplastic cells were present in the 
interfollicular areas, almost always as large aggregates and/or sheets of cells displaying 
prominent plasmacytic differentiation (Figure 6B.1.B) and cytoplasmic light chain 
restriction (14/15 cases), usually around the edges of the infiltrate.  The one case with 
an interfollicular pattern of growth not showing plasmacytic differentiation was 
characterized by diffuse sheets of intermediate sized lymphocytes with moderate 
amounts of pale cytoplasm (marginal zone cells) growing in a perifollicular distribution.  
Light chain restriction was not demonstrated in this case.  The remaining three cases 
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were devoid of intact lymphoid follicles, comprising diffuse sheets of neoplastic 
lymphoid cells.  These infiltrates consisted predominantly of marginal zone cells, 
although sheets of plasma cells were also present in one.  Light chain restriction was 
demonstrated in all three cases. Estimates of the ratio of reactive to neoplastic cells in 
the eighteen biopsies designated as cutaneous MALT lymphoma indicated that the 
neoplastic clone constituted  ≥ 50% of the total cells present in the infiltrate in only 9/18 
cases.  
 
6B.3.2. Dendritic cell immunohistochemistry  
 
6B.3.2.1. B-CLH vs all cases of cutaneous MALT lymphoma 
 
The median number of Langerin-positive cells in B-CLH and cutaneous MALT 
lymphoma was only 26.5/mm2 and 9.0/mm2 respectively.  This difference was not 
significant and the results suggest that very few LCs are present in association with the 
dermal infiltrates in these disorders.  Conversely, DC-SIGN and BDCA-2 positive cells 
were far more numerous in B-CLH (97.0/mm2 and 385.5/mm2 respectively), implying 
that DDCs and PDCs constitute the predominant DC subtype.  The median number of 
these cells was significantly lower in cutaneous MALT lymphoma (1.0/mm2 and 
255.0/mm2; p=0.0094 and p=0.0319 respectively), although large numbers of BDCA-2 
positive cells were still present.  The staining pattern for CD123 mirrored that seen for 
BDCA-2, with a reduction in the median number of cells in cutaneous MALT 
lymphoma compared to B-CLH (349.0/mm2 in B-CLH; 147.0/mm2 in cutaneous MALT 
lymphoma).  This difference was not significant but this may be at least partly explained 
by the somewhat variable intensity of staining observed with antibodies to this antigen  
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 Median No. +ve cells/mm
2 
  B-CLH Cut. MALT p 
LANGERIN 26.5 9.0 0.903 
DC-SIGN 97.0 1.0 0.0094 
  BDCA-2     385.5 255.0 0.0319 
 
Table 6B.2.  Subtypes of DC in B-CLH and cutaneous MALT lymphoma. There were 
very few LCs in B-CLH or cutaneous MALT lymphoma; difference not significant.  
DDCs and PDCs constitute the predominant DC subtypes.  There were significantly 
fewer DDCs and PDCs in cutaneous MALT lymphoma vs B-CLH .  See Table 6.5B for 
ranges. 
  
Significantly greater numbers of CD1a and DC-LAMP positive cells were seen in B-
CLH than in cutaneous MALT lymphoma (298.0/mm2 vs. 128.0/mm2; p=0.035, and 
110.5/mm2 vs. 55.0/mm2; p=0.0421, respectively). CD83 positive cells were also more 
frequently encountered in B-CLH than cutaneous MALT lymphoma (80.5/mm2 vs. 
39.5/mm2 respectively; p=0.0872).   
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 Median No. +ve cells/mm
2 
  B-CLH Cut. MALT     p 
CD1a 298.0 128.0 0.0350 
DC-LAMP 110.5 55.0  0.0421 
 
Table 6B.3. Molecules associated with antigen presentation. There were significantly 
fewer CD1a and DC-LAMP positive cells in cutaneous MALT lymphoma vs B-CLH. 
See Table 6.5B for ranges. 
 
Sizeable numbers of FXIIIA positive cells were present in both types of lesion, with a 
median of 212.5 cells/mm2 in B-CLH and 145.5 cells/mm2 in cutaneous MALT 
lymphoma.  The reduction in number of FXIIIA positive cells was not significant.  In 
fact, if the cumulative number of Langerin, DC-SIGN and BDCA-2 positive cells is 
taken as an indicator of the total number of DCs present, then the relative proportion of 
FXIIIA positive DCs was higher in cutaneous MALT lymphoma than in B-CLH (45.6% 
vs. 32.3%).   
 
 Median No. +ve cells/mm
2 
 LANGERIN  DC-SIGN BDCA-2  FXIIIA      % FXIIIA 
B-CLH 26.5 97.0 385.5 212.5 32.3 
Cut. MALT            9.0 1.0 255.0 145.5 45.6 
 
Table 6B.4. Relative proportion of FXIIIA+ve cells. The relative proportion of 
FXIIIA+ve cells appears to be greater in cutaneous MALT lymphoma than B-CLH.  
See Table 6.5B for ranges. 
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 6B.3.2.2.   B-CLH vs cases of cutaneous MALT lymphoma with ≥50% 
neoplastic cells 
 
A significant reactive component of lymphoid tissue was present in many cases of 
cutaneous MALT lymphoma.  In these lesions, the values obtained from counting 
positive cells stained with each antibody are likely to include DCs associated with this 
ongoing benign reactive lymphoproliferation, as well as tumour-related and/or tumour 
specific DCs.  This may mask any subtle differences that exist between the DCs 
involved in these two biologically distinct processes. For this reason a further analysis 
was done in which the median number of cells staining with each antibody in B-CLH 
was compared only with the median number in cases of cutaneous MALT lymphoma 
with a high content (≥50%) of neoplastic cells.   
 
The median number of dermal LCs was low in both types of lesion (26.5/mm2 in B-
CLH vs. 9.0/mm2 in cutaneous MALT lymphoma), and the difference in numbers was 
not significant (p=0.2973).  All other types of DC were present in significantly lower 
numbers in cases of cutaneous MALT lymphoma with a high tumour cell (MALT high) 
content than in B-CLH.  Thus, the median number of DC-SIGN positive cells reduced 
from 97.0/mm2 (B-CLH) to 0.0/mm2 (MALT high) (p=0.0094 to p=0.0058), indicating 
a loss of DDCs, and PDCs were also greatly reduced, since the median number of 
BDCA-2 positive cells dropped from 385.5/mm2 (B-CLH) to 62.0/mm2 (MALT high) 
(p=0.0319 to p=0.0128). The number of CD1a positive cells also dramatically reduced 
(298.0/mm2 (B-CLH) vs. 15.0/mm2 (MALT high); p=0.0350 to p=0.0182).  In addition, 
the number of mature DCs present also appeared to be much lower in cutaneous MALT 
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lymphoma than B-CLH since the median number of CD83 positive cells dropped from 
80.5/mm2 (B-CLH) to 34.0/mm2 (MALT high) (p=0.0872 to p=0.005) and the median 
number of DC-LAMP positive cells from 110.5/mm2 (B-CLH) to 39.0/mm2 (MALT 
high) (p=0.0421 to p=0.0166).  The number of FXIIIA positive cells was also 
significantly higher in B-CLH than in cutaneous MALT lymphoma with ≥50% tumour 
cells (212.5/mm2 vs. 57.0/mm2; p=0.0089).  However, when expressed as a proportion 
of all DCs present, there was a higher percentage of FXIIIA positive DCs in cutaneous 
MALT lymphoma with ≥50% tumour cells than in B-CLH (46.7% versus 32.3%).  
Although not statistically significant this difference was greater than when all cases of 
cutaneous MALT lymphoma were used in the analysis (Table 6B.4.).  
 
 Variable N Mean SEMean StDev Min Q1 Median Q3 Max 1.96*SEM Nor Test 
CD1a 14 387.8 82.3 308.1 4 150.3 298 716.3 895 161.308 y MW 
LANG 14 29.86 6.45 24.14 0 9.25 26.5 45.25 89 12.642 y MW 
CD83 14 88.5 16.8 63 3 44.3 80.5 104 254 32.928 y MW 
DCLAMP 14 142.6 29.5 110.4 49 59.8 110.5 193.5 421 57.82 n MW 
CD123 10 368.2 61.4 194.1 166 224 349 421.5 836 120.344 y 2t 
FXIIIA 14 209.5 30.1 112.6 0 150.8 212.5 243.8 501 58.996 n MW 
BDCA2 14 462.6 68 254.3 77 317.3 385.5 652 1042 133.28 y MW 
B-CLH 
DC-SIGN 12 156.9 45.9 158.9 0 36.8 97 272.5 440 89.964 n MW 
 
 
CD1a 18 178.4 42.6 180.7 0 13.8 128 290.3 568 83.496 n  
LANG 18 17.39 5.47 23.2 0 2.75 9 23.25 93 10.7212 n 
 
CD83 18 55.22 7.82 33.16 19 31.75 39.5 91.25 120 15.3272 n 
 
DCLAMP 18 82.4 15.1 64.1 13 37.3 55 123.5 243 29.596 n 
 
CD123 10 226.4 71.1 224.7 17 61.8 147 337.8 752 139.356 y 
 
FXIIIA 18 139.7 19.2 81.6 24 55.8 145.5 214.5 288 37.632 y 
 
BDCA2 18 257.3 43.5 184.4 42 60.5 255 408.3 609 85.26 n 
 
Cut. 
MALT 
lymphoma 
DC-SIGN 10 31.8 19.3 60.9 0 0 1 46.5 171 37.828 n 
 
 
 
Table 6B.5. Descriptive statistics B-CLH vs all cases of cutaneous MALT lymphoma. 
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Figure 6B.3. Median number of +ve cells/mm2 B-CLH vs all cases cutaneous MALT 
lymphoma. 
 
6B.4. DISCUSSION 
 
DDCs constitute the major DC subtype resident in the dermis of normal human skin.  In 
the absence of inflammation most are in an immature or inactivated state (Toebak et al., 
2009). Typically, very few dermal LCs or PDCs are seen (Zaba et al., 2009, Wollenberg 
et al., 2002). In certain skin conditions, so-called inflammatory DCs augment the 
normal resident DDC population and the number of PDCs may also increase 
significantly (Wollenberg et al., 2002).  However, the relative number of DCs, and their 
biological characteristics, varies according to the disease process.  For example, whilst 
the number of DDCs increases in both psoriasis and atopic dermatitis, the increase is 
less marked in the former (Guttman-Yassky et al., 2007). Moreover, the inflammatory 
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DDCs in psoriasis produce a different array of chemokines and cytokines to those seen 
in atopic dermatitis (Guttman-Yassky et al., 2007, Lowes et al., 2005). Similarly, PDCs 
are increased in the dermis in contact dermatitis and lupus erythematosus but not in 
atopic dermatitis (Wollenberg et al., 2002). 
 
This study used expression of langerin, DC-SIGN and BDCA-2 (or CD123) as 
approximate surrogates for LCs, DDCs and PDCs respectively, in order to enumerate 
and compare the relative numbers of DCs in B-CLH and cutaneous MALT lymphoma.  
The results show that very few LCs are present in association with the dermal infiltrates 
of either.  Conversely, numerous DDCs and PDCs were present in both types of 
lymphoproliferation, although they were significantly more numerous in B-CLH than 
cutaneous MALT lymphoma.  Using antibodies to CD83 and DC-LAMP, these results 
demonstrate that there were significantly more mature DCs in B-CLH than cutaneous 
MALT lymphoma, although the relative proportion of mature to immature DCs was 
roughly the same in each type of lesion.  A similar result was found for the number of 
DCs expressing CD1a.  Conversely, although the number of FXIIIA positive cells was 
greater in B-CLH than cutaneous MALT lymphoma, this difference was not statistically 
significant and the relative proportion of FXIIIA positive DCs was greater in cutaneous 
MALT lymphoma than B-CLH.    
 
The finding of more numerous PDCs in B-CLH than cutaneous MALT lymphoma is in 
contrast to one recent study (Kutzner et al., 2009). However, this result was confirmed 
with two separate markers of PDCs (BDCA-2 and CD123) and the counting technique 
employed here was more comprehensive with large numbers of cells enumerated in all 
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or large areas of tumour, in every case. It is worth noting that PDCs have previously 
been documented in B-CLH, albeit under their former name of plasmacytoid T-cells 
(Eckert and Schmid, 1989). Also, it is of interest that a relatively recent study has 
documented significant numbers of PDCs in Sjögren's syndrome (Gottenberg et al., 
2006) another reactive B-cell proliferation associated with progression to extranodal 
marginal zone lymphoma (Voulgarelis et al., 1999). 
 
In humans, expression of DC-SIGN distinguished DDCs from other cellular populations, 
although in certain circumstances DC-SIGN may also be observed on macrophages 
(Valladeau and Saeland, 2005). DDCs are well endowed with mechanisms that facilitate 
antigen recognition and capture.  As well as DC-SIGN, they possess other lectins, such 
as MMR/CD205, that allow them to interact with a wide variety of antigens and micro-
organisms (Soilleux et al., 2002a).  Following antigen uptake, DDC up-regulate cell 
surface co-stimulatory and class MHC II molecules that render them potent antigen 
specific activators of naïve T-cells.  Additional signals, principally other co-stimulatory 
molecules and cytokines, direct polarization of T-cells towards type 1 or type 2 T-helper 
cells (TH1, TH2), or a less polarized T-cell type (Toebak et al., 2009, Valladeau and 
Saeland, 2005). As discussed above, as well as stimulating the immune response, DDCs 
play a critical role in inducing tolerance.  Antigen binding to any of the three main types 
of DC receptor (C-type lectins, integrins, Fc receptors) in the absence of a pathogenic 
stimulus or inflammatory cytokines may result in tolerogenic or alternatively activated 
(FXIIIa+) DCs which increase IL-10 production (anti-inflammatory), decrease IL-12 
production (inflammatory) and fail to up-regulate T cell co-stimulatory molecules.  
Such down-regulation of immunity may result in induction of T regulatory or 
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suppressor cells which inhibit inflammatory responses (Mahnke et al., 2003). Mature, 
conventionally activated DCs may also play a role in tolerance. Under steady state 
conditions CD1a +ve DDCs, despite displaying an activated phenotype, express 
relatively high levels of IL-10 (Santegoets et al., 2008). 
  
PDCs are characterized by their plasmacytoid morphology, expression of BDCA-2 
(McKenna et al., 2005) and their ability to secrete large amounts of type 1 interferons 
(IFN) in response to a  variety of antigenic stimuli; principally viruses, but also certain 
bacteria and DNA containing unmethylated CpG sequences typical of microbial DNA 
(Colonna et al., 2004, Wollenberg et al., 2002, Kadowaki et al., 2000). The downstream 
consequences of type 1 IFN (IFN α/β) secretion are varied and include effects on NK 
cells, (Megjugorac et al., 2004), T-cells (Megjugorac et al., 2004), B-cells (Poeck et al., 
2004) and other DCs (Colonna et al., 2004, Wollenberg et al., 2002). Because of their 
pleotropic effects, PDCs are very flexible in directing T-cell responses.  Depending on 
their maturation stage, and the nature and concentration of antigen, they may induce 
either Th1 or Th2 polarisation (McKenna et al., 2005, Colonna et al., 2004). PDCs may 
also have tolerogenic functions, particularly when in an immature state, and can induce 
the formation of T-regulatory cells (Colonna et al., 2004). Although PDCs are able to 
activate memory T-cells with similar efficiency to other DC subtypes, they are much 
less efficient in priming antigen specific naïve T-cells, even after maturation with a 
potent stimulus (McKenna et al., 2005, O'Keeffe et al., 2003).  Also, whilst it is not yet 
known if PDCs can migrate into skin to encounter antigen, they can be recruited into 
inflamed skin.  For example, PDCs express CXCR3 and ChemR23, the ligands of 
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which are present in inflammatory skin and in inflamed dermal vessels respectively 
(Vermi et al., 2005, Valladeau and Saeland, 2005, Kohrgruber et al., 2004,).  
Since DDC are the principle resident immune sentinels in the dermis, are potent 
stimulators of naïve T-cells, and are present in significant number, it is likely that they 
play the major role in initiating and driving the lymphoproliferation that characterizes 
B-CLH.  The relatively numerous mature and/or CD1a positive DCs seen in B-CLH is 
consistent with ongoing T-cell priming and the hypothesis that B-CLH is due to chronic 
antigenic stimulation.  Conversely, PDCs are only present in small numbers in normal 
skin and are poor stimulators of naïve T-cells compared with DDCs, and are therefore 
less likely candidates for this role.  Nevertheless, in B-CLH (Kutzner et al., 2009), as in 
certain other inflammatory conditions (Zaba et al., 2009, Wollenberg et al., 2002) they 
appear to be recruited into the skin in large numbers and, in view of the fact that they 
constitute the predominant DC type, must have a major part to play.  It could be 
speculated that PDCs may be primarily involved in enhancing and regulating the 
function of the DDCs and that they may also influence which immune effector cells are 
recruited into the immune response, since they can produce a diverse array of cytokines 
and chemokines, the pattern of which depends on the activation stimulus (McKenna et 
al., 2005, Megjugorac et al., 2004). Therefore, PDCs may be responsible for polarizing 
the local immune response; this may be done in such a way that the consequent 
lymphoproliferation manifests histologically as the organised lymphoid tissue that 
characterizes B-CLH.  
 
The absolute number of DDC and PDC are significantly reduced in cutaneous MALT 
lymphoma compared with B-CLH, as are the number of mature and CD1a-positive DCs.  
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This implies that antigen presentation and T-cell priming are perhaps less important, 
consistent with the dogma that neoplastic clones are no longer dependant on 
physiological stimuli for growth.  Nevertheless, significant numbers of DCs, 
particularly PDCs, were present in the cases of cutaneous MALT lymphoma, and 
appears in agreement with others that they are likely to play a significant role in the 
pathogenesis of this neoplasm (Kutzner et al., 2009, Kempf et al., 2010).   In the correct 
conditions, both immature and mature DDCs and PDCs can have tolerogenic effects, 
induce the formation of T-regulatory cells, and stimulate T-cells to differentiate into T-
suppressor cells (McKenna et al., 2005, Moseman et al., 2004, Kuwana, 2002).   
Moreover, at certain stages in an immune response, type 1 IFN produced by PDCs can 
prime other DCs and T-cells to produce the anti-inflammatory cytokine, IL-10 (Liu, 
2005). Thus, in cutaneous MALT lymphoma, the prime action of DCs may be to 
suppress the anti-tumour immune response, facilitating outgrowth of the neoplastic 
clone.  The increased proportion of factor XIIIA positive DCs in cutaneous MALT 
lymphoma, implying the presence of alternatively activated cells, supports the notion of 
such a bias towards immunoregulatory activity (Mahnke et al., 2003, Jonuleit et al., 
2001). 
 
In addition, both DDCs and PDCs can direct directly stimulate B-cells to proliferate and 
mature into plasma cells (Poeck et al., 2004, Dubois et al., 1999).  For example, under 
certain conditions, PDCs induce expression of the B-cell activation and survival factor 
BAFF by myeloid DCs (Litinskiy et al., 2002). They can also stimulate activated B-
cells to differentiate into IgG secreting plasma cells through secretion of IFN-α/β and 
IL-6 (Jego et al., 2003).  Thus DCs may also directly stimulate proliferation of the 
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neoplastic clone in cutaneous MALT lymphoma and be at least partly responsible for 
the prominent degree of plasmacytic differentiation that is typically seen in this 
condition, including those cases described here (Willemze et al., 2005, LeBoit et al., 
1994, Rijlaarsdam et al., 1993). 
 
In summary, this study represents the first comprehensive analysis of DC subtype and 
maturation status in B-CLH and cutaneous MALT lymphoma, entities at either end of 
the spectrum of cutaneous B-cell lymphoproliferations.  The results support the concept 
that DCs play a central role in establishing B-cell proliferations in the skin.  It is 
possible that they may facilitate outgrowth of a neoplastic clone resulting in overt 
cutaneous MALT lymphoma.  LCs appear to play little or no role in the evolution of 
CBCLPs.  It may be that DDCs are largely responsible for driving the initial T-cell 
dependant B-cell proliferation, but that PDCs dictate the magnitude, duration and 
direction of the response.  In established cutaneous MALT lymphoma, PDCs are the 
dominant DC subtype and may act by damping down the anti-tumour host immune 
response, as well as directly stimulating the growth and differentiation of the neoplastic 
lymphocytes.  
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6B.5. CONCLUSIONS 
 
This work has defined the DC population in CBCLPs and suggests an important role for 
both PDCs and DDCs in disease evolution and progression.  The following may be 
concluded: 
 
1 PDCs and DDCs are the predominant DC subtypes in CBCLPs; LCs appear to have a 
minimal role. 
2 The number of ‘mature’ DCs in B-CLH suggests that T-cell priming is more 
important in such lesions, consistent with the hypothesis that B-CLH results from 
chronic antigenic stimulation. 
3 The relatively greater proportion of FXIIIA+ cells in cutaneous MALT lymphoma 
may imply an important role for alternatively activated DCs and/or  macrophages. 
4 These findings suggest immunomodulatory DCs/macrophages may be involved in 
suppressing the tumour immune response in cutaneous MALT lymphoma facilitating 
survival of the neoplastic clone.   
 
 
184 
7. REFERENCES 
 
 
AARNOUDSE, C. A., GARCIA VALLEJO, J. J., SAELAND, E. & VAN KOOYK, Y. 
(2006) Recognition of tumor glycans by antigen-presenting cells. Curr Opin 
Immunol, 18, 105-11. 
ABKOWITZ, J. L., OTT, R. M., HOLLY, R. D. & ADAMSON, J. W. (1988) Clonal 
evolution following chemotherapy-induced stem cell depletion in cats 
heterozygous for glucose-6-phosphate dehydrogenase. Blood, 71, 1687-92. 
ACKERMAN, A. B. & FLAXMAN, B. A. (1970) Granulomatous mycosis fungoides. 
Br J Dermatol, 82, 397-401. 
ADORINI, L., GIARRATANA, N. & PENNA, G. (2004) Pharmacological induction of 
tolerogenic dendritic cells and regulatory T cells. Semin Immunol, 16, 127-34. 
ADU-POKU, K., THOMAS, D. W., KHAN, M. K., HOLGATE, C. S. & SMITH, M. E. 
(2005) Langerhans cell histiocytosis in sequential discordant lymphoma. J Clin 
Pathol, 58, 104-6. 
ALBERT, M. L., SAUTER, B. & BHARDWAJ, N. (1998) Dendritic cells acquire 
antigen from apoptotic cells and induce class I-restricted CTLs. Nature, 392, 86-
9. 
ALLEN, C. E. & MCCLAIN, K. L. (2007) Langerhans cell histiocytosis: a review of 
past, current and future therapies. Drugs Today (Barc), 43, 627-43. 
ALLEN, R. C., ZOGHBI, H. Y., MOSELEY, A. B., ROSENBLATT, H. M. & 
BELMONT, J. W. (1992) Methylation of HpaII and HhaI sites near the 
polymorphic CAG repeat in the human androgen-receptor gene correlates with 
X chromosome inactivation. Am J Hum Genet, 51, 1229-39. 
AMOS-LANDGRAF, J. M., COTTLE, A., PLENGE, R. M., FRIEZ, M., SCHWARTZ, 
C. E., LONGSHORE, J. & WILLARD, H. F. (2006) X chromosome-
inactivation patterns of 1,005 phenotypically unaffected females. Am J Hum 
Genet, 79, 493-9. 
ANNELS, N. E., DA COSTA, C. E., PRINS, F. A., WILLEMZE, A., HOGENDOORN, 
P. C. & EGELER, R. M. (2003) Aberrant chemokine receptor expression and 
chemokine production by Langerhans cells underlies the pathogenesis of 
Langerhans cell histiocytosis. J Exp Med, 197, 1385-90. 
ARAI, E., SHIMIZU, M. & HIROSE, T. (2005) A review of 55 cases of cutaneous 
lymphoid hyperplasia: reassessment of the histopathologic findings leading to 
reclassification of 4 lesions as cutaneous marginal zone lymphoma and 19 as 
pseudolymphomatous folliculitis. Hum Pathol, 36, 505-11. 
BALDASSANO, M. F., BAILEY, E. M., FERRY, J. A., HARRIS, N. L. & DUNCAN, 
L. M. (1999) Cutaneous lymphoid hyperplasia and cutaneous marginal zone 
lymphoma: comparison of morphologic and immunophenotypic features. Am J 
Surg Pathol, 23, 88-96. 
BANCHEREAU, J. & STEINMAN, R. M. (1998) Dendritic cells and the control of 
immunity. Nature, 392, 245-52. 
BARR-NEA, L., SANDBANK, M. & ISHAY, J. (1976) Pseudolymphoma of skin 
induced by oriental hornet (Vespa orientalis) venom. Experientia, 32, 1564-5. 
BEISSERT, S., HOSOI, J., GRABBE, S., ASAHINA, A. & GRANSTEIN, R. D. 
(1995) IL-10 inhibits tumor antigen presentation by epidermal antigen-
presenting cells. J Immunol, 154, 1280-6. 
 
 
185 
BERGFELT, L., EMILSON, A., LINDBERG, M. & SCHEYNIUS, A. (1994) 
Quantitative and 3-dimensional analysis of Langerhans cells in basal cell 
carcinoma. A comparative study using light microscopy and confocal laser 
scanning microscopy. Br J Dermatol, 130, 273-80. 
BERNSTRAND, C., CARSTENSEN, H., JAKOBSEN, B., SVEJGAARD, A., 
HENTER, J. I. & OLERUP, O. (2003) Immunogenetic heterogeneity in single-
system and multisystem langerhans cell histiocytosis. Pediatr Res, 54, 30-6. 
BETTS, D. R., LEIBUNDGUT, K. E., FELDGES, A., PLUSS, H. J. & NIGGLI, F. K. 
(1998) Cytogenetic abnormalities in Langerhans cell histiocytosis. British 
Journal of Cancer, 77, 552-555. 
BEVERLEY, P. C. L., EGELER, R. M., ARCECI, R. J. & PRITCHARD, J. (2005) 
Science and society - The Nikolas Symposia and histiocytosis. Nature Reviews 
Cancer, 5, 488-494. 
BHARDWAJ, N., YOUNG, J. W., NISANIAN, A. J., BAGGERS, J. & STEINMAN, R. 
M. (1993) Small amounts of superantigen, when presented on dendritic cells, are 
sufficient to initiate T cell responses. J Exp Med, 178, 633-42. 
BJERCKE, S., GAUDERNACK, G. & BRAATHEN, L. R. (1985) Enriched 
Langerhans cells express more HLA-DR determinants than blood-derived 
adherent cells (monocytes and dendritic cells). Scand J Immunol, 21, 489-92. 
BLOMBERG, S., ELORANTA, M. L., MAGNUSSON, M., ALM, G. V. & 
RONNBLOM, L. (2003) Expression of the markers BDCA-2 and BDCA-4 and 
production of interferon-alpha by plasmacytoid dendritic cells in systemic lupus 
erythematosus. Arthritis Rheum, 48, 2524-32. 
BOGUNOVIC, M., GINHOUX, F., WAGERS, A., LOUBEAU, M., ISOLA, L. M., 
LUBRANO, L., NAJFELD, V., PHELPS, R. G., GROSSKREUTZ, C., 
SCIGLIANO, E., FRENETTE, P. S. & MERAD, M. (2006) Identification of a 
radio-resistant and cycling dermal dendritic cell population in mice and men. J 
Exp Med, 203, 2627-38. 
BOULOC, A., DELFAU-LARUE, M. H., LENORMAND, B., MEUNIER, F., 
WECHSLER, J., THOMINE, E., REVUZ, J., FARCET, J. P., JOLY, P. & 
BAGOT, M. (1999) Polymerase chain reaction analysis of immunoglobulin gene 
rearrangement in cutaneous lymphoid hyperplasias. French Study Group for 
Cutaneous Lymphomas. Arch Dermatol, 135, 168-72. 
BRADY, S. P., MAGRO, C. M., DIAZ-CANO, S. J. & WOLFE, H. J. (1999) Analysis 
of clonality of atypical cutaneous lymphoid infiltrates associated with drug 
therapy by PCR/DGGE. Hum Pathol, 30, 130-6. 
BRINKMAN, A. B., ROELOFSEN, T., PENNINGS, S. W., MARTENS, J. H., 
JENUWEIN, T. & STUNNENBERG, H. G. (2006) Histone modification 
patterns associated with the human X chromosome. EMBO Rep, 7, 628-34. 
BROCKER, T. (1997) Survival of mature CD4 T lymphocytes is dependent on major 
histocompatibility complex class II-expressing dendritic cells. J Exp Med, 186, 
1223-32. 
BROWN, R. D., POPE, B., MURRAY, A., ESDALE, W., SZE, D. M., GIBSON, J., 
HO, P. J., HART, D. & JOSHUA, D. (2001) Dendritic cells from patients with 
myeloma are numerically normal but functionally defective as they fail to up-
regulate CD80 (B7-1) expression after huCD40LT stimulation because of 
inhibition by transforming growth factor-beta1 and interleukin-10. Blood, 98, 
2992-8. 
 
 
186 
BURG, G., KEMPF, W., COZZIO, A., FEIT, J., WILLEMZE, R., E, S. J., DUMMER, 
R., BERTI, E., CERRONI, L., CHIMENTI, S., DIAZ-PEREZ, J. L., GRANGE, 
F., HARRIS, N. L., KAZAKOV, D. V., KERL, H., KURRER, M., KNOBLER, 
R., MEIJER, C. J., PIMPINELLI, N., RALFKIAER, E., RUSSELL-JONES, R., 
SANDER, C., SANTUCCI, M., STERRY, W., SWERDLOW, S. H., 
VERMEER, M. H., WECHSLER, J. & WHITTAKER, S. (2005) WHO/EORTC 
classification of cutaneous lymphomas 2005: histological and molecular aspects. 
J Cutan Pathol, 32, 647-74. 
BUSQUE, L., MIO, R., MATTIOLI, J., BRAIS, E., BLAIS, N., LALONDE, Y., 
MARAGH, M. & GILLILAND, D. G. (1996) Nonrandom X-inactivation 
patterns in normal females: lyonization ratios vary with age. Blood, 88, 59-65. 
BUSQUE, L., PAQUETTE, Y., PROVOST, S., ROY, D. C., LEVINE, R. L., 
MOLLICA, L. & GARY GILLILAND, D. (2009) Skewing of X-inactivation 
ratios in blood cells of aging women is confirmed by independent methodologies. 
Blood, 113, 3472-4. 
CAMINATI, A. & HARARI, S. (2006) Smoking-related interstitial pneumonias and 
pulmonary Langerhans cell histiocytosis. Proc Am Thorac Soc, 3, 299-306. 
CAO, X., SUGITA, M., VAN DER WEL, N., LAI, J., ROGERS, R. A., PETERS, P. J. 
& BRENNER, M. B. (2002) CD1 molecules efficiently present antigen in 
immature dendritic cells and traffic independently of MHC class II during 
dendritic cell maturation. J Immunol, 169, 4770-7. 
CARBONNELLE, A., MARTIN-GARCIA, N., ORTONNE, N., LAROCHE, L., 
BAGOT, M., MOLINIER-FRENKEL, V. & WECHSLER, J. (2007) Study of 
the reactive dendritic cells in small B-cell lymphoproliferations of the skin. 
Virchows Arch, 450, 441-7. 
CARREL, L., HUNT, P. A. & WILLARD, H. F. (1996) Tissue and lineage-specific 
variation in inactive X chromosome expression of the murine Smcx gene. Hum 
Mol Genet, 5, 1361-6. 
CAUX, C., VANBERVLIET, B., MASSACRIER, C., DEZUTTER-DAMBUYANT, C., 
DE SAINT-VIS, B., JACQUET, C., YONEDA, K., IMAMURA, S., SCHMITT, 
D. & BANCHEREAU, J. (1996) CD34+ hematopoietic progenitors from human 
cord blood differentiate along two independent dendritic cell pathways in 
response to GM-CSF+TNF alpha. J Exp Med, 184, 695-706. 
CELLA, M., JARROSSAY, D., FACCHETTI, F., ALEBARDI, O., NAKAJIMA, H., 
LANZAVECCHIA, A. & COLONNA, M. (1999) Plasmacytoid monocytes 
migrate to inflamed lymph nodes and produce large amounts of type I interferon. 
Nat Med, 5, 919-23. 
CELLA, M., SALLUSTO, F. & LANZAVECCHIA, A. (1997) Origin, maturation and 
antigen presenting function of dendritic cells. Curr Opin Immunol, 9, 10-6. 
CELLA, M., SCHEIDEGGER, D., PALMER-LEHMANN, K., LANE, P., 
LANZAVECCHIA, A. & ALBER, G. (1996) Ligation of CD40 on dendritic 
cells triggers production of high levels of interleukin-12 and enhances T cell 
stimulatory capacity: T-T help via APC activation. J Exp Med, 184, 747-52. 
CHAMPION, K. M., GILBERT, J. G., ASIMAKOPOULOS, F. A., HINSHELWOOD, 
S. & GREEN, A. R. (1997) Clonal haemopoiesis in normal elderly women: 
implications for the myeloproliferative disorders and myelodysplastic 
syndromes. Br J Haematol, 97, 920-6. 
 
 
187 
CHANG, K. C., HUANG, G. C., JONES, D. & LIN, Y. H. (2007) Distribution patterns 
of dendritic cells and T cells in diffuse large B-cell lymphomas correlate with 
prognoses. Clin Cancer Res, 13, 6666-72. 
CHATURVEDI, V., CHU, M. S., CARROL, B. M., BRENNER, B. J. & NICKOLOFF, 
B. J. (2002) Estimation of size of clonal unit for keratinocytes in normal human 
skin. Arch Pathol Lab Med, 126, 420-4. 
CHAUX, P., FAVRE, N., MARTIN, M. & MARTIN, F. (1997) Tumor-infiltrating 
dendritic cells are defective in their antigen-presenting function and inducible 
B7 expression in rats. Int J Cancer, 72, 619-24. 
CHEN, G. L. & PRCHAL, J. T. (2007) X-linked clonality testing: interpretation and 
limitations. Blood, 110, 1411-9. 
CHRISTENSEN, K., KRISTIANSEN, M., HAGEN-LARSEN, H., SKYTTHE, A., 
BATHUM, L., JEUNE, B., ANDERSEN-RANBERG, K., VAUPEL, J. W. & 
ORSTAVIK, K. H. (2000) X-linked genetic factors regulate hematopoietic stem-
cell kinetics in females. Blood, 95, 2449-51. 
COLASANTE, A., CASTRILLI, G., AIELLO, F. B., BRUNETTI, M. & MUSIANI, P. 
(1995) Role of cytokines in distribution and differentiation of dendritic 
cell/Langerhans' cell lineage in human primary carcinomas of the lung. Hum 
Pathol, 26, 866-72. 
COLONNA, M., TRINCHIERI, G. & LIU, Y. J. (2004) Plasmacytoid dendritic cells in 
immunity. Nat Immunol, 5, 1219-26. 
CUMBERBATCH, M., GOULD, S. J., PETERS, S. W. & KIMBER, I. (1991) MHC 
class II expression by Langerhans' cells and lymph node dendritic cells: possible 
evidence for maturation of Langerhans' cells following contact sensitization. 
Immunology, 74, 414-9. 
DABBS, D. J. (2002) Diagnostic immunohistochemistry, New York, Churchill 
Livingstone. 
DE GRAAF, J. H., TAMMINGA, R. Y., DAM-MEIRING, A., KAMPS, W. A. & 
TIMENS, W. (1996) The presence of cytokines in Langerhans' cell histiocytosis. 
J Pathol, 180, 400-6. 
DE GRAAF, J. H., TAMMINGA, R. Y., KAMPS, W. A. & TIMENS, W. (1994) 
Langerhans' cell histiocytosis: expression of leukocyte cellular adhesion 
molecules suggests abnormal homing and differentiation. Am J Pathol, 144, 
466-72. 
DE PANFILIS, G., SOLIGO, D., MANARA, G. C., FERRARI, C., TORRESANI, C. & 
ZUCCHI, A. (1990) Human normal-resting epidermal Langerhans cells do 
express the type 3 complement receptor. Br J Dermatol, 122, 127-36. 
DE SAINT-VIS, B., VINCENT, J., VANDENABEELE, S., VANBERVLIET, B., PIN, 
J. J., AIT-YAHIA, S., PATEL, S., MATTEI, M. G., BANCHEREAU, J., 
ZURAWSKI, S., DAVOUST, J., CAUX, C. & LEBECQUE, S. (1998) A novel 
lysosome-associated membrane glycoprotein, DC-LAMP, induced upon DC 
maturation, is transiently expressed in MHC class II compartment. Immunity, 9, 
325-36. 
DE SMEDT, T., PAJAK, B., MURAILLE, E., LESPAGNARD, L., HEINEN, E., DE 
BAETSELIER, P., URBAIN, J., LEO, O. & MOSER, M. (1996) Regulation of 
dendritic cell numbers and maturation by lipopolysaccharide in vivo. J Exp Med, 
184, 1413-24. 
 
 
188 
DENG, G., LU, Y., ZLOTNIKOV, G., THOR, A. D. & SMITH, H. S. (1996) Loss of 
heterozygosity in normal tissue adjacent to breast carcinomas. Science, 274, 
2057-9. 
DHODAPKAR, M. V., STEINMAN, R. M., KRASOVSKY, J., MUNZ, C. & 
BHARDWAJ, N. (2001) Antigen-specific inhibition of effector T cell function 
in humans after injection of immature dendritic cells. J Exp Med, 193, 233-8. 
DIAMANDIDOU, E., COLOME-GRIMMER, M., FAYAD, L., DUVIC, M. & 
KURZROCK, R. (1998) Transformation of mycosis fungoides/Sezary 
syndrome: clinical characteristics and prognosis. Blood, 92, 1150-9. 
DUBOIS, B., BARTHELEMY, C., DURAND, I., LIU, Y. J., CAUX, C. & BRIERE, F. 
(1999) Toward a role of dendritic cells in the germinal center reaction: triggering 
of B cell proliferation and isotype switching. J Immunol, 162, 3428-36. 
DUMMER, R., KAMARASHEV, J., KEMPF, W., HAFFNER, A. C., HESS-SCHMID, 
M. & BURG, G. (2002) Junctional CD8+ cutaneous lymphomas with 
nonaggressive clinical behavior: a CD8+ variant of mycosis fungoides? Arch 
Dermatol, 138, 199-203. 
DZIONEK, A., FUCHS, A., SCHMIDT, P., CREMER, S., ZYSK, M., MILTENYI, S., 
BUCK, D. W. & SCHMITZ, J. (2000) BDCA-2, BDCA-3, and BDCA-4: three 
markers for distinct subsets of dendritic cells in human peripheral blood. J 
Immunol, 165, 6037-46. 
DZIONEK, A., SOHMA, Y., NAGAFUNE, J., CELLA, M., COLONNA, M., 
FACCHETTI, F., GUNTHER, G., JOHNSTON, I., LANZAVECCHIA, A., 
NAGASAKA, T., OKADA, T., VERMI, W., WINKELS, G., YAMAMOTO, T., 
ZYSK, M., YAMAGUCHI, Y. & SCHMITZ, J. (2001) BDCA-2, a novel 
plasmacytoid dendritic cell-specific type II C-type lectin, mediates antigen 
capture and is a potent inhibitor of interferon alpha/beta induction. J Exp Med, 
194, 1823-34. 
EBNER, S., EHAMMER, Z., HOLZMANN, S., SCHWINGSHACKL, P., FORSTNER, 
M., STOITZNER, P., HUEMER, G. M., FRITSCH, P. & ROMANI, N. (2004) 
Expression of C-type lectin receptors by subsets of dendritic cells in human skin. 
Int Immunol, 16, 877-87. 
ECKERT, F. & SCHMID, U. (1989) Identification of plasmacytoid T cells in lymphoid 
hyperplasia of the skin. Arch Dermatol, 125, 1518-24. 
EDWARDS, C. A., RENS, W., CLARKE, O., MUNGALL, A. J., HORE, T., GRAVES, 
J. A., DUNHAM, I., FERGUSON-SMITH, A. C. & FERGUSON-SMITH, M. A. 
(2007) The evolution of imprinting: chromosomal mapping of orthologues of 
mammalian imprinted domains in monotreme and marsupial mammals. BMC 
Evol Biol, 7, 157. 
EGELER, R. M., FAVARA, B. E., LAMAN, J. D. & CLAASSEN, E. (2000) Abundant 
expression of CD40 and CD40-ligand (CD154) in paediatric Langerhans cell 
histiocytosis lesions. Eur J Cancer, 36, 2105-10. 
EGELER, R. M., FAVARA, B. E., VAN MEURS, M., LAMAN, J. D. & CLAASSEN, 
E. (1999) Differential In situ cytokine profiles of Langerhans-like cells and T 
cells in Langerhans cell histiocytosis: abundant expression of cytokines relevant 
to disease and treatment. Blood, 94, 4195-201. 
EGELER, R. M., NEGLIA, J. P., ARICO, M., FAVARA, B. E., HEITGER, A., 
NESBIT, M. E. & NICHOLSON, H. S. (1998) The relation of Langerhans cell 
histiocytosis to acute leukemia, lymphomas, and other solid tumors - The LCH-
 
 
189 
Malignancy Study Group of the Histiocyte Society. Hematology-Oncology 
Clinics of North America, 12, 369-+. 
EGELER, R. M., NEGLIA, J. P., PUCCETTI, D. M., BRENNAN, C. A. & NESBIT, M. 
E. (1993) Association of Langerhans Cell Histiocytosis with Malignant 
Neoplasms. Cancer, 71, 865-873. 
EMILE, J. F., WECHSLER, J., BROUSSE, N., BOULLAND, M. L., COLOGON, R., 
FRAITAG, S., VOISIN, M. C., GAULARD, P., BOUMSELL, L. & ZAFRANI, 
E. S. (1995) Langerhans' cell histiocytosis. Definitive diagnosis with the use of 
monoclonal antibody O10 on routinely paraffin-embedded samples. Am J Surg 
Pathol, 19, 636-41. 
ENGERING, A., VAN VLIET, S. J., HEBEDA, K., JACKSON, D. G., PREVO, R., 
SINGH, S. K., GEIJTENBEEK, T. B., VAN KRIEKEN, H. & VAN KOOYK, 
Y. (2004) Dynamic populations of dendritic cell-specific ICAM-3 grabbing 
nonintegrin-positive immature dendritic cells and liver/lymph node-specific 
ICAM-3 grabbing nonintegrin-positive endothelial cells in the outer zones of the 
paracortex of human lymph nodes. Am J Pathol, 164, 1587-95. 
FEARON, E. R., KOHN, D. B., WINKELSTEIN, J. A., VOGELSTEIN, B. & BLAESE, 
R. M. (1988) Carrier detection in the Wiskott Aldrich syndrome. Blood, 72, 
1735-9. 
FELDMAN, A. L., BERTHOLD, F., ARCECI, R. J., ABRAMOWSKY, C., 
SHEHATA, B. M., MANN, K. P., LAUER, S. J., PRITCHARD, J., RAFFELD, 
M. & JAFFE, E. S. (2005) Clonal relationship between precursor T-
lymphoblastic leukaemia/lymphoma and Langerhans-cell histiocytosis. Lancet 
Oncol, 6, 435-7. 
FELDMAN, M. Y. (1973) Reactions of nucleic acids and nucleoproteins with 
formaldehyde. Prog Nucleic Acid Res Mol Biol, 13, 1-49. 
FERREIRA, L. M., EMERICH, P. S., DINIZ, L. M., LAGE, L. & REDIGHIERI, I. 
(2009) [Langerhans cell histiocytosis: Letterer-Siwe disease - the importance of 
dermatological diagnosis in two cases]. An Bras Dermatol, 84, 405-9. 
FEY, M. F., LIECHTI-GALLATI, S., VON ROHR, A., BORISCH, B., THEILKAS, L., 
SCHNEIDER, V., OESTREICHER, M., NAGEL, S., ZIEMIECKI, A. & 
TOBLER, A. (1994) Clonality and X-inactivation patterns in hematopoietic cell 
populations detected by the highly informative M27 beta DNA probe. Blood, 83, 
931-8. 
FEY, M. F., PETER, H. J., HINDS, H. L., ZIMMERMANN, A., LIECHTI-GALLATI, 
S., GERBER, H., STUDER, H. & TOBLER, A. (1992) Clonal analysis of 
human tumors with M27 beta, a highly informative polymorphic X 
chromosomal probe. J Clin Invest, 89, 1438-44. 
FIALKOW, P. J. (1973) Primordial cell pool size and lineage relationships of five 
human cell types. Ann Hum Genet, 37, 39-48. 
FIDLER, I. J. & KRIPKE, M. L. (1977) Metastasis results from preexisting variant cells 
within a malignant tumor. Science, 197, 893-5. 
FLAIG, M. J., SCHUHMANN, K. & SANDER, C. A. (2000) Impact of molecular 
analysis in the diagnosis of cutaneous lymphoid infiltrates. Semin Cutan Med 
Surg, 19, 87-90. 
FRIEDRICH, U., WARBURG, M. & JORGENSEN, A. L. (1993) X-inactivation 
pattern in carriers of X-linked retinitis pigmentosa: a valuable means of 
prognostic evaluation? Hum Genet, 92, 359-63. 
 
 
190 
FUJITA, S., SEINO, K., SATO, K., SATO, Y., EIZUMI, K., YAMASHITA, N. & 
TANIGUCHI, M. (2006) Regulatory dendritic cells act as regulators of acute 
lethal systemic inflammatory response. Blood, 107, 3656-64. 
GABRILOVICH, D. I., CIERNIK, I. F. & CARBONE, D. P. (1996) Dendritic cells in 
antitumor immune responses. I. Defective antigen presentation in tumor-bearing 
hosts. Cell Immunol, 170, 101-10. 
GABRILOVICH, D. I., CORAK, J., CIERNIK, I. F., KAVANAUGH, D. & 
CARBONE, D. P. (1997) Decreased antigen presentation by dendritic cells in 
patients with breast cancer. Clin Cancer Res, 3, 483-90. 
GALE, R. E., FIELDING, A. K., HARRISON, C. N. & LINCH, D. C. (1997) Acquired 
skewing of X-chromosome inactivation patterns in myeloid cells of the elderly 
suggests stochastic clonal loss with age. Br J Haematol, 98, 512-9. 
GALE, R. E., WHEADON, H., BOULOS, P. & LINCH, D. C. (1994) Tissue specificity 
of X-chromosome inactivation patterns. Blood, 83, 2899-905. 
GALLARDO, F., BARRANCO, C., TOLL, A. & PUJOL, R. M. (2002) CD30 antigen 
expression in cutaneous inflammatory infiltrates of scabies: a dynamic 
immunophenotypic pattern that should be distinguished from lymphomatoid 
papulosis. J Cutan Pathol, 29, 368-73. 
GARBE, C., STEIN, H., DIENEMANN, D. & ORFANOS, C. E. (1991) Borrelia 
burgdorferi-associated cutaneous B cell lymphoma: clinical and 
immunohistologic characterization of four cases. J Am Acad Dermatol, 24, 584-
90. 
GEISSMANN, F., EMILE, J. F., ANDRY, P., THOMAS, C., FRAITAG, S., DE 
PROST, Y. & BROUSSE, N. (1997) Lack of expression of E-cadherin is 
associated with dissemination of Langerhans' cell histiocytosis and poor 
outcome. J Pathol, 181, 301-4. 
GEISSMANN, F., LEPELLETIER, Y., FRAITAG, S., VALLADEAU, J., BODEMER, 
C., DEBRE, M., LEBORGNE, M., SAELAND, S. & BROUSSE, N. (2001) 
Differentiation of Langerhans cells in Langerhans cell histiocytosis. Blood, 97, 
1241-8. 
GIONA, F., CARUSO, R., TESTI, A. M., MOLETI, M. L., MALAGNINO, F., 
MARTELLI, M., RUCO, L., GIANNETTI, G. P., ANNIBALI, S. & 
MANDELLI, F. (1997) Langerhans' cell histiocytosis in adults: a clinical and 
therapeutic analysis of 11 patients from a single institution. Cancer, 80, 1786-91. 
GLASEL, J. A. (1995) Validity of nucleic acid purities monitored by 260nm/280nm 
absorbance ratios. Biotechniques, 18, 62-3. 
GLOTZBECKER, M. P., CARPENTIERI, D. F. & DORMANS, J. P. (2004) 
Langerhans cell histiocytosis: a primary viral infection of bone? Human herpes 
virus 6 latent protein detected in lymphocytes from tissue of children. J Pediatr 
Orthop, 24, 123-9. 
GLOTZBECKER, M. P., DORMANS, J. P., PAWEL, B. R., WILLS, B. P., JOSHI, Y., 
ELKAN, M. & HODINKA, R. L. (2006) Langerhans cell histiocytosis and 
human herpes virus 6 (HHV-6), an analysis by real-time polymerase chain 
reaction. J Orthop Res, 24, 313-20. 
GOELZ, S. E., HAMILTON, S. R. & VOGELSTEIN, B. (1985) Purification of DNA 
from Formaldehyde Fixed and Paraffin Embedded Human-Tissue. Biochemical 
and Biophysical Research Communications, 130, 118-126. 
 
 
191 
GONG, L., ZHANG, W., LI, Y. H., LI, G., ZHU, S. J., TONG, X., ZHANG, Y. Q., LI, 
H. T. & SU, Q. (2007) [Fibrous dysplasia: molecular clonality analysis of 21 
cases]. Zhonghua Bing Li Xue Za Zhi, 36, 592-5. 
GOODLAD, J. R., DAVIDSON, M. M., HOLLOWOOD, K., BATSTONE, P. & HO-
YEN, D. O. (2000) Borrelia burgdorferi-associated cutaneous marginal zone 
lymphoma: a clinicopathological study of two cases illustrating the temporal 
progression of B. burgdorferi-associated B-cell proliferation in the skin. 
Histopathology, 37, 501-8. 
GOTTENBERG, J. E., CAGNARD, N., LUCCHESI, C., LETOURNEUR, F., 
MISTOU, S., LAZURE, T., JACQUES, S., BA, N., ITTAH, M., LEPAJOLEC, 
C., LABETOULLE, M., ARDIZZONE, M., SIBILIA, J., FOURNIER, C., 
CHIOCCHIA, G. & MARIETTE, X. (2006) Activation of IFN pathways and 
plasmacytoid dendritic cell recruitment in target organs of primary Sjogren's 
syndrome. Proc Natl Acad Sci U S A, 103, 2770-5. 
GRANT, M., ZUCCOTTI, M. & MONK, M. (1992) Methylation of CpG sites of two 
X-linked genes coincides with X-inactivation in the female mouse embryo but 
not in the germ line. Nat Genet, 2, 161-6. 
GREENBERGER, J. S., CROCKER, A. C., VAWTER, G., JAFFE, N. & CASSADY, J. 
R. (1981) Results of treatment of 127 patients with systemic histiocytosis. 
Medicine (Baltimore), 60, 311-38. 
GREER, C. E., LUND, J. K. & MANOS, M. M. (1991) PCR amplification from 
paraffin-embedded tissues: recommendations on fixatives for long-term storage 
and prospective studies. PCR Methods Appl, 1, 46-50. 
GROIS, N., POTSCHGER, U., PROSCH, H., MINKOV, M., ARICO, M., BRAIER, J., 
HENTER, J. I., JANKA-SCHAUB, G., LADISCH, S., RITTER, J., STEINER, 
M., UNGER, E. & GADNER, H. (2006) Risk factors for diabetes insipidus in 
langerhans cell histiocytosis. Pediatr Blood Cancer, 46, 228-33. 
GROUARD, G., RISSOAN, M. C., FILGUEIRA, L., DURAND, I., BANCHEREAU, J. 
& LIU, Y. J. (1997) The enigmatic plasmacytoid T cells develop into dendritic 
cells with interleukin (IL)-3 and CD40-ligand. J Exp Med, 185, 1101-11. 
GUTTMAN-YASSKY, E., LOWES, M. A., FUENTES-DUCULAN, J., WHYNOT, J., 
NOVITSKAYA, I., CARDINALE, I., HAIDER, A., KHATCHERIAN, A., 
CARUCCI, J. A., BERGMAN, R. & KRUEGER, J. G. (2007) Major differences 
in inflammatory dendritic cells and their products distinguish atopic dermatitis 
from psoriasis. J Allergy Clin Immunol, 119, 1210-7. 
HAITEL, A., WIENER, H. G., NEUDERT, B., MARBERGER, M. & SUSANI, M. 
(2001) Expression of the cell cycle proteins p21, p27, and pRb in clear cell renal 
cell carcinoma and their prognostic significance. Urology, 58, 477-81. 
HART, D. N. (1997) Dendritic cells: unique leukocyte populations which control the 
primary immune response. Blood, 90, 3245-87. 
HATAKEYAMA, C., ANDERSON, C. L., BEEVER, C. L., PENAHERRERA, M. S., 
BROWN, C. J. & ROBINSON, W. P. (2004) The dynamics of X-inactivation 
skewing as women age. Clin Genet, 66, 327-32. 
HAWTHORN, R. J. & MACLEAN, A. B. (1987) Langerhans' cell density in the normal 
exocervical epithelium and in the cervical intraepithelial neoplasia. Br J Obstet 
Gynaecol, 94, 815-8. 
HORE, T. A., KOINA, E., WAKEFIELD, M. J. & MARSHALL GRAVES, J. A. 
(2007) The region homologous to the X-chromosome inactivation centre has 
 
 
192 
been disrupted in marsupial and monotreme mammals. Chromosome Res, 15, 
147-61. 
HSU, F. J., BENIKE, C., FAGNONI, F., LILES, T. M., CZERWINSKI, D., TAIDI, B., 
ENGLEMAN, E. G. & LEVY, R. (1996) Vaccination of patients with B-cell 
lymphoma using autologous antigen-pulsed dendritic cells. Nat Med, 2, 52-8. 
IMBEAUD, S., GRAUDENS, E., BOULANGER, V., BARLET, X., ZABORSKI, P., 
EVENO, E., MUELLER, O., SCHROEDER, A. & AUFFRAY, C. (2005) 
Towards standardization of RNA quality assessment using user-independent 
classifiers of microcapillary electrophoresis traces. Nucleic Acids Res, 33, e56. 
IZIKSON, L., VANDERPOOL, J., BRODSKY, G., MIHM, M. C., JR. & 
ZEMBOWICZ, A. (2004) Combined basal cell carcinoma and Langerhans cell 
histiocytosis of the scrotum in a patient with occupational exposure to coal tar 
and dust. Int J Dermatol, 43, 678-80. 
JAHNSEN, F. L., LUND-JOHANSEN, F., DUNNE, J. F., FARKAS, L., HAYE, R. & 
BRANDTZAEG, P. (2000) Experimentally induced recruitment of plasmacytoid 
(CD123high) dendritic cells in human nasal allergy. J Immunol, 165, 4062-8. 
JEGO, G., PALUCKA, A. K., BLANCK, J. P., CHALOUNI, C., PASCUAL, V. & 
BANCHEREAU, J. (2003) Plasmacytoid dendritic cells induce plasma cell 
differentiation through type I interferon and interleukin 6. Immunity, 19, 225-34. 
JEZIORSKI, E., SENECHAL, B., MOLINA, T. J., DEVEZ, F., LERUEZ-VILLE, M., 
MORAND, P., GLORION, C., MANSUY, L., GAUDELUS, J., DEBRE, M., 
JAUBERT, F., SEIGNEURIN, J. M., THOMAS, C., JOAB, I., DONADIEU, J. 
& GEISSMANN, F. (2008) Herpes-virus infection in patients with Langerhans 
cell histiocytosis: a case-controlled sero-epidemiological study, and in situ 
analysis. PLoS ONE, 3, e3262. 
JIH, D. M., SALCEDO, S. L. & JAWORSKY, C. (2002) Benign cephalic histiocytosis: 
a case report and review. J Am Acad Dermatol, 47, 908-13. 
JONES, P. A. (1996) DNA methylation errors and cancer. Cancer Res, 56, 2463-7. 
JONULEIT, H., SCHMITT, E., SCHULER, G., KNOP, J. & ENK, A. H. (2000) 
Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with 
regulatory properties by repetitive stimulation with allogeneic immature human 
dendritic cells. J Exp Med, 192, 1213-22. 
JONULEIT, H., SCHMITT, E., STEINBRINK, K. & ENK, A. H. (2001) Dendritic cells 
as a tool to induce anergic and regulatory T cells. Trends Immunol, 22, 394-400. 
JOVANOVIC, L., DELAHUNT, B., MCIVER, B., EBERHARDT, N. L. & GREBE, S. 
K. (2003) Thyroid gland clonality revisited: the embryonal patch size of the 
normal human thyroid gland is very large, suggesting X-chromosome 
inactivation tumor clonality studies of thyroid tumors have to be interpreted with 
caution. J Clin Endocrinol Metab, 88, 3284-91. 
KADOWAKI, N., ANTONENKO, S., LAU, J. Y. & LIU, Y. J. (2000) Natural 
interferon alpha/beta-producing cells link innate and adaptive immunity. J Exp 
Med, 192, 219-26. 
KANZLER, H., KUPPERS, R., HANSMANN, M. L. & RAJEWSKY, K. (1996) 
Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth 
of a dominant tumor clone derived from (crippled) germinal center B cells. J 
Exp Med, 184, 1495-505. 
KATZ, S. I., TAMAKI, K. & SACHS, D. H. (1979) Epidermal Langerhans cells are 
derived from cells originating in bone marrow. Nature, 282, 324-6. 
 
 
193 
KEMPF, W., KERL, H. & KUTZNER, H. (2010) CD123-positive plasmacytoid 
dendritic cells in primary cutaneous marginal zone B-cell lymphoma: A crucial 
role and a new lymphoma paradigm. Am J Dermatopathol, 32, 194-6. 
KIM, Y. H., CHOW, S., VARGHESE, A. & HOPPE, R. T. (1999) Clinical 
characteristics and long-term outcome of patients with generalized patch and/or 
plaque (T2) mycosis fungoides. Arch Dermatol, 135, 26-32. 
KIM, Y. H. & HOPPE, R. T. (1999) Mycosis fungoides and the Sezary syndrome. 
Semin Oncol, 26, 276-89. 
KIM, Y. H., JENSEN, R. A., WATANABE, G. L., VARGHESE, A. & HOPPE, R. T. 
(1996) Clinical stage IA (limited patch and plaque) mycosis fungoides. A long-
term outcome analysis. Arch Dermatol, 132, 1309-13. 
KIM, Y. H., LIU, H. L., MRAZ-GERNHARD, S., VARGHESE, A. & HOPPE, R. T. 
(2003) Long-term outcome of 525 patients with mycosis fungoides and Sezary 
syndrome: clinical prognostic factors and risk for disease progression. Arch 
Dermatol, 139, 857-66. 
KNUDSEN, G. P., PEDERSEN, J., KLINGENBERG, O., LYGREN, I. & ORSTAVIK, 
K. H. (2007) Increased skewing of X chromosome inactivation with age in both 
blood and buccal cells. Cytogenet Genome Res, 116, 24-8. 
KOCH, F., STANZL, U., JENNEWEIN, P., JANKE, K., HEUFLER, C., KAMPGEN, 
E., ROMANI, N. & SCHULER, G. (1996) High level IL-12 production by 
murine dendritic cells: upregulation via MHC class II and CD40 molecules and 
downregulation by IL-4 and IL-10. J Exp Med, 184, 741-6. 
KOHRGRUBER, N., GROGER, M., MERANER, P., KRIEHUBER, E., 
PETZELBAUER, P., BRANDT, S., STINGL, G., ROT, A. & MAURER, D. 
(2004) Plasmacytoid dendritic cell recruitment by immobilized CXCR3 ligands. 
J Immunol, 173, 6592-602. 
KRISTIANSEN, M., KNUDSEN, G. P., BATHUM, L., NAUMOVA, A. K., 
SORENSEN, T. I., BRIX, T. H., SVENDSEN, A. J., CHRISTENSEN, K., 
KYVIK, K. O. & ORSTAVIK, K. H. (2005) Twin study of genetic and aging 
effects on X chromosome inactivation. Eur J Hum Genet, 13, 599-606. 
KUTZNER, H., KERL, H., PFALTZ, M. C. & KEMPF, W. (2009) CD123-positive 
plasmacytoid dendritic cells in primary cutaneous marginal zone B-cell 
lymphoma: diagnostic and pathogenetic implications. Am J Surg Pathol, 33, 
1307-13. 
KUWANA, M. (2002) Induction of anergic and regulatory T cells by plasmacytoid 
dendritic cells and other dendritic cell subsets. Hum Immunol, 63, 1156-63. 
LEBOIT, P. E., MCNUTT, N. S., REED, J. A., JACOBSON, M. & WEISS, L. M. 
(1994) Primary cutaneous immunocytoma. A B-cell lymphoma that can easily 
be mistaken for cutaneous lymphoid hyperplasia. Am J Surg Pathol, 18, 969-78. 
LEBON, J. M., TAM, P. P., SINGER-SAM, J., RIGGS, A. D. & TAN, S. S. (1995) 
Mouse endogenous X-linked genes do not show lineage-specific delayed 
inactivation during development. Genet Res, 65, 223-7. 
LECHMANN, M., KROOSHOOP, D. J., DUDZIAK, D., KREMMER, E., KUHNT, C., 
FIGDOR, C. G., SCHULER, G. & STEINKASSERER, A. (2001) The 
extracellular domain of CD83 inhibits dendritic cell-mediated T cell stimulation 
and binds to a ligand on dendritic cells. J Exp Med, 194, 1813-21. 
LECLAIR, B., FREGEAU, C. J., BOWEN, K. L. & FOURNEY, R. M. (2004) 
Systematic analysis of stutter percentages and allele peak height and peak area 
 
 
194 
ratios at heterozygous STR loci for forensic casework and database samples. J 
Forensic Sci, 49, 968-80. 
LEGGE, K. L., GREGG, R. K., MALDONADO-LOPEZ, R., LI, L., CAPRIO, J. C., 
MOSER, M. & ZAGHOUANI, H. (2002) On the role of dendritic cells in 
peripheral T cell tolerance and modulation of autoimmunity. J Exp Med, 196, 
217-27. 
LEHMANN, U. & KREIPE, H. (2001) Real-time PCR analysis of DNA and RNA 
extracted from formalin-fixed and paraffin-embedded biopsies. Methods, 25, 
409-18. 
LEVINGS, M. K., GREGORI, S., TRESOLDI, E., CAZZANIGA, S., BONINI, C. & 
RONCAROLO, M. G. (2005) Differentiation of Tr1 cells by immature dendritic 
cells requires IL-10 but not CD25+CD4+ Tr cells. Blood, 105, 1162-9. 
LI, S. & BOROWITZ, M. J. (2001) CD79a(+) T-cell lymphoblastic lymphoma with 
coexisting Langerhans cell histiocytosis. Arch Pathol Lab Med, 125, 958-60. 
LINDER, D. & GARTLER, S. M. (1965) Glucose-6-phosphate dehydrogenase 
mosaicism: utilization as a cell marker in the study of leiomyomas. Science, 150, 
67-9. 
LITINSKIY, M. B., NARDELLI, B., HILBERT, D. M., HE, B., SCHAFFER, A., 
CASALI, P. & CERUTTI, A. (2002) DCs induce CD40-independent 
immunoglobulin class switching through BLyS and APRIL. Nat Immunol, 3, 
822-9. 
LIU, Y. (2005) IPC: Professional Type 1 Interferon-Producing Cells and Plasmacytoid 
Dendritic Cell Precursors. Annu Rev Immunol, 23, 275-306. 
LOCK, L. F., TAKAGI, N. & MARTIN, G. R. (1987) Methylation of the Hprt gene on 
the inactive X occurs after chromosome inactivation. Cell, 48, 39-46. 
LOPATINA, N., HASKELL, J. F., ANDREWS, L. G., POOLE, J. C., SALDANHA, S. 
& TOLLEFSBOL, T. (2002) Differential maintenance and de novo methylating 
activity by three DNA methyltransferases in aging and immortalized fibroblasts. 
J Cell Biochem, 84, 324-34. 
LOWES, M. A., CHAMIAN, F., ABELLO, M. V., FUENTES-DUCULAN, J., LIN, S. 
L., NUSSBAUM, R., NOVITSKAYA, I., CARBONARO, H., CARDINALE, I., 
KIKUCHI, T., GILLEAUDEAU, P., SULLIVAN-WHALEN, M., 
WITTKOWSKI, K. M., PAPP, K., GAROVOY, M., DUMMER, W., 
STEINMAN, R. M. & KRUEGER, J. G. (2005) Increase in TNF-alpha and 
inducible nitric oxide synthase-expressing dendritic cells in psoriasis and 
reduction with efalizumab (anti-CD11a). Proc Natl Acad Sci U S A, 102, 19057-
62. 
LUCAS, A. D. & HALLIDAY, G. M. (1999) Progressor but not regressor skin tumours 
inhibit Langerhans' cell migration from epidermis to local lymph nodes. 
Immunology, 97, 130-7. 
LYON, M. F. (1961) Gene action in the X-chromosome of the mouse (Mus musculus 
L.). Nature, 190, 372-3. 
MACAK, J. & MICHAL, M. (1993) Diffuse sclerosing variant of papillary thyroid 
carcinoma. Cesk Patol, 29, 6-8. 
MACATONIA, S. E., DOHERTY, T. M., KNIGHT, S. C. & O'GARRA, A. (1993) 
Differential effect of IL-10 on dendritic cell-induced T cell proliferation and 
IFN-gamma production. J Immunol, 150, 3755-65. 
 
 
195 
MAGNI, M., DI NICOLA, M., CARLO-STELLA, C., MATTEUCCI, P., LAVAZZA, 
C., GRISANTI, S., BIFULCO, C., PILOTTI, S., PAPINI, D., ROSAI, J. & 
GIANNI, A. M. (2002) Identical rearrangement of immunoglobulin heavy chain 
gene in neoplastic Langerhans cells and B-lymphocytes: evidence for a common 
precursor. Leuk Res, 26, 1131-3. 
MAHNKE, K., KNOP, J. & ENK, A. H. (2003) Induction of tolerogenic DCs: 'you are 
what you eat'. Trends Immunol, 24, 646-51. 
MASUDA, N., OHNISHI, T., KAWAMOTO, S., MONDEN, M. & OKUBO, K. (1999) 
Analysis of chemical modification of RNA from formalin-fixed samples and 
optimization of molecular biology applications for such samples. Nucleic Acids 
Res, 27, 4436-43. 
MAY, S. A., NETTO, G., DOMIATI-SAAD, R. & KASPER, C. (2005) Cutaneous 
lymphoid hyperplasia and marginal zone B-cell lymphoma following 
vaccination. J Am Acad Dermatol, 53, 512-6. 
MCARDLE, J. P., KNIGHT, B. A., HALLIDAY, G. M., MULLER, H. K. & 
ROWDEN, G. (1986) Quantitative assessment of Langerhans cells in actinic 
keratosis, Bowen's disease, keratoacanthoma, squamous cell carcinoma and 
basal cell carcinoma. Pathology, 18, 212-6. 
MCCLAIN, K., JIN, H., GRESIK, V. & FAVARA, B. (1994) Langerhans cell 
histiocytosis: lack of a viral etiology. Am J Hematol, 47, 16-20. 
MCKENNA, K., BEIGNON, A. S. & BHARDWAJ, N. (2005) Plasmacytoid dendritic 
cells: linking innate and adaptive immunity. J Virol, 79, 17-27. 
MEDEIROS, L. J., PICKER, L. J., ABEL, E. A., HU, C. H., HOPPE, R. T., WARNKE, 
R. A. & WOOD, G. S. (1989) Cutaneous lymphoid hyperplasia. Immunologic 
characteristics and assessment of criteria recently proposed as diagnostic of 
malignant lymphoma. J Am Acad Dermatol, 21, 929-42. 
MEDEMA, R. H. & BURGERING, B. M. (2007) The X factor: skewing X inactivation 
towards cancer. Cell, 129, 1253-4. 
MEGJUGORAC, N. J., YOUNG, H. A., AMRUTE, S. B., OLSHALSKY, S. L. & 
FITZGERALD-BOCARSLY, P. (2004) Virally stimulated plasmacytoid 
dendritic cells produce chemokines and induce migration of T and NK cells. J 
Leukoc Biol, 75, 504-14. 
MEISSNER, K., LONING, T. & REHPENNING, W. (1993) Epidermal Langerhans 
cells and prognosis of patients with mycosis fungoides and Sezary syndrome. In 
Vivo, 7, 277-80. 
MERAD, M., MANZ, M. G., KARSUNKY, H., WAGERS, A., PETERS, W., CHARO, 
I., WEISSMAN, I. L., CYSTER, J. G. & ENGLEMAN, E. G. (2002) 
Langerhans cells renew in the skin throughout life under steady-state conditions. 
Nat Immunol, 3, 1135-41. 
MIERAU, G. W., FAVARA, B. E. & BRENMAN, J. M. (1982) Electron microscopy in 
histiocytosis X. Ultrastruct Pathol, 3, 137-42. 
MIYAGI, J., KINJO, T., TSUHAKO, K., HIGA, M., IWAMASA, T., KAMADA, Y. & 
HIRAYASU, T. (2001) Extremely high Langerhans cell infiltration contributes 
to the favourable prognosis of HPV-infected squamous cell carcinoma and 
adenocarcinoma of the lung. Histopathology, 38, 355-67. 
MOSEMAN, E. A., LIANG, X., DAWSON, A. J., PANOSKALTSIS-MORTARI, A., 
KRIEG, A. M., LIU, Y. J., BLAZAR, B. R. & CHEN, W. (2004) Human 
 
 
196 
plasmacytoid dendritic cells activated by CpG oligodeoxynucleotides induce the 
generation of CD4+CD25+ regulatory T cells. J Immunol, 173, 4433-42. 
MURAKAMI, I., GOGUSEV, J., FOURNET, J. C., GLORION, C. & JAUBERT, F. 
(2002) Detection of molecular cytogenetic aberrations in langerhans cell 
histiocytosis of bone. Hum Pathol, 33, 555-60. 
NAGEL, S., BORISCH, B., THEIN, S. L., OESTREICHER, M., NOTHIGER, F., 
BIRRER, S., TOBLER, A. & FEY, M. F. (1995) Somatic mutations detected by 
mini- and microsatellite DNA markers reveal clonal intratumor heterogeneity in 
gastrointestinal cancers. Cancer Res, 55, 2866-70. 
NAKAJIMA, T., WATANABE, S., SATO, Y., SHIMOSATO, Y., MOTOI, M. & 
LENNERT, K. (1982) S-100 protein in Langerhans cells, interdigitating 
reticulum cells and histiocytosis X cells. Gann, 73, 429-32. 
NASREEN, M., UENO, T., SAITO, F. & TAKAHAMA, Y. (2003) In vivo treatment of 
class II MHC-deficient mice with anti-TCR antibody restores the generation of 
circulating CD4 T cells and optimal architecture of thymic medulla. J Immunol, 
171, 3394-400. 
NAUMOVA, A. K., OLIEN, L., BIRD, L. M., SMITH, M., VERNER, A. E., 
LEPPERT, M., MORGAN, K. & SAPIENZA, C. (1998) Genetic mapping of X-
linked loci involved in skewing of X chromosome inactivation in the human. 
Eur J Hum Genet, 6, 552-62. 
NEFEDOVA, Y., NAGARAJ, S., ROSENBAUER, A., MURO-CACHO, C., SEBTI, S. 
M. & GABRILOVICH, D. I. (2005) Regulation of dendritic cell differentiation 
and antitumor immune response in cancer by pharmacologic-selective inhibition 
of the janus-activated kinase 2/signal transducers and activators of transcription 
3 pathway. Cancer Res, 65, 9525-35. 
NESTLE, F. O., ZHENG, X. G., THOMPSON, C. B., TURKA, L. A. & NICKOLOFF, 
B. J. (1993) Characterization of dermal dendritic cells obtained from normal 
human skin reveals phenotypic and functionally distinctive subsets. J Immunol, 
151, 6535-45. 
NEUMANN, M. P. & FRIZZERA, G. (1986) The Coexistence of Langerhans Cell 
Granulomatosis and Malignant-Lymphoma May Take Different Forms - Report 
of 7 Cases with a Review of the Literature. Human Pathology, 17, 1060-1065. 
NIHAL, M., MIKKOLA, D., HORVATH, N., GILLIAM, A. C., STEVENS, S. R., 
SPIRO, T. P., COOPER, K. D. & WOOD, G. S. (2003) Cutaneous lymphoid 
hyperplasia: a lymphoproliferative continuum with lymphomatous potential. 
Hum Pathol, 34, 617-22. 
NOVELLI, M., COSSU, A., OUKRIF, D., QUAGLIA, A., LAKHANI, S., POULSOM, 
R., SASIENI, P., CARTA, P., CONTINI, M., PASCA, A., PALMIERI, G., 
BODMER, W., TANDA, F. & WRIGHT, N. (2003) X-inactivation patch size in 
human female tissue confounds the assessment of tumor clonality. Proc Natl 
Acad Sci U S A, 100, 3311-4. 
O'KEEFFE, M., HOCHREIN, H., VREMEC, D., SCOTT, B., HERTZOG, P., 
TATARCZUCH, L. & SHORTMAN, K. (2003) Dendritic cell precursor 
populations of mouse blood: identification of the murine homologues of human 
blood plasmacytoid pre-DC2 and CD11c+ DC1 precursors. Blood, 101, 1453-9. 
ODA, T., TSUDA, H., SCARPA, A., SAKAMOTO, M. & HIROHASHI, S. (1992) 
Mutation pattern of the p53 gene as a diagnostic marker for multiple 
hepatocellular carcinoma. Cancer Res, 52, 3674-8. 
 
 
197 
PARK, J. G. & CHAPMAN, V. M. (1994) CpG island promoter region methylation 
patterns of the inactive-X-chromosome hypoxanthine phosphoribosyltransferase 
(Hprt) gene. Mol Cell Biol, 14, 7975-83. 
PATTERSON, S., RAE, A., HOCKEY, N., GILMOUR, J. & GOTCH, F. (2001) 
Plasmacytoid dendritic cells are highly susceptible to human immunodeficiency 
virus type 1 infection and release infectious virus. J Virol, 75, 6710-3. 
PENNA, G., VULCANO, M., RONCARI, A., FACCHETTI, F., SOZZANI, S. & 
ADORINI, L. (2002) Cutting edge: differential chemokine production by 
myeloid and plasmacytoid dendritic cells. J Immunol, 169, 6673-6. 
PIGOZZI, B., BORDIGNON, M., BELLONI FORTINA, A., MICHELOTTO, G. & 
ALAIBAC, M. (2006) Expression of the CD1a molecule in B- and T-
lymphoproliferative skin conditions. Oncol Rep, 15, 347-51. 
PILERI, S. A., GROGAN, T. M., HARRIS, N. L., BANKS, P., CAMPO, E., CHAN, J. 
K., FAVERA, R. D., DELSOL, G., DE WOLF-PEETERS, C., FALINI, B., 
GASCOYNE, R. D., GAULARD, P., GATTER, K. C., ISAACSON, P. G., 
JAFFE, E. S., KLUIN, P., KNOWLES, D. M., MASON, D. Y., MORI, S., 
MULLER-HERMELINK, H. K., PIRIS, M. A., RALFKIAER, E., STEIN, H., 
SU, I. J., WARNKE, R. A. & WEISS, L. M. (2002) Tumours of histiocytes and 
accessory dendritic cells: an immunohistochemical approach to classification 
from the International Lymphoma Study Group based on 61 cases. 
Histopathology, 41, 1-29. 
PINKUS, G. S., LONES, M. A., MATSUMURA, F., YAMASHIRO, S., SAID, J. W. & 
PINKUS, J. L. (2002) Langerhans cell histiocytosis immunohistochemical 
expression of fascin, a dendritic cell marker. Am J Clin Pathol, 118, 335-43. 
PLENGE, R. M., HENDRICH, B. D., SCHWARTZ, C., ARENA, J. F., NAUMOVA, 
A., SAPIENZA, C., WINTER, R. M. & WILLARD, H. F. (1997) A promoter 
mutation in the XIST gene in two unrelated families with skewed X-
chromosome inactivation. Nat Genet, 17, 353-6. 
POECK, H., WAGNER, M., BATTIANY, J., ROTHENFUSSER, S., WELLISCH, D., 
HORNUNG, V., JAHRSDORFER, B., GIESE, T., ENDRES, S. & 
HARTMANN, G. (2004) Plasmacytoid dendritic cells, antigen, and CpG-C 
license human B cells for plasma cell differentiation and immunoglobulin 
production in the absence of T-cell help. Blood, 103, 3058-64. 
PRCHAL, J. T. & GUAN, Y. L. (1993) A novel clonality assay based on transcriptional 
analysis of the active X chromosome. Stem Cells, 11 Suppl 1, 62-5. 
QUINTANILLA-MARTINEZ, L., ZUKERBERG, L. R. & HARRIS, N. L. (1992) 
Prethymic adult lymphoblastic lymphoma. A clinicopathologic and 
immunohistochemical analysis. Am J Surg Pathol, 16, 1075-84. 
RAUSCH, E., KAISERLING, E. & GOOS, M. (1977) Langerhans cells and 
interdigitating reticulum cells in the thymus-dependent region in human 
dermatopathic lymphadenitis. Virchows Arch B Cell Pathol, 25, 327-43. 
REIS E SOUSA, C., STAHL, P. D. & AUSTYN, J. M. (1993) Phagocytosis of antigens 
by Langerhans cells in vitro. J Exp Med, 178, 509-19. 
RIBOLDI, E., MUSSO, T., MORONI, E., URBINATI, C., BERNASCONI, S., 
RUSNATI, M., ADORINI, L., PRESTA, M. & SOZZANI, S. (2005) Cutting 
edge: proangiogenic properties of alternatively activated dendritic cells. J 
Immunol, 175, 2788-92. 
 
 
198 
RICHMOND, I., EYDEN, B. P. & BANERJEE, S. S. (1995) Intranodal Langerhans' 
cell histiocytosis associated with malignant melanoma. Histopathology, 26, 380-
2. 
RIGAT, B., HUBERT, C., CORVOL, P. & SOUBRIER, F. (1992) PCR detection of the 
insertion/deletion polymorphism of the human angiotensin converting enzyme 
gene (DCP1) (dipeptidyl carboxypeptidase 1). Nucleic Acids Res, 20, 1433. 
RIJLAARSDAM, J. U., VAN DER PUTTE, S. C., BERTI, E., KERL, H., RIEGER, E., 
TOONSTRA, J., GEERTS, M. L., MEIJER, C. J. & WILLEMZE, R. (1993) 
Cutaneous immunocytomas: a clinicopathologic study of 26 cases. 
Histopathology, 23, 117-25. 
RISDALL, R. J., DEHNER, L. P., DURAY, P., KOBRINSKY, N., ROBISON, L. & 
NESBIT, M. E., JR. (1983) Histiocytosis X (Langerhans' cell histiocytosis). 
Prognostic role of histopathology. Arch Pathol Lab Med, 107, 59-63. 
RISSOAN, M. C., SOUMELIS, V., KADOWAKI, N., GROUARD, G., BRIERE, F., 
DE WAAL MALEFYT, R. & LIU, Y. J. (1999) Reciprocal control of T helper 
cell and dendritic cell differentiation. Science, 283, 1183-6. 
ROMANI, N., HOLZMANN, S., TRIPP, C. H., KOCH, F. & STOITZNER, P. (2003) 
Langerhans cells - dendritic cells of the epidermis. APMIS, 111, 725-40. 
ROMANI, N., LENZ, A., GLASSEL, H., STOSSEL, H., STANZL, U., MAJDIC, O., 
FRITSCH, P. & SCHULER, G. (1989) Cultured human Langerhans cells 
resemble lymphoid dendritic cells in phenotype and function. J Invest Dermatol, 
93, 600-9. 
ROWDEN, G., CONNELLY, E. M. & WINKELMANN, R. K. (1983) Cutaneous 
histiocytosis X. The presence of S-100 protein and its use in diagnosis. Arch 
Dermatol, 119, 553-59. 
SALHANY, K. E., COUSAR, J. B., GREER, J. P., CASEY, T. T., FIELDS, J. P. & 
COLLINS, R. D. (1988) Transformation of cutaneous T cell lymphoma to large 
cell lymphoma. A clinicopathologic and immunologic study. Am J Pathol, 132, 
265-77. 
SALOTTI, J. A., NANDURI, V., PEARCE, M. S., PARKER, L., LYNN, R. & 
WINDEBANK, K. P. (2009) Incidence and clinical features of Langerhans cell 
histiocytosis in the UK and Ireland. Arch Dis Child, 94, 376-80. 
SANDOVICI, I., NAUMOVA, A. K., LEPPERT, M., LINARES, Y. & SAPIENZA, C. 
(2004) A longitudinal study of X-inactivation ratio in human females. Hum 
Genet, 115, 387-92. 
SANGUEZA, O. P., YADAV, S., WHITE, C. R., JR. & BRAZIEL, R. M. (1992) 
Evolution of B-cell lymphoma from pseudolymphoma. A multidisciplinary 
approach using histology, immunohistochemistry, and Southern blot analysis. 
Am J Dermatopathol, 14, 408-13. 
SANTEGOETS, S. J., GIBBS, S., KROEZE, K., VAN DE VEN, R., SCHEPER, R. J., 
BORREBAECK, C. A., DE GRUIJL, T. D. & LINDSTEDT, M. (2008) 
Transcriptional profiling of human skin-resident Langerhans cells and CD1a+ 
dermal dendritic cells: differential activation states suggest distinct functions. J 
Leukoc Biol, 84, 143-51. 
SAVELL, V. H., JR., SHERMAN, T., SCHEUERMANN, R. H., SIDDIQUI, A. M. & 
MARGRAF, L. R. (1998) Bcl-2 expression in Langerhans' cell histiocytosis. 
Pediatr Dev Pathol, 1, 210-5. 
 
 
199 
SCHAERLI, P., WILLIMANN, K., EBERT, L. M., WALZ, A. & MOSER, B. (2005) 
Cutaneous CXCL14 targets blood precursors to epidermal niches for Langerhans 
cell differentiation. Immunity, 23, 331-42. 
SCHMITT, D. A., BIEBER, T., CAZENAVE, J. P. & HANAU, D. (1990) Fc receptors 
of human Langerhans cells. J Invest Dermatol, 94, 15S-21S. 
SCHMUTH, M., SIDOROFF, A., DANNER, B., TOPAR, G. & SEPP, N. T. (2001) 
Reduced number of CD1a+ cells in cutaneous B-cell lymphoma. Am J Clin 
Pathol, 116, 72-8. 
SCHOFIELD, J. B., ALSANJARI, N. A., DAVIS, J. & MACLENNAN, K. A. (1992) 
Eosinophilic granuloma of lymph nodes associated with metastatic papillary 
carcinoma of the thyroid. Histopathology, 20, 181-3. 
SCHWARTZ, R. H. (1992) Costimulation of T lymphocytes: the role of CD28, CTLA-
4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell, 71, 1065-8. 
SHAN, L., KAKUDO, K., NAKAMURA, M., NAKAMURA, Y., YOKOI, T., 
ISHIMOTO, J., KAWAHARA, K. & TAKAMI, H. (1997) Clonality of the 
parathyroid nodules with uremic parathyroid hyperplasia. Pathol Oncol Res, 3, 
198-203. 
SHARP, A., ROBINSON, D. & JACOBS, P. (2000) Age- and tissue-specific variation 
of X chromosome inactivation ratios in normal women. Hum Genet, 107, 343-9. 
SHIBATA, D., MARTIN, W. J. & ARNHEIM, N. (1988) Analysis of DNA-Sequences 
in 40-Year-Old Paraffin-Embedded Thin-Tissue Sections - a Bridge between 
Molecular-Biology and Classical Histology. Cancer Research, 48, 4564-4566. 
SILBERBERG-SINAKIN, I., THORBECKE, G. J., BAER, R. L., ROSENTHAL, S. A. 
& BEREZOWSKY, V. (1976) Antigen-bearing langerhans cells in skin, dermal 
lymphatics and in lymph nodes. Cell Immunol, 25, 137-51. 
SINGH, A., PRIETO, V. G., CZELUSTA, A., MCCLAIN, K. L. & DUVIC, M. (2003) 
Adult Langerhans cell histiocytosis limited to the skin. Dermatology, 207, 157-
61. 
SINGHAL, R. P., MAYS-HOOPES, L. L. & EICHHORN, G. L. (1987) DNA 
methylation in aging of mice. Mech Ageing Dev, 41, 199-210. 
SLONE, S. P., FLEMING, D. R. & BUCHINO, J. J. (2003) Sinus histiocytosis with 
massive lymphadenopathy and Langerhans cell histiocytosis express the cellular 
adhesion molecule CD31. Arch Pathol Lab Med, 127, 341-4. 
SMITH, J. H., FULTON, L. & O'BRIEN, J. M. (1999) Spontaneous regression of 
orbital Langerhans cell granulomatosis in a three-year-old girl. Am J Ophthalmol, 
128, 119-21. 
SMYTH, M. J., GODFREY, D. I. & TRAPANI, J. A. (2001) A fresh look at tumor 
immunosurveillance and immunotherapy. Nat Immunol, 2, 293-9. 
SOBHANI, I., WALKER, F., APARICIO, T., ABRAMOWITZ, L., HENIN, D., 
CREMIEUX, A. C. & SOULE, J. C. (2002) Effect of anal epidermoid cancer-
related viruses on the dendritic (Langerhans') cells of the human anal mucosa. 
Clin Cancer Res, 8, 2862-9. 
SOCIETY, H.  
Treatment. Clinical Trials, Treatment Guidelines and References 
 
SOILLEUX, E. J., MORRIS, L. S., LESLIE, G., CHEHIMI, J., LUO, Q., LEVRONEY, 
E., TROWSDALE, J., MONTANER, L. J., DOMS, R. W., WEISSMAN, D., 
COLEMAN, N. & LEE, B. (2002a) Constitutive and induced expression of DC-
 
 
200 
SIGN on dendritic cell and macrophage subpopulations in situ and in vitro. J 
Leukoc Biol, 71, 445-57. 
SOILLEUX, E. J., MORRIS, L. S., RUSHBROOK, S., LEE, B. & COLEMAN, N. 
(2002b) Expression of human immunodeficiency virus (HIV)-binding lectin 
DC-SIGNR: Consequences for HIV infection and immunity. Hum Pathol, 33, 
652-9. 
SPECHT, K., RICHTER, T., MULLER, U., WALCH, A., WERNER, M. & HOFLER, 
H. (2001) Quantitative gene expression analysis in microdissected archival 
formalin-fixed and paraffin-embedded tumor tissue. Am J Pathol, 158, 419-29. 
STEFANATO, C. M., ANDERSEN, W. K., CALONJE, E., SWAIN, F. A., BORGHI, 
S., MASSONE, L., KOWALSKI, J. V. & BHAWAN, J. (1998) Langerhans cell 
histiocytosis in the elderly: a report of three cases. J Am Acad Dermatol, 39, 
375-8. 
STEINBRINK, K., WOLFL, M., JONULEIT, H., KNOP, J. & ENK, A. H. (1997) 
Induction of tolerance by IL-10-treated dendritic cells. J Immunol, 159, 4772-80. 
STEINMAN, R. M. (1991) The dendritic cell system and its role in immunogenicity. 
Annu Rev Immunol, 9, 271-96. 
STEINMAN, R. M. & DHODAPKAR, M. (2001) Active immunization against cancer 
with dendritic cells: the near future. Int J Cancer, 94, 459-73. 
STEINMAN, R. M., HAWIGER, D. & NUSSENZWEIG, M. C. (2003) Tolerogenic 
dendritic cells. Annu Rev Immunol, 21, 685-711. 
STEINMAN, R. M. & NUSSENZWEIG, M. C. (2002) Avoiding horror autotoxicus: 
the importance of dendritic cells in peripheral T cell tolerance. Proc Natl Acad 
Sci U S A, 99, 351-8. 
STINGL, G., WOLFF-SCHREINER, E. C., PICHLER, W. J., GSCHNAIT, F., KNAPP, 
W. & WOLFF, K. (1977) Epidermal Langerhans cells bear Fc and C3 receptors. 
Nature, 268, 245-6. 
STOITZNER, P., PFALLER, K., STOSSEL, H. & ROMANI, N. (2002) A close-up 
view of migrating Langerhans cells in the skin. J Invest Dermatol, 118, 117-25. 
STREILEIN, J. W. & BERGSTRESSER, P. R. (1984) Langerhans cells: antigen 
presenting cells of the epidermis. Immunobiology, 168, 285-300. 
STROBL, H., SCHEINECKER, C., RIEDL, E., CSMARITS, B., BELLO-
FERNANDEZ, C., PICKL, W. F., MAJDIC, O. & KNAPP, W. (1998) 
Identification of CD68+lin- peripheral blood cells with dendritic precursor 
characteristics. J Immunol, 161, 740-8. 
STRUNK, D., EGGER, C., LEITNER, G., HANAU, D. & STINGL, G. (1997) A skin 
homing molecule defines the langerhans cell progenitor in human peripheral 
blood. J Exp Med, 185, 1131-6. 
SU, L. D., KIM, Y. H., LEBOIT, P. E., SWETTER, S. M. & KOHLER, S. (2002) 
Interstitial mycosis fungoides, a variant of mycosis fungoides resembling 
granuloma annulare and inflammatory morphea. J Cutan Pathol, 29, 135-41. 
SUGITA, M., GRANT, E. P., VAN DONSELAAR, E., HSU, V. W., ROGERS, R. A., 
PETERS, P. J. & BRENNER, M. B. (1999) Separate pathways for antigen 
presentation by CD1 molecules. Immunity, 11, 743-52. 
SUNDAR, K. M., GOSSELIN, M. V., CHUNG, H. L. & CAHILL, B. C. (2003) 
Pulmonary Langerhans cell histiocytosis: emerging concepts in pathobiology, 
radiology, and clinical evolution of disease. Chest, 123, 1673-83. 
 
 
201 
TAKAGI, N. & SASAKI, M. (1975) Preferential inactivation of the paternally derived 
X chromosome in the extraembryonic membranes of the mouse. Nature, 256, 
640-2. 
TAN, S. S., WILLIAMS, E. A. & TAM, P. P. (1993) X-chromosome inactivation 
occurs at different times in different tissues of the post-implantation mouse 
embryo. Nat Genet, 3, 170-4. 
TANG, A., AMAGAI, M., GRANGER, L. G., STANLEY, J. R. & UDEY, M. C. 
(1993) Adhesion of epidermal Langerhans cells to keratinocytes mediated by E-
cadherin. Nature, 361, 82-5. 
TAZI, A. (2006) Adult pulmonary Langerhans' cell histiocytosis. Eur Respir J, 27, 
1272-85. 
TAZI, A., MOREAU, J., BERGERON, A., DOMINIQUE, S., HANCE, A. J. & SOLER, 
P. (1999) Evidence that Langerhans cells in adult pulmonary Langerhans cell 
histiocytosis are mature dendritic cells: importance of the cytokine 
microenvironment. J Immunol, 163, 3511-5. 
TOEBAK, M. J., GIBBS, S., BRUYNZEEL, D. P., SCHEPER, R. J. & 
RUSTEMEYER, T. (2009) Dendritic cells: biology of the skin. Contact 
Dermatitis, 60, 2-20. 
TONON, L., BERGAMASCHI, G., DELLAVECCHIA, C., ROSTI, V., LUCOTTI, C., 
MALABARBA, L., NOVELLA, A., VERCESI, E., FRASSONI, F. & 
CAZZOLA, M. (1998) Unbalanced X-chromosome inactivation in haemopoietic 
cells from normal women. Br J Haematol, 102, 996-1003. 
TORIYAMA, K., WEN, D. R., PAUL, E. & COCHRAN, A. J. (1993) Variations in the 
distribution, frequency, and phenotype of Langerhans cells during the evolution 
of malignant melanoma of the skin. J Invest Dermatol, 100, 269S-273S. 
TOSHIYA, O. (1999) Mosaicism in human liver tissue: Expansion of monoclonal 
patches during chronic viral infection. Journal of Kyoto Prefectural University 
of Medicine, 108, 317-329. 
TSAI, Y. C., LU, Y., NICHOLS, P. W., ZLOTNIKOV, G., JONES, P. A. & SMITH, H. 
S. (1996) Contiguous patches of normal human mammary epithelium derived 
from a single stem cell: implications for breast carcinogenesis. Cancer Res, 56, 
402-4. 
TSUJITANI, S., FURUKAWA, T., TAMADA, R., OKAMURA, T., YASUMOTO, K. 
& SUGIMACHI, K. (1987) Langerhans cells and prognosis in patients with 
gastric carcinoma. Cancer, 59, 501-5. 
TURVILLE, S. G., CAMERON, P. U., HANDLEY, A., LIN, G., POHLMANN, S., 
DOMS, R. W. & CUNNINGHAM, A. L. (2002) Diversity of receptors binding 
HIV on dendritic cell subsets. Nat Immunol, 3, 975-83. 
VALLADEAU, J., CAUX, C., LEBECQUE, S. & SAELAND, S. (2001) [Langerin: a 
new lectin specific for Langerhans cells induces the formation of Birbeck 
granules]. Pathol Biol (Paris), 49, 454-5. 
VALLADEAU, J., RAVEL, O., DEZUTTER-DAMBUYANT, C., MOORE, K., 
KLEIJMEER, M., LIU, Y., DUVERT-FRANCES, V., VINCENT, C., 
SCHMITT, D., DAVOUST, J., CAUX, C., LEBECQUE, S. & SAELAND, S. 
(2000) Langerin, a novel C-type lectin specific to Langerhans cells, is an 
endocytic receptor that induces the formation of Birbeck granules. Immunity, 12, 
71-81. 
 
 
202 
VALLADEAU, J. & SAELAND, S. (2005) Cutaneous dendritic cells. Semin Immunol, 
17, 273-83. 
VALLEY, C. M., PERTZ, L. M., BALAKUMARAN, B. S. & WILLARD, H. F. (2006) 
Chromosome-wide, allele-specific analysis of the histone code on the human X 
chromosome. Hum Mol Genet, 15, 2335-47. 
VAN KOOYK, Y. & GEIJTENBEEK, T. B. (2003) DC-SIGN: escape mechanism for 
pathogens. Nat Rev Immunol, 3, 697-709. 
VAN POTTELBERGE, G. R., BRACKE, K. R., DEMEDTS, I. K., DE RIJCK, K., 
REINARTZ, S. M., VAN DRUNEN, C. M., VERLEDEN, G. M., 
VERMASSEN, F. E., JOOS, G. F. & BRUSSELLE, G. G. Selective 
accumulation of langerhans-type dendritic cells in small airways of patients with 
COPD. Respir Res, 11, 35. 
VASSALLO, R. & LIMPER, A. H. (2002) Pulmonary Langerhans' cell histiocytosis. 
Semin Respir Crit Care Med, 23, 93-101. 
VERGIER, B., DE MURET, A., BEYLOT-BARRY, M., VAILLANT, L., EKOUEVI, 
D., CHENE, G., CARLOTTI, A., FRANCK, N., DECHELOTTE, P., 
SOUTEYRAND, P., COURVILLE, P., JOLY, P., DELAUNAY, M., BAGOT, 
M., GRANGE, F., FRAITAG, S., BOSQ, J., PETRELLA, T., DURLACH, A., 
DE MASCAREL, A., MERLIO, J. P. & WECHSLER, J. (2000) Transformation 
of mycosis fungoides: clinicopathological and prognostic features of 45 cases. 
French Study Group of Cutaneious Lymphomas. Blood, 95, 2212-8. 
VERMI, W., BONECCHI, R., FACCHETTI, F., BIANCHI, D., SOZZANI, S., FESTA, 
S., BERENZI, A., CELLA, M. & COLONNA, M. (2003) Recruitment of 
immature plasmacytoid dendritic cells (plasmacytoid monocytes) and myeloid 
dendritic cells in primary cutaneous melanomas. J Pathol, 200, 255-68. 
VERMI, W., RIBOLDI, E., WITTAMER, V., GENTILI, F., LUINI, W., MARRELLI, 
S., VECCHI, A., FRANSSEN, J. D., COMMUNI, D., MASSARDI, L., SIRONI, 
M., MANTOVANI, A., PARMENTIER, M., FACCHETTI, F. & SOZZANI, S. 
(2005) Role of ChemR23 in directing the migration of myeloid and 
plasmacytoid dendritic cells to lymphoid organs and inflamed skin. J Exp Med, 
201, 509-15. 
VERNON, M. L., FOUNTAIN, L., KREBS, H. M., HORTA-BARBOSA, L., 
FUCCILLO, D. A. & SEVER, J. L. (1973) Birbeck granules (Langerhans' cell 
granules) in human lymph nodes. Am J Clin Pathol, 60, 771-9. 
VOGELSTEIN, B., FEARON, E. R., HAMILTON, S. R. & FEINBERG, A. P. (1985) 
Use of restriction fragment length polymorphisms to determine the clonal origin 
of human tumors. Science, 227, 642-5. 
VOULGARELIS, M., DAFNI, U. G., ISENBERG, D. A. & MOUTSOPOULOS, H. M. 
(1999) Malignant lymphoma in primary Sjogren's syndrome: a multicenter, 
retrospective, clinical study by the European Concerted Action on Sjogren's 
Syndrome. Arthritis Rheum, 42, 1765-72. 
WAINSCOAT, J. S. & FEY, M. F. (1990) Assessment of clonality in human tumors: a 
review. Cancer Res, 50, 1355-60. 
WAKKACH, A., FOURNIER, N., BRUN, V., BREITTMAYER, J. P., COTTREZ, F. 
& GROUX, H. (2003) Characterization of dendritic cells that induce tolerance 
and T regulatory 1 cell differentiation in vivo. Immunity, 18, 605-17. 
 
 
203 
WATANABE, S., NAKAJIMA, T., SHIMOSATO, Y., SATO, Y. & SHIMIZU, K. 
(1983) Malignant histiocytosis and Letterer-Siwe disease. Neoplasms of T-zone 
histiocyte with S100 protein. Cancer, 51, 1412-24. 
WEISS LM, G. T., MULLER-HERMELINK HK, ET AL. (Ed.) (2001) Tumours of the 
Haematopoetic and Lymphoid Tissues., Lyon, IARC Press. 
WEST, J. D., FRELS, W. I., CHAPMAN, V. M. & PAPAIOANNOU, V. E. (1977) 
Preferential expression of the maternally derived X chromosome in the mouse 
yolk sac. Cell, 12, 873-82. 
WESTER, S. M., BEABOUT, J. W., UNNI, K. K. & DAHLIN, D. C. (1982) 
Langerhans' cell granulomatosis (histiocytosis X) of bone in adults. Am J Surg 
Pathol, 6, 413-26. 
WILLEMZE, R., JAFFE, E. S., BURG, G., CERRONI, L., BERTI, E., SWERDLOW, 
S. H., RALFKIAER, E., CHIMENTI, S., DIAZ-PEREZ, J. L., DUNCAN, L. M., 
GRANGE, F., HARRIS, N. L., KEMPF, W., KERL, H., KURRER, M., 
KNOBLER, R., PIMPINELLI, N., SANDER, C., SANTUCCI, M., STERRY, 
W., VERMEER, M. H., WECHSLER, J., WHITTAKER, S. & MEIJER, C. J. 
(2005) WHO-EORTC classification for cutaneous lymphomas. Blood, 105, 
3768-85. 
WILLEMZE, R., KERL, H., STERRY, W., BERTI, E., CERRONI, L., CHIMENTI, S., 
DIAZ-PEREZ, J. L., GEERTS, M. L., GOOS, M., KNOBLER, R., 
RALFKIAER, E., SANTUCCI, M., SMITH, N., WECHSLER, J., VAN 
VLOTEN, W. A. & MEIJER, C. J. (1997) EORTC classification for primary 
cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group 
of the European Organization for Research and Treatment of Cancer. Blood, 90, 
354-71. 
WILLMAN, C. L. (1994) Detection of clonal histiocytes in Langerhans cell 
histiocytosis: biology and clinical significance. Br J Cancer Suppl, 23, S29-33. 
WILLMAN, C. L., BUSQUE, L., GRIFFITH, B. B., FAVARA, B. E., MCCLAIN, K. 
L., DUNCAN, M. H. & GILLILAND, D. G. (1994) Langerhans'-cell 
histiocytosis (histiocytosis X)--a clonal proliferative disease. N Engl J Med, 331, 
154-60. 
WOLFE, J. T., CHOOBACK, L., FINN, D. T., JAWORSKY, C., ROOK, A. H. & 
LESSIN, S. R. (1995) Large-cell transformation following detection of minimal 
residual disease in cutaneous T-cell lymphoma: molecular and in situ analysis of 
a single neoplastic T-cell clone expressing the identical T-cell receptor. J Clin 
Oncol, 13, 1751-7. 
WOLLENBERG, A., WAGNER, M., GUNTHER, S., TOWAROWSKI, A., TUMA, E., 
MODERER, M., ROTHENFUSSER, S., WETZEL, S., ENDRES, S. & 
HARTMANN, G. (2002) Plasmacytoid dendritic cells: a new cutaneous 
dendritic cell subset with distinct role in inflammatory skin diseases. J Invest 
Dermatol, 119, 1096-102. 
WOOD, G. S., BAHLER, D. W., HOPPE, R. T., WARNKE, R. A., SKLAR, J. L. & 
LEVY, R. (1993) Transformation of mycosis fungoides: T-cell receptor beta 
gene analysis demonstrates a common clonal origin for plaque-type mycosis 
fungoides and CD30+ large-cell lymphoma. J Invest Dermatol, 101, 296-300. 
WOOD, G. S., NGAN, B. Y., TUNG, R., HOFFMAN, T. E., ABEL, E. A., HOPPE, R. 
T., WARNKE, R. A., CLEARY, M. L. & SKLAR, J. (1989) Clonal 
 
 
204 
rearrangements of immunoglobulin genes and progression to B cell lymphoma 
in cutaneous lymphoid hyperplasia. Am J Pathol, 135, 13-9. 
WU, C. D., WICKERT, R. S., WILLIAMSON, J. E., SUN, N. C., BRYNES, R. K. & 
CHAN, W. C. (1999) Using fluorescence-based human androgen receptor gene 
assay to analyze the clonality of microdissected dendritic cell tumors. Am J Clin 
Pathol, 111, 105-10. 
YASSIN, T. M. & TONER, P. G. (1976) Langerhans cells in the human oesophagus. J 
Anat, 122, 435-45. 
YOSHIDA, R., IMAI, T., HIESHIMA, K., KUSUDA, J., BABA, M., KITAURA, M., 
NISHIMURA, M., KAKIZAKI, M., NOMIYAMA, H. & YOSHIE, O. (1997) 
Molecular cloning of a novel human CC chemokine EBI1-ligand chemokine that 
is a specific functional ligand for EBI1, CCR7. J Biol Chem, 272, 13803-9. 
YOSHIOKA, M., YORIFUJI, T. & MITUYOSHI, I. (1998) Skewed X inactivation in 
manifesting carriers of Duchenne muscular dystrophy. Clin Genet, 53, 102-7. 
YOUSEM, S. A., COLBY, T. V., CHEN, Y. Y., CHEN, W. G. & WEISS, L. M. (2001) 
Pulmonary Langerhans' cell histiocytosis: molecular analysis of clonality. Am J 
Surg Pathol, 25, 630-6. 
YU, R. C., CHU, C., BULUWELA, L. & CHU, A. C. (1994) Clonal proliferation of 
Langerhans cells in Langerhans cell histiocytosis. Lancet, 343, 767-8. 
ZABA, L. C., FUENTES-DUCULAN, J., STEINMAN, R. M., KRUEGER, J. G. & 
LOWES, M. A. (2007) Normal human dermis contains distinct populations of 
CD11c+BDCA-1+ dendritic cells and CD163+FXIIIA+ macrophages. J Clin 
Invest, 117, 2517-25. 
ZABA, L. C., KRUEGER, J. G. & LOWES, M. A. (2009) Resident and "inflammatory" 
dendritic cells in human skin. J Invest Dermatol, 129, 302-8. 
ZHOU, L. J. & TEDDER, T. F. (1995) Human blood dendritic cells selectively express 
CD83, a member of the immunoglobulin superfamily. J Immunol, 154, 3821-35. 
ZHUANG, Z., MERINO, M. J., CHUAQUI, R., LIOTTA, L. A. & EMMERT-BUCK, 
M. R. (1995) Identical allelic loss on chromosome 11q13 in microdissected in 
situ and invasive human breast cancer. Cancer Res, 55, 467-71. 
 
 
 
 
205 
8. APPENDICES 
 
8.1. APPENDIX A: HISTIOCYTE SOCIETY GUIDELINES 
 
http://www.histiocytesociety.org/document.doc?id=290 
 
 
Clinical classification of LCH: 
 
 
Single System LCH (SS-LCH) 
 
 
 
One organ/system involved (uni- or multifocal): 
• Bone: unifocal (single bone) or multifocal (>1 bone) 
• Skin 
• Lymph node (not the draining lymph node of another 
LCH lesion) 
• Lungs 
• Hypothalamic-pituitary / Central nervous system 
• Other (e.g.thyroid, thymus) 
Multisystem LCH (MS-LCH) Two or more organs/systems involved 
 
 With or without involvement of “Risk Organs” 
 
 
The following localisations and disease extent categories are considered indications for 
systemic therapy: 
 
• SS-LCH with “CNS-risk” lesions 
• SS-LCH with multifocal bone lesions  
• SS-LCH with “special site” lesions 
• MS-LCH with/without involvement of “risk organs” 
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8.2. APPENDIX B: MATERIALS 
 
Suppliers’ addresses 
Abcam         Cambridge UK 
Ambion        Paisley, UK 
Applied Biosystems    Paisley, UK 
Arcturus        Paisley, UK 
BDH         Lutterworth, Leics, UK 
Bioline        London, UK 
Dakocytomation     Ely, Cambridgeshire, UK 
Dendritics       Lyon, France 
InVivoScribe Tech.     La Ciotat, France 
Lab Vision Corp.     Runcorn, Cheshire, UK 
MWG        Ebersberg, Germany 
Novocastra       Newcastle-upon-Tyne, UK 
Qiagen         Crawley, West Sussex, UK 
Roche        Welwyn Garden City, UK 
Sigma        Watford, Herts, UK     
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Supplier     Catalogue No.   Description 
 
Bioline      41028      Agarose tablets 
Arcturus      10824-06     CapSure HS LCM Caps 
Sigma      F9037      deionised formamide 
Sigma      D5758      DEPC 
Qiagen      201900      DNTP mix 
BDH       100935V      EDTA 
Sigma      HT0-2-32     Eosin 
Novocastra     PA0449      Factor XIIIA 
Applied Biosystems  403039      GS500 size standard 
Arcturus      KIT0401      HistoGene Frozen Section Kit 
Qiagen      203203      HotStarTaq and buffer 
Qiagen      203203      HotStarTaq DNA polymerase 
Roche      10656330001    HpaII enzyme and buffer 
MWG      custom primers    HUMAR primers 
Bioline      33029      Hyperladder IV 
BDH       BDH0258     KCl  
Abcam      ab49730      Langerin 
BDH       101494V      MgCl2 
Applied Biosystems  N8010611     MicroAmp reaction tube 
BDH       102524      NaOH  
Qiagen      129114      Nuclease free water 
BDH       100584S      Orthoboric acid 
MWG      Custom primers   PCR primers  
Applied Biosystems  Inventoried     Primers: GAPDH, actin, 18s, P21 
Arcturus      KIT0103      PicoPure™ DNA Extraction Kit 
 
 
208 
Qiagen      19131      Proteinase K 
Qiagen      28104      Qiaquick PCR Purification kit 
Ambion      AM1975      RecoverAll™ TNA Isolation Kit 
Arcturus      KIT0205      RiboAmp RNA Amplification Kit 
Agilent      5067-1513     RNA 6000 Pico Kit 
Molecular Bioproducts 7000       RNase away 
InVivoScribe Tech.  2-096-0021     Specimen size ladder – 6FAM 
BDH       443864E      Tris HCl 
BDH       10035V      Tween 
 
 
ANTIBODIES 
Supplier      Description 
 
Dakocytomation    Bcl2 
Dendritics      BDCA-2 
Novocastra      CD1a 
Novocastra      CD2 
Novocastra      CD3 
Novocastra      CD4 
Novocastra      CD5 
Novocastra      CD7 
Novocastra      CD8 
Novocastra      CD10 
Dakocytomation    CD20 
Dakocytomation    CD21 
Novocastra      CD23 
Dakocytomation    CD30 
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Dakocytomation    CD34 
Dakocytomation    CD43 
Lab Vision      CD56 
Dakocytomation    CD68 
Dendritics      DC-LAMP 
Dendritics      DC- SIGN  
Novocastra      Factor XIIIA 
Abcam       Langerin 
Dakocytomation    S100 
Novocastra      TdT 
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8.3. APPENDIX C: PUBLICATIONS 
 
A Original Publications 
 
Christie LJ, McKenzie C, Palmer TJ, Baker L, Goodlad JR. Type and Maturational 
status of Dendritic Cells in Cutaneous B-Cell Lymphoproliferative Disorders.  Accepted 
for publication in Histopathology Jan 2011. 
 
Christie LJ, Evans AT, Bray SE, Smith ME, Kernohan NM, Levison DA, Goodlad JR.  
Lesions resembling Langerhans cell histiocytosis in association with other 
lymphoproliferative disorders: a reactive or neoplastic phenomenon? Hum Pathol. 2006 
Jan;37(1):32-9. 
 
Christie L, Goodlad J. 
Response to Langerhans cell component in bullous pemphigoid-like lesions associated 
with chronic lymphocytic leukemia. Hum Pathol. 2007 Jun;38(6):952-3; author reply 
953-54. 
 
B Abstracts of Conference Proceedings 
 
Variability in X Chromosome Inactivation Patterns in Multiple Tissues of Elderly 
Females.  Lesley Christie, Lynsey Bayer, John Goodlad, Neil Kernohan, Stewart 
Fleming. The Pathological Society of Great Britain and Ireland. St Andrews, July 2010. 
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Type and Maturational status of dendritic cells in cutaneous B-cell lymphoproliferative 
disorders.  Lesley Christie, Carol McKenzie, Tim Palmer, Lee Baker, John Goodlad 
Meeting of the European Association for Haematopathology (EAHP). Bordeaux, 
September 2008. 
 
Type and Maturational status of dendritic cells in cutaneous B-cell lymphoproliferative 
disorders.  Lesley Christie, Carol McKenzie, Tim Palmer, Lee Baker, John Goodlad. 
The Pathological Society of Great Britain and Ireland. Leeds, July 2008. 
 
Langerhan cell rich mycosis fungoides.  Lesley Christie, Alan Evans, John Goodlad. 
The Pathological Society of Great Britain and Ireland.  Oxford, January 2008. 
 
C Publications arising from technical experience gained during this  period 
of research 
 
 
Goudie DR, D'Alessandro M, Merriman B, Lee H,  Szeverényi I, Avery S, O'Connor 
BD, Nelson SF, Coats SE, Stewart A, Christie L, Pichert G,  Friedel J, Hayes I,  
Burrows N, Whittaker S, Gerdes AM, Broesby-Olsen S, Ferguson-Smith MA, Verma C, 
Lunny DP, Reversade B, Lane EB. 
Multiple self-healing squamous epithelioma is caused by a disease-specific spectrum of 
mutations in TGFBR1. Nat Med. 2011 Feb 27;43(4):365-69. 
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Housley SL, Lindsay RS, Young B, McConachie M, Mechan D, Baty D, Christie L, 
Rahilly M, Qureshi K, Fleming S. 
Renal carcinoma with giant mitochondria associated with germ-line mutation and 
somatic loss of the succinate dehydrogenase B gene. Histopathology. 2010 
Feb;56(3):405-08.  
 
Christie L, Bayer L, Pippard M, Smith R, Levison D. 
A difficult diagnosis confounded by laboratory error. Lessons learned. J Clin Path. 
2009 62: 862-64. 
 
Christie LJ, McKay FJ, Purdie CA, Robertson KE, Topping DA, Levison DA.  
A simple and rapid approach to the problem of tissue contamination and patient identity 
in histopathologic specimens. Hum Pathol. 2006 Dec;37(12):153-42. 
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8.4. APPENDIX D: ORAL PRESENTATIONS 
 
A National 
 
X inactivation ratios may vary widely between different tissues of the same individual.  
Association of Clinical Pathologists. Stirling. October 2009. 
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I present annually at the University of Dundee Postgraduate Research Symposium and 
have presented at three meetings of the Association of Clinical Pathologists. 
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